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Cytochrome family P450 4A encode a major group of enzymes which are 
involved in the mechanism of peroxisome proliferation in rodents. Induction of 
CYP4A expression by peroxisome proliferators is due to transcriptional 
activation, mediated via the peroxisome proliferator activated receptor alpha. 
Cyp4a enzymes catalyse the ω-hydroxylation of fatty acids and eicosanoids, 
and it has been suggested they thereby play a pivotal role in blood pressure 
regulation. Murine Cyp4a10, Cyp4a14 and Cyp4a12 genes have been 
reported by Bell et al (1993) and Heng, et al (1997). There is contradictory 
evidence in the literature concerning the expression of lauric acid hydroxylase 
(LAH) and Cyp4a-related protein in mouse liver and kidney. We have 
previously shown that Cyp4a12 is expressed at high level in a male-specific 
fashion in liver and kidney of mouse (Bell et al 1993). However, various 
workers have reported the presence, or absence, of Cyp4a proteins, or LAH, 
in male mouse liver. Work by Hiratsuka et al (1996) demonstrate that ddY 
mice show a male specific expression of LAH and Cyp4a-related protein in the 
liver, while other strains Balb/c and C57BL/6 exhibit no sex difference in 
neither enzyme or protein. In the kidney, ddY, Balb/c and C57BL/6 all show 
sexual dimorphism in the expression of both LAH and Cyp4a related protein. 
The aim of this project was to characterise the expression of mouse Cyp4a12 
and resolve the conflicting results in the literature. 
 
Findings demonstrate that there is a male specific expression of Cyp4a12 in 
male liver and kidney. The data differs from Hiratsuka et al in that their 
 findings present no sex difference in Balb/c and C57BL/6 expression of Cyp4a 
proteins. Hiratsuka et al also determined that in the kidney of ddY, Balb/c and 
C57BL/6 there is no sex difference in expression of neither enzyme or protein. 
Data here agrees with these findings and suggests that the sexual 
dimorphism exhibited by the LAH and Cyp4a related protein in the kidney is 
due to constitutive expression of Cyp4a12. Thus it appears that there is still a 
discrepancy between the Cyp4a12 hepatic expression pattern presented here 
and that of the enzyme and protein determined by Hiratsuka et al. An 
explanation may infer that the LAH and Cyp4a-related protein measured by 
Hiratsuka et al is not only Cyp4a12 but also another member of the Cyp4a 
family. Further work is required to establish what Cyp4a is expressed 
predominately in the female. Work by Henderson et al (1994) supports the 
case that this Cyp4a candidate may be Cyp4a10. Continuing studies will 
clarify the expression pattern of the Cyp4a and also investigate the 
mechanism of regulation of the Cyp4a family genes and the expression of 
male specific genes. 
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Chapter 1 Introduction 
Section 1.1 Peroxisome proliferation 
 
Section 1.1.1 Peroxisomes and their function 
 
Peroxisomes are spherical organelles, which are single membrane bound and 
present in almost all eukaryotic cells (Baudhuin et al 1965, De Duve and 
Baudhuin 1966). Amongst the enzymes they contain are those that use 
molecular oxygen to remove hydrogen atoms from specific organic substrates 
to produce hydrogen peroxide. Peroxisomes are approximately 0.5µm in 
diameter and contain high concentrations of catalase and urate oxidase 
(Wilcke et al 1995). In the liver and kidney, peroxisomes are found in high 
numbers with 600 individual organelles present in one cell and representing 
2% cell volume (Masters and Crane 1995). 
 
Mammalian peroxisomes contain more than 50 proteins associated with lipid 
metabolism (Mannerts and van Veldhoven, 1993), and are essential elements 
of the glucose fatty acid cycle, which metabolises carbohydrate and fatty acids 
to generate ATP (Reddy and Hasimoto 2001). During periods of starvation, 
energy is generated from the metabolism of carbohydrates to free fatty acids 
and their ketone derivatives (Salway et al 1998). The essential role of 
peroxisomes in this process is emphasized when their function is impaired. 
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Zellwegers syndrome is an inheritable genetic disorder that results in a 
deficiency of functional peroxisomes. This disorder impairs β-oxidation of fatty 
acids (due to the lack of peroxisomal â -oxidation enzymes) leading to 
accumulation of long chain fatty acids in tissues and blood of patients. 
(Schutgens et al 1986; Moser 1987; Lazarow and Moser 1989). Another 
disorder which results in long chain fatty acid accumulation is X-linked 
adrenoleukpdystrophy which effects the peroxisomal enzyme very-long-chain 
acyl-CoA (VLCFA-CoA) synthase (Wanders et al 1988; Lazo et al 1988). 
 
Section 1.1.2. β-oxidation of fatty acids in peroxisomes 
 
β-oxidation is the predominant mechanism of fatty acid oxidation. This may 
occur either in the peroxisomes of mitochondria however the enzymes 
involved are different (table 1.1). 
 




Long chain acyl-CoA synthetase 
Carnitine octaoyltransferase 
Carnitine acetyltransferase 
Straight-chain acyl-CoA oxidase 




Sterol carrier protein 2/3-ketoacyl-
CoA thiolase 
2,4-dienoyl-CoA reductase 
r3, 2-Enoyl-CoA isomerase 
r3,5,2,4-Dienoyl-CoA isomerase 
 
Peroxisomes work in concert with mitochondria but contain enzymes that 
perform additional reactions such as very-long chain acyl CoA synthetase 
responsible for the metabolism of VLCFA’s (>C20). Peroxisomal β-oxidation 
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also metabolises long chain dicarboxylic acids, eicosanoids, and bile acid 
precursors. Two pathways are thought to exist for peroxisomal β-oxidation 
(figure 1.1). Oxidation of straight-chain fatty acids is catalysed by the enzymes 
AOX, L-PBE and thiolase. 2-methyl branched fatty acids and the bile acid 
intermediates, di- and trihydroxycoprostanoic acids, occurs via a second 
pathway (figure 1.1). 
 
Fatty acids in the liver are predominantly non-esterified fatty acids transported 
by serum albumin and triglycerides carried by chylomicrons. Triglyerides are 
hydrolysed to glycerol and fatty acids by lipoprotein lipase (LPL). Before 
entering the peroxisomes fatty acids are activated to acyl-CoA thioesters by 
removal of two carbon atoms. These are converted to acetyl CoA, which is 
returned to the cytosol for recycling. The flux of fatty acids into mitochondria is 
regulated by a carnitine-dependent transport system of which carinitine 
octanoyltransferase is a critical component. Acyl-CoA derivatives of fatty acids 
are carried to the peroxisomes where they are subjected to oxidation by acyl-
CoA oxidases. Acyl-CoA oxidases contain FAD as a prosthetic group that use 
molecular O2 to oxidize fatty acids, yielding hydrogen peroxide as a byproduct 
(Van den Bosch et al., 1992; Schultz 1991) 
 
Bifunctional enzyme catalyses the hydration and dehydrogenation in the 
subsequent steps of β-oxidation, although it may also possess 3,2-enoyl- CoA 
isomerase, 2-enoyl-CoA hydratase and 3-h ydroxyacyl-CoA dehydro-genase 
activities (Palosaari and Hiltunen, 1990). Peroxisomosal â -oxidation is 
completed by the thiolytic cleavage of oxo-acyl-CoA (3-ketoacyl-CoA) by CoA-
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SH catalysed by 3-keoa-cyl-CoA thiolase (Salway 1987, figure 1.1 shows an 
example of peroxisomal â -oxidation of a fatty acids) 
 
Fatty Acid β-oxidation 


























Acyl-Coa  Acetyl-CoA 
 
Figure 1.1. Enzymology of peroxisomal β-oxidation systems in humans: Inducible straight 
chain and the non-inducible branched chain fatty acid β-oxidation. SCPx- sterol carrier protein 
x., Modified by Reddy and Hashimoto (2001) 
 
Section 1.1.2 Peroxisome Proliferators 
Peroxisome proliferators are a class of structurally diverse chemicals (figure 
1.2) that cause a dramatic increase in the size and number of peroxisomes in 
 
Acyl-CoA synthetase 





Straight chain & branched 





















NADH + H+ 
H2O 
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susceptible species (Reddy et al., 1980; Lock et al., 1989). In addition these 
compounds cause a range of biochemical and morphological changes. These 
include the induction of both peroxisomal and microsomal fatty acid-oxidising 




Figure 1.2. Chemical structures of some peroxisome proliferators. 
 
Although their structures are diverse, many contain a functional group that is 
either carboxylic or acidic. For example clofibrate is metabolised to clofibric 
acid. The acidic group of the peroxisome proliferators may be an integral part 
of the parent structure or it may be a metabolite. However phase II 
metabolism such as glucoronidation is not thought to generate peroxisome 
proliferators in rodents (Lake and Lewis 1993). 
 
Figure 1.2 shows the structure of some known peroxisome proliferators. 
Peroxisome proliferators form a group of chemicals that have a wide range of 
uses, including hypolipidemic agents, herbicides, and plasticizers. (Moody et 
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al 1991, Bentely et al 1993). Peroxisome proliferation may also occur without 
exposure to these chemicals. Conditions including starvation, high-fat diets, 
cold temperature, and diabetes mellitus also result in peroxisome proliferation. 
Historically this phenomenon was first identified in rodents, and it is this 
species that peroxisome proliferation is best described (Chu et al 1996, Lock 
et al 1989, Reddy et al 1983). 
 
Section 1.1.3 Acute effects of peroxisome proliferators 
 
Exposure to PPs result in a set of responses in the liver, kidney and heart 
(Reddy and Lalwani et 1983). These include increased liver weight, due to 
hepatocyte hypertrophy and hyperplasia, and transcriptional increases of 
enzymes involved in the metabolism of fatty acids (Reddy and Lalwani et 
1983). The increase in liver weight is rapid with administration of  Wy14, 643, 
a potent PP, with organ weight reaching a maximum by day 14. (Marsman et 
al 1988). Hepatocyte hypertrophy is a result of an increase in the size of 
individual cells due to a proliferation in sub-cellular organelles such as smooth 
endoplasmic reticulum, golgi bodies, mitochondria and peroxisomes (Reddy et 
al., 1980; Lock et al., 1989). Hepatomegaly continues for the duration of PP 
exposure. Cessation of treatment results in the liver reducing to its original 
size (Cohen and Crasso 1981). Treatment with PPs increases peroxisome 
number and size to up to 25% of the cytoplasmic volume (Moody and Reddy 
1976, Nemali et al 1989). Despite an increase in the number of hepatocyte 
peroxisomes, the organelles may lack cores containing urate oxidase (Stott 
1988). 
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Section 1.1.4 Peroxisome proliferation - Biochemical characteristics 
 
The major biochemical alterations consist of the induction of both peroxisomal 
and microsomal fatty acid oxidizing enzyme activities. (Hawkins et al 1987; 
Auwerex et al 1996; Lazarow and De Duve 1976, Lazarow, 1977; Norseth and 
Thomassen, 1983; Veerkamp and Van Moerker, 1986). Enzyme activity of 
peroxisomal β-oxidation maybe determined by measuring overall activity or by 
assaying the rate-limiting enzyme of the cycle i.e. acyl-CoA oxidase. 
Peroxisomal enzyme activities are differentially induced as enzymes such as 
acyl-CoA oxidase activity may increase 30-fold, while catalase increases by 
only 3-fold. (Reedy and Lalwani, 1983; Lock et al., 1989). Peroxisome 
proliferation also includes an increase in smooth endoplasmic reticulum and 
associated levels of microsomal lauric acid ù -hydroxylase activity resulting 
from high level of induction of cytochrome P-4504A family (Kimura et al., 
1989, Bell and Elcombe, 1991a). Rodents administered methylclofenapate 
exhibit CYP4A1 induction (Bell et al 1991). Induction of CYP4A1 followed by 
peroxisomal acyl-CoA oxidase suggests that peroxisomal and microsomal 
genes are regulated in a coordinated manner and are frequently used as a 
marker of peroxisome proliferation. Table 1.2 shows a list of some of the 
enzymes induced by PPs. 
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Enzyme  Cellular Localization Reference 
Cytochrome P450 4A1 Smooth ER Gibson et al., 1982 
Carnitine Palmitoyl-CoA transferase Total cellular Sakuma et al., 1992 
Acyl-CoA oxidase Peroxisome Osumi et al., 1987 
Bifunctional enzyme Peroxisome Reddy et al., 1986 
Thiolase Peroxisome Baumgart et al., 1990 
Catalase Peroxisome Pacot et al., 1993 
Urate oxidase Peroxisome Nemali et al 1988 
HMG-CoA Synthase Mitochondrial Rodriguez et al., 1994 
Malic enzyme Cytosolic Sakuma et al., 1992 
Fatty acid binding protein Cytosolic Kaikaus et al., 1993 
Epoxide hydrolase Cytosolic Schladt et al., 1987 
 
Table 1.2 Enzymes induced by peroxisome proliferators. 
 
Section 1.1.5 Hyperplastic response to peroxisome proliferators 
 
Peroxisome proliferators induced hepatomegaly is a result of an increase in 
size and number of parenchymal cells. PPs mitogenic properties are 
demonstrated by the induction of DNA synthesis (Styles et al, 1988; Roberts 
et al., 1995; Marsman et al., 1988). DNA synthesis as measured by 
bromodeoxyuridine (BrdU) incorporation shows that relatively high doses of 
MCP (25mg/kg bw i.p.) result in maximal induction 20-30 hours after 
administration (Styles et al 1988). Induction of unscheduled DNA synthesis is 
limited to the periportal region of the liver acini (Roberts et al 1995, Barrass et 
al 1993). DNA synthesis by PPs occurs in the binucleated hepatocyte 
population which exhibit amitotic cytokinesis to form 4N cells following their 
stimulation to S-phase, since the proportion of 2x2N cells was reduced while 
the fraction of 4N cells was increased by MCP treatment (Styles et al 1988). 
 
The molecular mechanisms responsible for PP-induced liver growth are not 
fully understood. Several workers have reported that the proto-oncogenes c-
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fos, c-myc and c-jun are not induced after PP dosing. (Coni et al 1993 and 
Hasmall et al 1997) suggesting a different mechanism to that involved in 
compensatory hyperplasia induced by partial hepatectomy or CCl4 
(Goldsworthy et al 1994; Coni et al., 1993; Hasmall et al., 1997). 
 
Section 1.1.6 Chronic exposure to peroxisome proliferators 
 
Sustained exposure to synthetic peroxisome proliferators and the chronic 
induction of peroxisome proliferation in livers leads to the development of 
hepatocellular carcinoma in rats and mice (Gonzalez et al 1998, Rao and 
Reddy 1996, Reddy et al 1980). The carcinogenic potency of the PP MCP and 
Wy-14,643 is greater than that of DEHP, as studies have shown that while the 
former result in a 100% incidence of tumours in rat liver after 12 months, the 
latter requires higher doses with longer periods of exposure (>2 years. Reedy 
et al., 1982; Rao et al., 1984; Cattley et al., 1987; Kluwe et al., 1982). 
 
Section 1.1.7 Peroxisome proliferators are non-genotoxic carcinogens 
 
Conventional tests for genotoxicity of PPs have failed to detect any direct 
interaction or damage to DNA. PPs ability to induce hepatocarcinogenesis in 
rodents is not accompanied by a positive result in the Ames Salmonella 
mutagenesis assay (Warren et al., 1980; Reedy and Lalwani et al., 1983; 
Bentley et al., 1987). Furthermore study of the genotoxic properties of PPs 
have been examined using 32P-post labelling assays for DNA adduct 
formation (Gupta et al., 1985), unscheduled DNA synthesis (Cattley et al., 
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1986), chromosomal aberrations (Nilsson et al., 1991) and DNA repair assay 
(Butterworth et al., 1989). All these in vitro and in vivo assays for genotoxicity 
indicate that PPs are not direct mutagens and do not directly damage DNA 
(Ashby et al 1994). PPs have been termed non-genotoxic carcingens to reflect 
these results and it is unclear how chronic exposure to PPs result in 
hepatocarcinogenesis. Several hypotheses have been proposed but as yet 
none have been substantiated. 
 
Section 1.1.8 Models of PP-induced hepatocarcinogenesis 
 
Proposed mechanisms for the initiation of peroxisome proliferation in rodents 
include the role of the PPARα receptor, and the oxidative stress hypothesis. 
The identification and role of the PPARα receptor is discussed later (pg 30). 
The oxidative stress hypothesis proposes that peroxisome proliferation is an 
adaptive response to the alteration of lipid metabolism and involves the 
induction of CYP4A enzymes. Peroxisome proliferators have been shown to 
inhibit fatty acid oxidation (Lock et al 1989), form coenzyme A esters (Bentley 
et al 1993), increase levels of fatty acids (Lake and Lewis 1993), and fatty 
acids from cytosolic fatty-acid binding protein (Brandes et al 1990). Due to the 
differential induction of peroxisomal enzymes involved in the peroxisomal β-
oxidation of fatty acids (e.g. acyl-CoA oxidase) by PPs the generation of H2O2 
byproduct is not balanced by its degradation (Rao and Reddy, 1987 and 1991; 
Reedy and Rao, 1989, Lake 1993). Excess H2O2 may diffuse out of the 
peroxisome in the cell and form reactive oxygen species that react with DNA 
to form adducts. 
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H2O2 is normally degraded in the peroxisome by the enzyme catalase. 
However PPs induce catalase activity by only 2-3-fold above normal levels 
and under conditions of excessive H2O2 production is unable to degrade the 
reactive byproduct (Nemali et al., 1988, Reedy and Rao, 1989). Reactive 
oxygen species (ROS) generated from H2O2 are also cleared by other 
enzymes whose expression is reduced by PPs. This includes, superoxide 
dismuatse (Ciriolo et al 1982, Elliot and Elcombe 1987); glutathione-S-
transferase (Foliot et al, 1986; Lake et al, 1989; Furukawa et al., 1985; 
Tamura et al., 1990b) and glutathione peroxidase (Tamura et al, 1990a and 
1990b, Furukawa et al, 1985).  
 
Weak evidence exists for the hypothesis that PPs increase H2O2 
concentrations in the cell and lead to DNA adduct formation resulting in 
mutagenesis. A number of researchers have measured H2O2 and acyl-CoA 
oxidase concentrations under conditions of substrates saturation, and found 
that although the activity of the latter is high, there is a relatively small 
increase in intracellular H2O2. (Lake 1993, Foerster et al., 1981; Handler et al., 
1988). Formation of DNA adducts after exposure to PPs is also very low. The 
adduct 8-hydro-2-deoxyguanosine (8-OHdG) was found at levels only 0.5-2.5-
fold greater than controls (Kasai et al, 1989; Takagi et al, 1990 and 1991, 
Huang et al, 1994, Catley and Glover, 1993). In addition studies that use 
whole liver homogenates contain nuclear and mitochondrial DNA that is 16-
fold more susceptible to oxidative damage, this is due to the extensive oxygen 
metabolism in these organelles (Richter et al., 1988). In whole liver 
homogenate treated with Wy-14,643 , 8-OhdG levels were 2-fold greater than 
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controls, but this increase included a 3-fold increase in mitochondrial levels. 
(Sausen et al 1995). Isolated hepatic nuclei also showed no increase in 8-
OHdG after PP administration (Cattley and Glover 1993). Studies that have 
examined other measures of DNA damage have also showed that PPs do not 
signicantly increase the incidence of modified DNA bases or breaks (Elliott 
and Elcombe 1987, Tamara et al, 1991). This body of evidence does not 
support the mechanism of oxidative stress and DNA damage for PP-induced 
hepatocarcinogenesis 
 
Section 1.1.9 Peroxisome proliferators and tumourgenesis 
 
Perturbation in normal hepatocyte growth has also been suggested as a 
mechanism of PP-induced tumour growth in rodents. Hyperplasia as a result 
of amitotic cytokinesis by PPs maybe acute, chronic or result in preneoplastic 
lesions (Butterworth et al 1991). Increases in cell proliferation at all three 
stages could increase the frequency of spontaneous mutations and result in 
clonal expansion. Upon PP administration, rodent liver weights increase 
during a 2-7 day period as a result of a burst of hepatocyte replication that this 
localized in the periportal region (James and Roberts, 1996, Prince et al, 
1992, Melchiorri et al, 1993, Ohmura et al, 1996, Styles et al, 1988, Lake et al, 
1993; Lalwani et al, 1997, Eldridge et al, 1990; Styles et al, 1988). During PP-
induced hepatomegaly there is suppression of apoptosis (Marsman et al 
1988), which is restored after cessation of PP exposure (Roberts 1996). 
During PP exposure in rodents in concert with the proliferative response by 
hepatocytes (i.e. cell proliferation) it has also been shown to suppress 
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apoptosis in hepatocytes. PPs have been shown to affect the apoptotic 
process of the liver that may play an important role in the promotion of PP-
induced liver carcinogenesis. PPs were found to suppress both spontaneous 
and TGFβ induced apoptosis in rat hepatocytes (Bayly et al., 1993; Roberts et 
al., 1995; James and Roberts, 1996) and in the FAO hepatoma cell line (Bayly 
et al., 1993). It is thought that PPs induce liver cancer by inducing cell 
proliferation and at the same time suppressing apoptosis. Thus, DNA 
damaged cells that are normally removed by apoptosis are allowed to survive, 
and upon PP-induced mitogenic stimulation they may proliferate (clonal 
expansion) and accumulate further genetic changes that may ultimately lead 
to liver cancer (Cattley et al 1994). 
 
Chronic exposure to PPs also results in cell proliferation but the sustained 
exposure leading to tumour growth is dependent on PP potency, route of 
administration and the dose (Marsman et al, 1988; Eacho et al, 1991, Price et 
al 1992). For example high doses of MCP, nafenopin and Wy-14,643 do 
induce cell replication while lower doses fail to stimulate DNA synthesis (Price 
et al., 1992; Lake et al., 1993). Thus while for potent PPs the magnitude of the 
sustained increase in cell proliferation result in tumours, this is not the case 
when the level of exposure (time course) and PP potency is low (Eacho et al 
1991, Barrass et al 1993, Tanaka et al 1992). 
 
In models that use preneoplastic foci initiated by genotoxic carcinogens 
exposure to PPs result in the selective growth of hepatocytes (Cattley and 
Popp, 1989, Ward et al, 1983, 84 and 86; Glaurent and Clarke, 1989). In mice 
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pretreated with N-nitrosodiethylamine (DEN), DEHP was found to promote 
initiated focal hepatocellular proliferative lesions (Ward et al 1986), When 
DEN and clofibrate were co-administered to rats there was a significant 
increase in the number of hepatic tumours formed compared to rats 
administered DEN alone (Mochizuki et al 1983). Age is another determinant of 
PP-induced tumour progression in rodents. Older animals have a higher 
incidence of pre-neoplastic lesions and spontaneously initiated cells, which 
are thought to accumulate over a lifetime. PPs, nafenopin and Wy-14,643 
both produce more liver adenomas and carcinomas in older rats than younger 
rats (Cattley et al 1991; Kraupp-Grasl et al 1991). 
 
Section 1.2 Cytochrome P450 monooxygenase system 
 
Cytochrome P450 were first identified by Klingenberg (1958) and Garfinkel 
(1958) as a pigment whose maximum absorption wavelength after binding 
carbon monoxide was 450nm. To date, 481 P450 genes have been reported. 
These genes have been described in 85 eukaryote and 20 prokaryote 
species. Of 74 gene families so far described, 14 families comprise 26 
mammalian subfamilies. Each subfamily usually represents a cluster of tightly 
linked genes widely scattered throughout the genome 
(http://drnelson.utmem.edu/CytochromeP450.html). 
 
The role of this pigment was later characterized as the terminal component of 
the microsomal mixed function monooxygenase system of which the other key 
enzymatic component is NADPH-cytochrome P450-oxidoreductase (Werck-
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Reichhart & Feyereisen 2001). P450’s metabolise a wide range of chemicals 
including endogenous substances such as vitamins, steroids, fatty acids and 
prostaglandins as well as xenobiotics. (Mansuy 1998) For example, P450s 
can convert fatty acids and to their ω and/or ω-1 hydroxylated form (by the 
CYP4 family, Gibson et al 1982 Bains et al 1985), or be involved in drug 
metabolism (by the CYP2D subfamily) (Distlerath et al 1985).  
 
Cytochromes P450 are also found in other organelles such as the inner 
membrane of mitochondria where they are involved in steroid biosynthetic 
reactions and are mainly found in steroidogenic organs such as the adrenal 
glands. Cytochrome P450’s catalyse phase I oxygenation reactions in 
detoxification, a prerequisite for further phase II reactions involving 
glucoronidation and conjugation with glutathione, sulphate or glycine. 
 
P450-mediated metabolism not only catalyzes regiospecific and stereospecific 
oxidation of hydrocarbons but other reactions such as oxidative and reductive 
dehalogenation, N-hydroxylation and N-oxidation, oxidative deamination, S-, 
N- and O- dealkylation and aliphatic and aromatic hydroxylation are possible 
depending on the substrate. The most intensely researched of P450’s 
reactions is it’s mono-oxygenase activity The active center for catalysis is the 
iron –protoporphyrin IX (haem) with the thiolate of the conserved cysteine 
residue as fifth ligand. In the resting state P450’s are ferric. The catalytic cycle 
of the cytochrome P450 is shown in Figure 1.3.  
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Four steps are involved in the catalytic sequence. Substrate binding occurs 
first, which results in a change in the absorbance, redox potential and spin 
state of the haem group. Step 2 involves reduction of the iron atom to the 
ferrous state by the gain of an electron from NADPH via the reductase. The 
P450-substrate complex then binds molecular oxygen (step 3) whereby the 
superoxide is reduced by another electron, again from NADPH reductase. 
Complex rearrangement of the complex with the insertion of oxygen results in 
the final product, including either water or hydrogen peroxide.  
 
Substrate specificity and the type of reaction catalysed are governed by the 








Figure 1.3: Catalytic mechanism of P450 enzymes. Monooxygenase P450s catalyse the 
insertion of one of the atoms of molecular oxygen into a substrate, the second atom of oxygen 
being reduced to water. A major reaction catalysed by the P450s is hydroxylation (O 
insertion) involving the reactive and electrophilic iron-oxo intermediate (species [C], bottom 
row). The electrophilic hydroperoxo form of the enzyme (species, [B-]) also catalyses OH+ 
insertion. Nucleophilic attack can be catalysed by species [A]2 and [B] ; reduction, 
isomerisation or dehydration are catalysed by the oxygen-free forms of the enzyme. Copied 
from Werck-Reichhart and Feyereisen (2001) 
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Section 1.2.1 P450 Nomenclature 
 
The P450 super-family are subdivided and classified by Nelson and coworkers 
(1996) who have created a nomenclature system that is constantly reviewed and 
updated, on the basis of amino acid identity, phylogenetic criteria and gene 
organization. 
 
Originally discovered in rat liver microsomes (Klingenberg 1958) P450 genes 
exist in plants, animals and bacteria and yeast. P450 families are formed from 
proteins with 40% amino acid sequence identity. Subfamilies contain proteins 
that share 55% identity homology and P450 clans are formed from P450 genes 
that have diverged from a single common ancestor (Nelson et al 1996). Table 1.3 
lists the current number of genes found in a number of organisms. 
Organism Number of P450 genes 
Escherichia coli 0 
Saccharomyces cerevisiae 3 
Mycobacterium tuberculosis 20 
Caenorhabditis elegans 80 
Drosophilia melanogaster 83 
Arabidopsis thaliana 286 
Human 55 (25 pseudogenes) 
Table 1.3: Approximate number of P450 genes found in organisms. The number of genes reflect 
the process of gene duplication, amplifications, conversions, genome duplications, gene loss and 
lateral transfers. E.coli lacks any P450 genes, probably due to it’s origin in a oxygen free 
environment. 
 
P450s maybe divided into four classes based on the source of their reducing 
electrons. Class 1 proteins require FAD-reductase and an iron sulfur redoxin, 
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class 2 require FAD/FMN-containing P450 reductase, class 3 proteins require no 
electron donor, and class 4 proteins receiver electrons from NADPH. Class 2 
enzymes are the most common eukaryote P450 enzymes. P450 genes are 
classified first by the prefix CYP (‘Cyp’ for the mouse and Drosophila) describing 
it as a cytochrome P450, an Arabic number assigning a P450 family, a letter for 
the subfamily and an Arabic numeral representing the individual gene.  
 
Of the class 2 enzymes, the primary hepatic drug-metabolising enzymes 
currently consist of 4 gene families designated 1-4. Mouse Cyp4a12 refers to the 
cytochrome P450 gene number 12 of sub-family 4A. Genes of other species are 
scribed using italics and uppercased names e.g. CYP4A2 (in the rat). cDNA, 
mRNA and protein for all species are represented by Non-italicized and all capital 
letters. Although P450 gene family are classified based on 40% or more amino 
acid identity, exceptions include: the CYP2D subfamily which includes distant 
members of the CYP2 family, CYP4C1 (in the cockroach) is 32-36% identical to 
mammalian CYP4A and CYP4B enzymes (Bradfield et al 1991), but shares a 13-
amino acid peptide exclusive to CYP4As (Bradfield et al 1991) and CYP11A1 
and CYP11B1 (mitochondrial genes) which share 34-39% identity to the family 
sequences. 
 
CYP families in the human, rat, and mouse may also be split into two groups: 
those that show no variation in family or sub-family size (CYP1, CYP5 and 
higher) and those that exhibit variation (CYP2, 3 and 4). Most drug metabolising 
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enzymes are variable in size but those that are not are involved in the 
biosynthesis and metabolism of various endogenous compounds (Nelson 1999). 
 
Section 1.2.2 Cytochrome P450 4A subfamily 
 
The CYP4 family is related to the cholesterol metabolizing enzymes that are 
thought to have evolved about 1.25 billion years ago (Nerbert et al 1987). The 
Cyp4 gene family was first identified, after the sequence, and cloning of CYP4A1 
by Hardwick et al (1987). CYP4A1 was found to be expressed in the liver and 
kidney of the rat and its expression was inducible by the PP, clofibrate [2-(4-
chlorophenoxy)-2-methylpropionate]. The subfamily CYP4A encodes several 
cytochrome P450 enzymes that are capable of hydroxylating the terminal ω- and 
ω-1 carbon of saturated and unsaturated fatty acids and prostaglandins (Sharma 
et al 1989, Matsubara et al 1987). There are currently 26 genes in the CYP4A 
subfamily (table 1.4) although the current sequencing of the human genome is 
likely to identify several more CYP4 genes (Simpson et al 1997) 
 
The CYP4A subfamily genes are between 10-15kb in size and transcribe to 
mRNAs of approximately 1.5kb long. CYP4A proteins are comprised of 
approximately 509 amino acids. Expression of CYP4A varies between tissues 
and maybe subject to sex or tissue specific patterns. 
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Table 1.4 CYP4A Subfamily 
*: http://drnelson.utmem.edu/CytochromeP450.html 
P450 Species Tissue References 
4A1 Rat Liver, kidney 
ileum 
Kimura et al (1989). 
Hardwick et al (1987) 
 
4A1 Rabbit Aorta Irizar & Ioannides (1995) 
4A2 Rat Liver 
Kidney 
Kimura et al (1989). 
4A3 Rat Liver 
Kidney 
Kimura et al (1989). 
4A4 Rabbit Lung, Kidney, 
Uterus, Placenta 
Palmer et al (1993) 
Yoshimura et al (1990) 
Matsubara et al (1987) 
4A5 Rabbit Kidney, Liver, Small 
intestine 
Johnson et al (1990) 
Yokotani et al (1991) 
4A6 Rabbit Liver, Kidney Muerhoff et al (1992) 
Kikuta et al (1990) 
Yokotani et al (1991) 
Johnson et al (1990) 
4A7 Rabbit Kidney. Small 
intestine 
Liver 
Yoshimura et al (1990 Acc. No. 
AB017785) 
Yokotani et al (1989) 
Johnson et al (1990) 
4A8 Rat Prostate, Kidney, 
Retina 
Imaoka et al (1990) 
Stromstedt et al (1990) 
4A9 Human Liver Kawashima et al 1994 
4a10 Mouse Liver 
Kidney 
Henderson et al (1994) 
Bell et al (1993) 
Heng et al (1997) 
Yasumura et al (1998) 
4A11 Human Liver 
Kidney 
Palmer et al (1993) 
Bell et al (1993) 
Imaoka et al (1993) 
Kawashima et al (1994) 
Kikuta et al (1994) 
4a12 Mouse Liver 
Kidney 
Bell et al (1993) 
Heng et al (1997) 
Capdevila J. (1996) Abstract only 
4A13 Guinea Pig Liver Bell et al (1993) 
4a14 Mouse Liver, Kidney Heng et al (1997) 
Capdevila J. (1996) 
4A15 Koala Liver Ngo et al (2000) 
4A16 Cat Brain Gebremedhin et al (1997)* 
4A17 Hamster Liver Bell * 
4A18 Hamster Liver Bell* 
4a19 Hamster Liver Bell* 
4A20 Human  Gottgens B 2000* 
4A21 Pig Liver Lundell et al (2001)* 
4A22 Human  Kawashima et al (2000)* 
4A? Human  Grafham et al (2000) 
4A23 Pig Renal Van et al (2001)* 
4A24 Pig ?? Lundell (2001)* 
4A25 Pig ?? Lundell (2001)* 
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Section 1.2.3 Expression of Rat CYP4A genes 
 
CYP4A1 and 4A2 have been identified from genomic clones, while 4A3 and 4A8 
are cDNA clones. The CYP4A1 mRNA exhibits constitutive and inducible 
expression in the adult rat liver and kidney (Hardwick et al 1987, Kimura et al 
1989). CYP4A1 and 4A3 mRNA expression is induced by clofibrate, which like 
the constitutive expression is found in the centrilobular region (Kimura et al 1989, 
Bell et al 1991). However in the kidney the mRNAs of CYP4A1 and CYP4A3 are 
present at low levels, which are induced to liver levels after PP administration. In 
rat kidney CYP4A1 expression is localized in the proximal convoluted tubule (Bell 
et al 1991). Rat kidney CYP4A2 exhibits limited clofibrate inducibility (Kimura et 
al 1989). In addition to renal expression CYP4A2 has also been detected in male 
seminal vesicles, prostate, brain cerebellum, cortex and stem (Stromsteidt et al 
(1994). CYP4A2 is also expressed in a sex-specific manner with CYP4A2 mRNA 
not expressed in the liver or kidneys of female rats (Sundseth and Waxman 
1992). Hepatic CYP4A2 expression is suppressed by exposure to continuously 
high levels of growth hormone, which is present in female animals. In the kidney 
CYP4A2 expression is also male-specific but appears to be regulated by 
tesotosterone (Sunseth and Waxman 1992). 
 
Of the remaining rat CYP4A genes, 4A3 has been found in extraheptic tissues 
excluding the seminal vesicle (unlike 4A2), and 4A8 has been detected in the 
prostate, kidney and retina (Stromstedt et al 1994 and 1990).  
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Section 1.2.4 Expression of Mouse Cyp4a genes 
 
Henderson et al (1990) determined that mouse hepatic liver microsomes exhibit 
ω-hydroxylase activity in both control and MCP treated animals. Subsequent 
immunoblotting using a CYP4A1 antibody, detected an immunoreactive protein. 
The mouse homologue of CYP4A1, Cyp4a10 was identified by Bell et al (1993) 
using PCR to generate a cDNA clone. A full-length cDNA was determined later 
by Henderson et al (1994) using a full-length rat CYP4A1 cDNA probe to screen 
a mouse liver cDNA library. Methylclofenapate (MCP), a PP, was found to induce 
Cyp4a10 mRNA in mouse liver and kidney (Bell et al 1993). Cyp4a12 and 
Cyp4a14 were identified in mouse liver and found to be homologues of rat 
CYP4A8 and 4A2 respectively. Cyp4a14 is highly inducible by PPs in both male 
and female mouse liver (Heng et al 1997).  
 
CYP4A4, 4A5, 4A6 and 4A7 have been isolated in the rabbit and genomic 
sequences have been determined for CYP4A4 and 4A6. Rabbit 4A6, liver and 
kidney expression is low while CYP4A7 exhibits high constitutive expression in 
the liver, kidney and small intestine (Yokotani et al 1989; Roman et al 1993). 
Expression is induced by PPs in the liver and kidney for CYP4A6, CYP4A5 and 
liver for CYP4A7. In the guinea pig a partial cDNA clone was identified by Bell et 
al (1993), this was found to be non-inducible by MCP. Human CYP4A11 is 
expressed in the liver, kidney and lung (Palmer et al 1993, Imaoka et al (1993). 
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The mouse Cyp4a12 gene is expressed at high levels in the male liver and 
kidney and was not induced by treatment with MCP. However, there was a low 
level of expression of Cyp4a12 mRNA in the female liver and kidney, which was 
greatly induced by treatment with MCP (Bell et al, 1993).  
 
There is conflicting evidence about the sex-specific expression of the Cyp4a 




Mouse strain Constitutive expression pattern Author 
Cyp4a12 RNA CFLP Male-specific  Bell et al (1993) 
Cyp4a10 RNA CFLP Low level in both sexes Bell et al (1993) 
Cyp4a protein C57BL/6 Male specific Henderson et al (1994) 
Cyp4a protein ddY Male specific Hiratsuka et al (1996) 
Cyp4a protein C57BL/6 & Balb/c Found in both sexes Hiratsuka et al (1996) 
LAH activity ddY Male specific Hiratsuka et al (1996) 
LAH activity C57BL/6 & Balb/c Found in both sexes Hiratsuka et al (1996 
Cyp4a14 RNA NMC Low level in both sexes Heng et al (1997) 
Table 1.4. Mouse liver Cyp4a isoform, protein or LAH activity. A review of the literature 
indicates that Cyp4a RNA or protein expression is sex-dependent in a number of studies. 
However studies that determine Cyp4a protein levels use a non-specific polyclonal 
antibody to the rat CYP4A1 (Henderson et al 1994, Hiratsuka et al (1996). Conflicting 
evidence is derived from those studies that use a ribobrobe specific to a Cyp4a RNA 
isoform (Bell et al 1993 and Heng et al 1997). 
 
In ddY mice the hepatic level of Cyp4a related protein and LAH activity was 
higher in male mice than in female mice. No sex difference was observed in 
expression of Cyp4a related protein and LAH activity in mouse strains Balb/c and 
C57BL/6 (Hiratsuka et al 1996a). Renal Cyp4a related protein and LAH activity is 
greater in males than female mice although strain differences were not seen in 
the animals examined (ddY, Balb/c, C57BL/6, C3H/HeN and C3H/HeJ (Hiratsuka 
et al 1996b and Henderson et al 1990). In addition Henderson & Wolf (1991) also 
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described a female specific Cyp4a related protein detected in little testicular 
feminized mice (Tfm) when administered pulsatile growth hormone. Tfm animals 
possess a defunct androgen receptor, producing phenotypically female, yet 
genotypically males. Therefore not only it is unclear which protein is expressed 
but is it is also unclear how these genes are regulated. 
 
Male specific expression of hepatic Cyp4a related protein in ddy mice, absence 
of sex-specific expression in other strains, sex specific renal expression of Cyp4a 
protein without strain differences and the detection of a female specific Cyp4a 
protein in a transgenic animals suggest that the Cyp4a gene family is regulated 
in a sexually differentiated manner. It has been shown previously by RNase 
protection assay that Cyp4a12 is expressed at high level in a male-specific 
fashion in liver and kidney of mouse (Bell et al 1993). However Cyp4a10 has 
been shown to exhibit no sex- specific expression in the kidney suggesting that 
the use of polyclonal antibodies derived from CYP4A1, and LAH activity are not 
sufficient tools to investigate the expression and regulation of the different 
members of the Cyp4a family. It is also unclear what phenomenon gives rise to 
differential male-specific regulation of these genes in liver and kidney in the 
various mouse strains.  
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Section 1.2.5 Role of CYP4A in fatty acid metabolism and renal function 
 
Research has shown that P450 4A isoforms are the major mammalian 
arachidonic acid (AA) ω/ω-1 hydroxylases. Table 1.6 shows the metabolism of 
fatty acids and prostanoids by CYP4A isoforms. 
 
All 4A proteins catalyze AA ω-oxidation and most hydroxylate both the ω and ω-1 
carbons. This reaction generates hydroxyicosatetraenoic acids (HETEs), 
epoxyicosatetraenoic acids (EETs) and dihydroxyicosatet-raenoic acids (DHTs). 
CYP4A2, 4A3, and 4A8 exhibit different catalytic efficiencys for the production of 
20- and 19-HETE (Wang et al 1996 and Nguyen et al 1999). CYP4A1 exhibits 
the highest catalytic activity for 20-HETE formation, followed by 4A2 and 4A3. 
Arachidonic acid is not metabolized by CYP4A8 but catalyses the ω-
hydroxylation of short-chain unsaturated fatty acids, such as lauric acid. 
 
In the mouse targeted disruption of Cyp4a14 gene caused hypertension which 
was greater in males. Hypertension in Cyp4a14 -/- mice was sensitive to 
testosterone and was accompanied by induction of renal Cyp4a12, 20-HETE 
formation and renal vasoconstriction (Holla et al 2001).  
 
Arachidonic acids metabolites have been shown to have potent biological 
activities involved in renal vascular tone and platelet aggregation. For example 2-
HETE has been shown to be a potent vasoconstrictor in the renal and cerebral 
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microcirculations and an inhibitor of vascular calcium dependent K channels, a 
modulator of Ca2+ and Cl- fluxes and a mediator of EGF, vasopression, 
parathyroid hormone and norepinephrin signaling (Maier and Roman 2001, 
Moreno and Maier 2001). 
Table 1.6 Metabolism of fatty acids and prostanoids by CYP4A isoforms (Capdevila and 
Falck 2001) 
4A isoform Species Enzymatic activities 
4A1 Rat ω-oxidation of laurate and arachidonate 
4A2 Rat ω/ω-1 -oxidation of laurate and arachidonate 
4A3 Rat ω/ω-1 -oxidation of laurate and arachidonate 
4A8 Rat Unknown 
4A4 Rabbit ω-oxidation of palmitate, arachidonate and of prostaglandins A,E,D 
and F2α 
4A5 Rabbit ω/ω-1 -oxidation of laurate and palmitate some ω-oxidation of PGA1 
and arachidonate 
4A6 Rabbit ω/ω-1 -oxidation of laurate, palmitate, arachidonate and Low PGA1 
ω-oxidation. 
4A7 Rabbit ω/ω-1 -oxidation of laurate, palmitate, arachidonate and PGA1. 
Inactive towards PGE2 
4a10 Mouse ω-oxidation of laurate  
4a12 Mouse  ω-oxidation of laurate and arachidonate 
4a14 Mouse ω-oxidation of laurate 
4a11 Human ω-oxidation of laurate and arachidonate 
 
Section 1.2.6 Role of CYP4A in peroxisome proliferation 
 
Peroxisome proliferation involves an induction of the enzymes responsible for 
peroxisomal β-oxidation, and the ω-hydroxylation of fatty acids including CYP4A1 
(Bell and Elcombe 1991). The mechanisms, responsible for these changes are 
unclear but it has been speculated that CYP4A protein plays a pivotal role in 
peroxisome proliferation. Clofibrate-treatment results in lipid accumulation within 
the liver, similar to that seen in animals on a high-fat diet (Neat et al 1981). This 
observation supports the substrate overload hypothesis (figure 1.4) where the 
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fatty acid hydroxylase activity of CYP4A1 results in the production of long chain 
dicarboxylic acids in the cytosol. Mitochondrial β-oxidation is unable to 
metabolise these compounds and therefore peroxisomal β-oxidation is the 
preferred pathway (Kaikaus et al 1993). Peroxisomal β-oxidation of dicarboxylic 
acids results in fatty acids of shorter chain length available for mitochondrial 
metabolism (Lock et al., 1989; Sharma et al., 1988; Aoyama et al., 1990, Gibson 
et al 1991). CYP4A1 induction precedes acyl-CoA oxidase gene (Bell et al., 
1991; Bell and Elcombe, 1991). Primary hepatocyte studies using the protein 
synthesis inhibitor cyclohexamide show that after PP exposure CYP4A1 
induction is unaffected but acyl-CoA oxidase activity is absent suggesting that 












Figure 1.4 The role of CYP4A1 induction in peroxisome proliferation by hypolipidaemic 
agents (from Simpson 1997).
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It has been proposed that this induction of the fatty acid and β-oxidation 
metabolizing systems is an adaptive response by the hepatocyte to maintain 
cellular lipid homeostasis. 
 
CYP4A knockout mice will provide further information into their role in 
peroxisome proliferation and physiological systems. This has already been done 
in the case of Cyp4a14 -/- mice and the regulation of hypertension by Cyp4a 
genes  (Holla et al 2001). 
 
Section 1.3 The steroid hormone receptor super family 
Steroid hormone receptors (SHR) are structurally similar intra-cellular receptors 
that are ligand dependent transcription factors, which regulate gene expression 
SHRs play an important role in cell differentiation, and homeostasis. The nuclear 
hormone receptor super family represents the largest group of eukaryotic 
transcription factors and includes receptors for thyroid and steroid hormones, 
retinoids and vitamin D (Aranda et al 2001). In addition this super family includes 
receptors for which there is no identified ligand (e.g. NGFI-B). An example of the 
importance of these SHR is provided by the generation of transgenic mice which 
contain either mutant or are null for a specific receptor. ERα and β -/- mice 
provide an example of the importance of these SHR in reproductive function 
(Krege et al 1998, Lubahn et al 1993, Couse and Korach et al 1999). 
 
SHRs exhibit a modular structure with different regions for functional domains 
(figure 1.5). 
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Figure 1.5 Functional domains of nuclear hormone receptors. The variable NH2-terminal region 
(A/B) contains the ligand-independent AF-1 transactivation domain. The C region is the 
conserved DNA binding domain (DBD), which is responsible for the recognition of specific DNA 
sequences. Region D connects the DBD to the conserved E/F region that contains the ligand-
binding domain (LBD) as well as the dimerization surface. The A/B region contains the ligand-
independent transcriptional activation domain, and the ligand-dependent AF-2 core 
transactivation domain within the COOH-terminal portion of the LBD.No specific function of the 
variable C-terminal F domain has been determined. (Modified from Aranda and Pascual 2001). 
 
Section 1.3.1 Peroxisome proliferator activated receptors (PPARs) 
 
Isseman and Green et al (1990) first isolated the mouse PPARα (mPPARα) gene 
using a probe similar to other nuclear receptors to screen a mouse cDNA library. 
Since then several related PPAR subtypes have been isolated in different 
species e.g. Xenopus (Dreyer et al 1992), Rat (Gottlicher et al 1992), Hamster 
(Aperlo et al 1995), and human (Schmidt et 1992, Sher et al 1993, Greene et al 
1995). These receptors are members of the steroid hormone super family of 
ligand-activated transcription factors. Based on the mechanism of regulation of 
steroid hormone, it has been proposed that mPPARα mediates peroxisome 
proliferation in the mouse (Isseman and Green 1990). Full length PPARα cDNA 
encodes a 468 amino acid protein with a predicted molecular weight of 52kDa. 
A/B C D E F 
N C 
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Based on the analysis of the highly conserved DNA- and ligand-binding domains, 
the PPARs have been assigned to a subfamily of nuclear receptors that include 
the retinoic acid receptors (RARs), the thyroid hormone receptors (THRs) and 
the revErbAα-related orpan receptors (Laudet et al 1992, Desvergne and Wahli 
1995). Isseman and Green (1990) proposed that PPARα mediates the 
peroxisome proliferator after it was found that PP transcriptionally actives a 
reporter gene under the control of the chimeric receptor hER-PPARα which 
contains the putative ligand binding domain of PPARα and the N-terminal 
sequence and DNA-binding domain of human estrogen receptor (ER). A Vit-G-
CAT reporter plasmid that contains the bacterial chloramphenicol 
acetyltransferase (CAT) gene was used to screen activators for PPARα which 
included nafenopin, MCP, clofibrate, Wy-14,643, MEHP and trichloroacetic acid. 
 
Section 1.3.2 PPARs and tissue-specific expression 
 
PPAR may occur in three different isotypes α, β/δ, and γ. In the adult rat and 
mouse in situ hybridization and RNase protection assays showed that PPARα is 
predominantly expressed in brown adipose tissue, liver, kidney, duodenum, 
heart, skeletal muscle. PPARγ expression is mostly expressed in brown and 
white adipose tissues but is also found at lower levels in the large intestine, 
retina, and immune system. PPARβ/δ is the most ubiquitously expressed PPAR 
found in greater amounts that α or γ in all tissues except adipose tissue (Jones et 
al 1995, Braissant et al 1996). Two distinct isoforms of PPARγ (PPARγ1 and 
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PPARγ2) have been identified in mouse, rat and human. Both human and rat 
PPARγ1 and PPARγ2 are homologues of mouse PPARγ1 and PPARγ2 
respectively, and have been shown to be the products of alternative promoter 
usage and differential splicing. In other species PPARγ mRNA expression has 
also been found in adipose tissue of the rat, mouse and hamster (Kliewer et al., 
1994 Tontonoz et al 1994a and 1994b, Aperlo et al 1995; Elbrecht et al 1996, 
Mukherjee et al 1997). 
 
Differing levels of PPAR tissue expression suggests that they have different 
physiological roles. Adipose tissue is the major site of lipid homeostasis and the 
expression of PPARα and γ suggests that these receptors are involved in 
adipose tissue differentiation and fat storage. In addition to the involvement of 
PPARα in peroxisome proliferation, this receptor has been shown to be involved 
in fatty acid oxidation and ketone body synthesis as demonstrated in fasted 
PPARα knockout mice (Kersten et al 1999, Leone et al 1999). PPARγ and 
PPARα have also been found in atherosclerotic lesions suggesting that both 
these receptors are involved in the vascular disease (Tontonoz et al 1998, Ricote 
et al 1998, Fruchart et al 1999). 
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Section 1.3.3 PPARα activation and mechanism of gene expression 
 
The mechanism of PPARα gene expression is thought to be via the classical 
pathway for nuclear hormone receptors. In the cytosol PPARα binds to ligand. 
PPARα form heterodimers with the 9-cids retinoid X-receptor (RXR) (Bardot et al 
1993, Gearing et al 1993). Phosphorylation of the ligand-binding domain of 
PPARα enhances transcriptional activation (Shalev et al 1996, Juge-Aubry et al 
1999). The PPARα-RXR heterodimer binds to DNA specific sequences, called 
peroxisome proliferator response elements (PPREs). PPRE’s reside in the 5’-
flanking sequence of those genes that are regulated by peroxisome proliferators 
(Tugwood et al 1992, Osumi et al., 1991, Green, 1992). Functional PPREs are 
comprised of two copies of the binding motif hexanucleotide TGA(A/C/T)CT, 
separated by a single nucleotide (Bardot et al 1993, Muerhoff et al 1992, Zhang 
et al 1992). This arrangement is typical of other nuclear receptor response 
elements, including those for the thyroid hormone, vitamin D or retinoid X 
receptors (Umesono et al 1991, Yu et al 1992). Activated PPARα-RXR binds to 
the PPRE located upstream of the peroxiosme proliferator target gene leading to 
an increase in the transcription rate of the gene. Target genes of PPARα include 
rabbit CYP4A6 (Muerhoff et al 1992), rat CYP4A1 (Aldridge et al 1995), rat HMG-
CoA synthase (Rodriguez et al 1994), human fatty acyl-CoA oxidase (see table 
1.7).  
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Gene  PPRE sequence Reference 
Rat CYP4A1  TCCCCT C TGACCT Aldridge et al., 1995 
Rabbit CYP4A6 (z-element)  TCAACT T TGCCCT Muerhoff et al., 1992 
Rabbit CYP4A6  TGACCC T TGCCCA Palmer et al., 1994 
Rat acyl-CoA oxidase TGACCT T TGTCCT Tugwood et al., 1992 
Human fatty acyl-CoA  AGGTCA G CTGTCA Varanasi et al., 1996 
Rat acyl-CoA synthase TGACTG A TGCCCT Schoonjans et al., 1995 
Rat malic enzyme  GGACCT G TGCCCT Castelein et al., 1994 
Rat fatty acid binding protein TGACCT A TGGCCT Issemann et al., 1992 
Rat acyl CoA binding protein TCACCT T TGCACT Elholm et al., 1996 
HMG-CoA synthase  AGACCT T TGGCCC Rodriguez et al., 1994 
Human apolipoprotein A-I  TGACCC C TGCCCT Vu-Dac et al., 1994 
Human apolipoprotein C-III  TGACCT T TGCCCA Hertz et al., 1995 
Rat apolipoprotein C-III  TGACCT T TGACCA Hertz et al., 1995 
Human lipoprotein lipase  TGCCCT T TCCCCC Schoonjans et al., 1996 
 
Table 1.7 PPRE sequences in PPARα responsive genes. Sequences of functional PPRE 
identified in the promoter region of peroxisome proliferator responsive genes.  
 
Regulation of genes induced during peroxisome proliferation and the ω -oxidation 
of fatty acids is therefore by PPAR binding to specific DNA regulatory elements 
located in the upstream promoter region of these genes (Johnson et al 1996, 
figure 1.6). Gene regulated by PPRE’s may contain sequences that are not 
uniform, as they may differ by five nucleotides at a maximum (Table 1.6). Work 
by Isseman et al (1993), Palmer et al (1994) and Chen et al (1995) indicates that 
1-2 nucleotide mutations can reduce or abolish response to peroxisome 
proliferation. 
 
PPAR-ligand complexes result in conformational changes in receptor that lead to 
coactivation by cofactors such as steroid receptor coactivator 1 (SRC-1, Nolte et 
al 1998). SRC-1 interacts in a ligand dependent manner and exhibits intrinsic 
histone acetyltransferase activity, which modifies chromatin structure and 
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transcription factor gene expression (Onate et al 1995, Spencer et al 1997, Krey 













Figure 1.6. Cartoon of PPARα and its heterodimerization partner, RXRα, on a PPRE. The 
PPAR/RXR heterodimer binds to PPRE located in the promoter region of the PP-responsive gene 
through the C domain (DNA-binding domain) of PPAR and RXR. Phosphorylation of the receptor 
A/B and E/F domains regulates receptor activation. PPAR/RXR heterodimers with cofactors (e.g. 
SRC-1) containing histone acetyl-transferase activity (HAT) modify chromatin structure and 
transcription of transcription factors (RNA polymerase II).(Modified by Escher and Wahli 2000). 
 
Section 1.3.4 PPARα knockout mice 
 
The generation of PPARα null mice by Lee et al (1995) has done much to 
increase understanding of this receptor in peroxisome proliferation and lipid 
metabolism. The targeted disruption of the PPARα LBD in these mice results in 
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exhibit no detectable gross phenotypic defects but do not display the pleiotrophic 
effects of peroxisome proliferation, induction of any known target gene, and 
hepatocarcinogenesis (Gonzalez 1997,Peters et al 1997, Gonzalez et al 1998). 
PPARα null mice administered Wy-14,643 or clofibrate do not exhibit induction of 
acyl-CoA oxidase, bifunctional enzyme, CYP4A and fatty acid binding protein. 
PPARα null mice display a normal level of peroxisomes compared to wild types. 
PPARα null mice fed a high  fat diet for 10 weeks show massive accumulation of 
lipid in their livers. Starvation for 24 hours also displayed symptoms of fatty acid 
metabolism inhibition. These included hypoglycemia, hypoketonia, hypothermia, 
and elevated plasma free fatty acid levels (Kersten et al 1999). This study and 
others demonstrate that PPARα is a vital regulator of the genes involved in 
hepatic fatty acid oxidation in both peroxisomes and mitochondria (Aoyama et al 
1998; Peters et al 1997; Leone et al 1999, Kroetz et al 1998, Hashimoto et al 
1999). 
 
Bacterial endotoxin (lipopolysaccharide, LPS) increases levels of CYP4A mRNA 
and protein levels in Fischer 344 and Sprague-Dawley rats (Sewer et al 1996). 
Metabolism of arachidonic acid by CYP4A genes results in the formation of 
HETEs (McGiff et al 1999). These compounds have been shown to be mediators 
of the inflammatory response (Borish et al 1992, Capdevila et al 1992). Studies 
using PPARα null mice demonstrate that PPAR α is required for endotoxin-
induced renal expression of the Cyp4a gene, and endotoxin-induced 
inflammation is attenuated in knock out mice (Devchand et al 1996 Barclay et al 
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1999). PPARα null mice offer the opportunity to determine the molecular basis of 
lipid metabolism, inflammation and peroxisome proliferation. 
 
Section 1.3.5 Sex-specific gene expression  
 
Section 1.3.5.1  Cyp2d9 
 
Cyp2d9 is a member of the testosterone 16α-hydroxylase gene family which is 
4.5-5.2 kbp in size and consists of nine exons with junctions at identical sites 
(Wong et al 1989, Yoshioka et al 1990, Harada and Negishi 1984). Cyp2d9 
expression is male specific and androgen dependent in mouse liver and kidney 
and shares the same enzymatic activity as the female specific CYP2B gene 
(Park et al 1999). Cyp2d9 male specific expression in the liver is under the 
positive influence of pulsatile GH pulses. Cyp2d9 male-specific gene expression 
is thought to be regulated by the association between the DNA binding factors 
NF2d9 and GABP and a cis-acting element designated SDI (sex difference 
information). This contains a CpG site that is preferentially de-methylated in 
males (Noshiro et al 1986, Yoshioka et al 1991, Yokomori et al 1995, Gonzalez 
and Lee 1996). 
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Section 1.3.5.2  Sex-limited protein (Slp) 
 
The SDI element is shared by another sex-specific gene, Slp. Slp is a mouse 
serum protein encoded by a major histocampatibility complex class III gene and 
is thought to be involved in the EDTA-resistant complement activation pathway 
(Van der Berg et al 1992, Beurskens et al 1999). Slp is predominantly expressed 
in male liver and peritoneal macrophages but it is also present in the mammary 
gland, lung, spleen, and kidney. Lower levels are found in the testis, brain, heart, 
and submaxillary gland (Cox and Robins 1988). Slp may also be expressed in 
female mice who are homozygous recessive for the rsl gene (Jiang et al 1996). 
In hypophysectomised mice, Slp expression is refractory to testosterone but not 
growth hormone. In addition Slp expression is abolished in Tfm mice, which are 
absent of plasma GH. Hormonal treatment of these mice restores Slp expression 
independent of testosterone (Georgatsou et al 1993). Slp and Cyp2d9 share the 
same conserved sequence TTCCGGGC in their 5’-flanking regions in DBA/2 and 
CD-1 mice. Male-specific gene expression is thought to be regulated by SDI 
containing a CpG site that is preferentially de-methylated in males and binding of 
STAT5 (Yokomori et al 1995, Varin-Blank et al 1998). 
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Section 1.3.5.3  Mouse urinary protein (MUP) 
 
MUP is a family of α2-microglobulin-related liver secretory proteins that comprise 
a major protein component of mouse urine. In male mouse urine MUP protein 
levels are approximately 3-fold greater than in female urine. Male MUP liver 
mRNA is 6-fold greater than female liver (Derman 1981). Induction of MUP by 
pulsatile plasma GH has been demonstrated using GH-deficient Little mice 
(Norstedt and Palmiter 1984). Little mice have very low levels of MUP, and GH 
replacement by intermittent injection (pulsatile administration) increases MUP to 
normal male levels (Norstedt and Palmiter 1984). MUP and α2u-globulin have 
both been implicated in male specific hyaline droplet nephropathy caused by 2-
sec-butyl-4,5-dihydrothiazole (Lehman-McKeeman et al 1998) 
 
Section 1.3.6 Regulation of sex-specific gene expression 
 
To fully understand the interspecies and intraspecies differences in P450 
expression, the molecular mechanisms of gene expression is necessary. Several 
cytochrome P450’s are subject to hormonal regulation and sex-dependent 
expression. In the rat CYP2C11 (testosterone 16α and 2α-hydroxylase exhibits a 
male specific expression and CYP2C12 (steroid sulfate 15β-hydroxylase) 
expression is female specific (Sundseth et al 1992,Waxman et al 1996, Sasaki et 
al 1999, Agrawal and Shapiro 2000).  
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In the mouse Cyp2d9 (testosterone 16α-hydroxylase) and Cyp2a4 (testosterone 
15α-hydroxylase) is expressed in the male and female liver, respectively (Wong 
et al 1987, Noshiro et al 1986). Sexual dimorphic expression of liver cytochrome 
P450s is primarily determined by the differential pattern of plasma growth 
hormone (GH) secretion (Furukawa et al 1999). Growth hormone under the 
control of the suprachiasmatic nucleus (SCN) is excreted in a pulsatile manner in 
males (interpulse interval ~2.5h) and continuously in females (interpulse interval 
<1h).  
 
STAT5, a member of the Signal transducers and activators of transcription family 
(Horvath and Darnell 1997) is activated by pulsatile GH in the rat liver. Using 
western blotting it has been shown that STAT5 under the influence of pulsatile 
GH is translocated from the cytosol to the nucleus (Waxman et al 1995). 
Electromobility shift assays (EMSA) demonstrated that pulsatile GH activates the 
DNA binding activity of STAT5 (Ram et al 1996). Two homologous STAT5 genes 
have been identified, STAT5a and STAT5b (~90% sequence homology; Mui et al 
1995, Azam et al 1995). STAT5 is predominantly 5b isoform (Ram et al 1996, 
Ripperger et al 1995). Knockout mice have been generated by target disruption 
of the STAT5b and STAT5a genes (Udy et al 1997, Park et al 1999). The 
characteristic spurt in growth is absent in male STAT5b null mice that exhibited 
reduced growth from 3 weeks of age. Male-specific gene expression is also 
reduced in STAT5b mice (Park et al 1999). Northern blot analysis revealed that 
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Cyp2a4 expression was increased in STAT5b null male mice. Cyp2d9 protein 
concentrations were reduced in STAT5b null male mice; this protein in wild type 
mice is expressed in a male-specific pattern in mouse liver under the influence of 
plasma GH pulses (Udy et al 1997, Noshiro et al 1986). Levels of mouse urinary 
protein (see section 1.3.6) were reduced to female levels demonstrating that 
STAT5b is required for the male specific pulsatile GH induction of MUP. These 
results indicate that STAT5b, and specifically the formation of STAT5b-STAT5b 
homodimers play an essential role in mediating sexual dimorphism of body 
growth rates and liver gene expression. Cyp2d9 and MUP protein levels were not 
restored to male wild type levels when hypophysectomized STAT5b null mice 
were administered pulsatile GH further demonstrating that STAT5b is an 
important regulator of male specific gene expression (Davey et al 1999). STAT5a 
disruption was found to result in no loss of expression in male mice of Cyp2d9 
and no feminization of male livers (absence of CYP3A induction, Park et al 
1999). 
 
Work by Zhou et al (1999a/b) has investigated the potential cross talk between 
JAK-STAT (Janus Kinase-Signal Transducer and Activator of Transcription) and 
PPARα. Using COS-1 cells containing expression plasmids encoding growth 
hormone receptor (GHR), JAK2 kinase and STAT5b, and mouse PPARα, it was 
found that GH-activated STAT5b reduces the activation of the CYP4A6 promoter 
by Wy-14,643. GH was also found to inhibit PPARα induction of enoyl-CoA 
hydratase/3-hydroxyacyl-CoA dehydrogenase. However the mechanism for 
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these observations is not clear, as no interaction between STAT5b and PPARα, 
was determined by EMSA. STAT5b and PPARα do not compete for coactivators 
including SRC-1 or p300 but STAT5b was found to inhibit the ligand independent 
activation of the AF-1 domain of PPARα as shown using a chimera of yeast 
GAL4-CAT and AF-1. (Zhou et al 1999).  
 
Identification of Cytochrome P450 genes that exhibit sex-specific expression will 
provide model systems to further elucidate the molecular mechanisms of the GH-
STAT5b pathway.  
 
Section 1.4 Aims of the thesis 
 
Section 1.4.1 Cyp4a gene expression  
 
So far three members of the Cyp4a family have been identified in the mouse 
(Henderson et al 1994, Bell et al 1993, Heng et al 1997). There is conflicting 
evidence about the sex-specific expression of the Cyp4a protein and LAH 
activity. In ddY mice the hepatic level of Cyp4a related protein and LAH activity 
was higher in male mice than in female mice. No sex difference was observed in 
expression of Cyp4a related protein and LAH activity in mouse strains Balb/c and 
C57BL/6 (Hiratsuka et al 1996a). Renal Cyp4a related protein and LAH activity is 
greater in males than female mice although strain differences were not seen in 
the animals examined (ddY, Balb/c, C57BL/6, C3H/HeN and C3H/HeJ (Hiratsuka 
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et al 1996b and Henderson et al 1990). In addition Henderson & Wolf 1991 also 
described a female specific Cyp4a related protein detected in ‚little™ testicular 
feminized mice (Tfm) when administered pulsatile growth hormone. Tfm animals 
possess a defunct androgen receptor, producing phenotypically female, yet 
genotypically males. Therefore not only it is unclear which protein is expressed 
but is it is also unclear how there genes are regulated. Male specific expression 
of hepatic Cyp4a related protein in ddy mice, absence of sex-specific expression 
in other strains, sex specific renal expression of Cyp4a protein without strain 
differences and the detection of a female specific Cyp4a protein in a transgenic 
animals suggest that the Cyp4a gene family is regulated in a sexually 
differentiated manner. It has been shown previously by RNase protection assay 
that Cyp4a12 is expressed at high level in a male-specific fashion in liver and 
kidney of mouse (Bell et al 1993). However Cyp4a10 has been shown to exhibit 
no sex- specific expression in the kidney suggesting that the use of polyclonal 
antibodies derived from CYP4A1, and LAH activity are not sufficient tools to 
investigate the expression and regulation of the different members of the Cyp4a 
family. It is also unclear what phenomenon gives rise to differential male-specific 
regulation of these genes in liver and kidney in the various mouse strains. A 
more detailed knowledge of the murine Cyp4a gene family is essential for 
understanding the regulation and physiology of Cyp4a in mice or for establishing 
strategies for analysing the Cyp4a gene family in transgenic mice. 
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The aim of this study is to examine the expression of the Cyp4a12 gene in 
several inbred mouse strains in order to describe any strain or sex differences 
and determine whether Cyp4a12 is the gene, which exhibits sex and strain 
differences in expression  
 
Section 1.4.2 Immediate early gene (IEG) induction and PP-induced DNA 
synthesis. 
 
Several studies have shown that the PP, ciprofibrate induces DNA synthesis in 
vivo. Dietary administration of ciprofibrate to C57BL/6 mice for 2 weeks resulted 
in a 9 and 8-10-fold increase in peroxisomes and β-peroxisomal enzymes 
respectively. Chronic dietary administration of 0.025% w/w (15 months) followed 
by 0.0125% w/w ciprofibrate (6 months) resulted in a 57% incidence of hepatic 
adenomas and 21% hepatocellular carcinomas (Rao et al 1988). C57BL/6 and 
Balb/c male mice administered dietary ciprofibrate from 0.1-250ppm exhibited 
DNA synthesis at doses of >100ppm and 1ppm respectively over a 4-day period 
(Budroe et al 1992). Male F-344 rats (n=8) fed ciprofibrate (0.025% w/w) for 1-70 
weeks exhibited a biphasic pattern on hepatocyte proliferation. Labeling indices 
of hepatocyte nuclei revealed by [3H]-thymidine labeling, were increased by 35% 
(with a 170% increase in liver weight) after 1 week dosing. No such increase was 
seen in animals given ciprofibrate for 5 or 20 weeks. After 40 and 70 weeks 
labeling indices in ciprofibrate treated rats was significantly different to control 
animals coinciding with the appearance of preneoplastic changes (Yeldandi et al 
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1989). F-344 rats given 0.025% w/w ciprofibrate for 4 or 7 days showed a 2 and 
4.4 induction of DNA synthesis respectively (Rao and Subbarao 1997). As 
discussed in section 1.1.5 induction of DNA synthesis by PPs coincides with an 
increase in the 2X2N (binucleated) hepatocyte population (here N=chromosome 
number, Styles et al 1990, Styles et al 1990, Styles et al 1991). 25mg/kg bw 
MCP administered by gavage at time points 0,24,48 hours to wild type Snell 
dwarf mice resulted in an increase of hepatocytes in S-phase which peaked at 36 
hours but returned to near control levels after 72 hours (Styles et al 1990).  
 
Further to studies investigating PP-induced DNA synthesis in the liver, work has 
since focused on changes in expression of genes or proteins involved in the 
regulation of the cell cycle. Ciprofibrate (0.0125% w/w) administered for 2 years 
resulted in tumours that contained point mutations for the H-ras and K-ras genes 
dissimilar to those found in tumours caused by genotoxic carcinogens as found 
by oligonucleotide hydridisation analysis (Hegi et al 1993). PPs, nafenopin, and 
cyproterone acetate induced hepatocyte hyperplasia was not accompanied by an 
increase in the expression of c-jun or c-fos genes when administered orally (200 
and 60mg/kg bw respectively, Coni et al 1993). However a more potent PP, Wy-
14, 643 increased c-fos c-jun, jun-B and jun-D mRNA expression in vitro 1 hour 
post-administration demonstrating that the route and relative peroxisome 
proliferation potency determines the induction of IEG (Ledwith et al 1993,1996). 
Induction of CDK1 and PCNA proteins occurred within 24 hours when male 
Sprague-Dawley rats were administered 45mg/kg bw/day Wy-14, 643 indicating 
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that PP induce proteins associated with regulation of the cell cycle (Rininger et al 
1996). IEG expression and induction of DNA synthesis by PP was found to 
correlate when male F344 rats were given diethylhexyl phthalate (DEHP) and 
carbon tetrachloride. c-myc mRNA expression was detected 1 hour post-dose 
providing further evidence for the involvement of IEG in PP-induced DNA 
synthesis (Hasmall et al 1997). In F344 rats administered a single dose of 
100mg/kg bw (oral) Wy-14,643, levels of cell cycle proteins CDK1 and PCNA 
were increased 4.2 and 3.3-fold 48 hours post dose. p53, a protein implicated in 
regulation of the cell cycle and detection of DNA damage was found to be 
induced 24-36 hours after dosing (Rininger et al 1997). Studies using PPARα 
knockout mice have demonstrated that this receptor is required for PP-induced 
hepatocarcinogenesis (Peters et al 1998). Immediate early genes and cyclin 
dependent kinases are candidates for initiating the proliferative response (Holden 
et al 1998) however differences are observed in gene expression, for example c-
myc, in vitro and in vivo (Ledwith et al 1993,1996, Belury et al 1998).  
 
While these studies have identified genes or proteins that may mediate 
hepatocyte proliferation during peroxisome proliferation the molecular 
mechanisms involved are still unclear. This thesis aims to establish a time course 
for the immediate induction of DNA synthesis by the PP, ciprofibrate and 
determine changes in gene expression that mediate the hepatic proliferative 
response. 
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Chapter 2 Materials and Methods 
 
Section 2.1 Materials 
 
Section 2.1.1 General Materials 
 
All chemicals were obtained at the highest grade possible. [α-32P] CTP (>600 
Ci/mmol) was obtained from ICN. DNase-free RNase A>30 units/mg protein was 
obtained from Boehringer Mannheim. Ciprofibrate (synthesised by Sanofi-
Winthrop Ltd, Alnwick, Northumberland, UK.) was a kind gift of Dr.T.J.B. Gray. 
Oligonucleotides were synthesised by J.Keyte of the Biopolymer synthesis and 
analysis unit, Department of Biochemistry, University of Nottingham. UHP grade 
water > 13MΩ/cm was produced using a Purite Select Biosystem. DEPC water 
was produced by adding 1ml of diethyl pyrocarbonate (Sigma), dissolved in 5ml 
ethanol, to 1 litre of water. This was allowed to stand for 1 hour at 37°C and was 
then autoclaved for 1 hour. Sequagel stock acrylamide solution (19:1 
acrylamide:bisacrylamide) up to 20% was obtained from National Diagnostics. 
Lithium chloride , bromophenol blue, Ethanol and formamide were obtained from 
BDH. Sodium acetate, glacial acetic acid, boric acid, methanol, anhydrous di-
sodium hydrogen orthophosphate ammonium acetate, sodium chloride, phenol 
and chloroform were from Fisher Scientific International. Magnesium Chloride 
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was from Fisons Scientific Equipment. Dithiothreitol (DTT), 100bp ladder, 1Kb 
ladder, proteinase K, urea and Tris base were from Gibco Life Technologies. 
Isoamyl alcohol, sodium dodecyl sulphate, N,N,N’,N’-tetramethylethylenediamine 
(TEMED), ammonium persulphate, imidazole, xylene cyanole, 1,4-piperazine-
diethanesulphonic acid (PIPES), N-[2-hydroxyethyl]piperazine -N’[2—
ethanesulphonic acid], ethylenediamine-tetraacetic acid (EDTA), spermidine, 
tetracycline, ampicillin and ethidium bromide were obtained from Sigma. 
Agarose, EcoRI and SuRE/Cut Buffer H were from Boehringer Mannheim. ADP, 
dNTP’s, yeast tRNA, RNase guard, SP6 RNA polymerase (40300units/ml), 
RNase A (40µ/mg) and Ficoll were from Pharmacia Biotech. [α-32P]CTP specific 
activity - 800 Ci/mmol was from ICN. Liquid scintillation counter cocktail was from 
Parkard. Bacto-tryptone and bacto-yeast extract were from Difco. Klenow DNA 
polymerase (5-10U/µl), DNase 1 (1µ/µl) and the PGEMT-Easy vector cloning 
systemwere from Promega. 
 
Section 2.1.2 Plasmids 
 
PCR fragments of Cyp4a10 and Cyp4a1 in cloned pGEM7 (Promega) were 
described in Bell et al (1993). Cyp4a14 was isolated as described by Heng et al 
(1997). Genomic clones were initially isolated from a genomic library using 
riboprobes transcribed from Cyp4a10 and Cyp4a12 partial cDNA clones, 
originally described in Bell et al (1993). Since the exon sequences were distinct 
from both Cyp4a10 and Cyp4a12, this proved that l clone was part of a novel 
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murine gene. This gene has been designated Cyp4a14 by consultation with the 
Cytochrome P450 nomenclature committee A genomic clone of Cyp4a14 was 
cloned into pGEM7 in our laboratory to give the plasmid pGEM.4a14. This 
contains the 3’ non-coding region of the gene including all of exon 11 and half of 
exon 12. 
 
Section 2.1.4 Bacterial Genotypes 
 
The E.coli strains below had the following genotypes and were obtained from 
Stratagene. 
 
XL-1 Blue {recA1 and A1 gyrA96 thi -1 hsdR17 supE44 rel A1 lac [F’ proAB 
lacIq20M15 Tn10(Tetr); XL-1 Blue MRA {D(mcrA) 183, D (mcrCB-hsdSMR-
mrr)173,end A1, supE44, thi-1,gyrA96,relA1,lac}; XL-1 Blue Sure{e14-(mcrA-
)D(mcrCB-hsdSMR-rnrr)171 and A1 supE44 thi-1 gyrA96 rel A1 lac rec B rec J 
sbc C unu C::Tn5 (Kar)uvr C [F’ proAB lacIq2 DM15 Tn10 (Ter)} 
 
Section 2.1.5 Storage of Bacterial Strains 
 
Glycerol stocks were made by placing 10% glycerol into the bacterial culture, and 
storing at -80°C. 
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Section 2.2 Methods 
 
Section 2.2.2 Bacterial growth Media 
 
Luria-Bertani Broth (LB) consisted of: 10g Bactotryptone, 5g Bacto yeast extract, 
10g NaCl, and made up to 1 litre with Ultra High Pure (UHP) water and 
autoclaved. To make LB-Agar plates; 15g agar was added to 1 litre of LB and 
then autoclaved. Media was melted, antibiotics added and poured into 10cm petri 
dishes. Antibiotics were used at the following final concentrations; Tetracycline: 
50ug/ml; Ampicillin 10µg/ml; Kanamycin 12.5µg/ml Chloramphenicol 4µg/ml For 
blue/white selection 40µl of a 20mg IPTG solution and 40µl of 20mg/ml 5-bromo-
4-chloro-3-indolyl-b-D-galactoside (X-gal) solution was added per plate.  
 
Section 2.2.2.1 Preparation of competent XL-1 blue E.coli cells using CaCl 
 
Single colonies of XL-1 Blue E.coli were inoculated in 10ml of LB-Tet/Amp media. 
Cultures were grown over night in a shaking incubator at 37oC. A 500ml culture 
of LB/tetracycline medium was inoculated with 1ml of the fresh overnight culture 
of bacteria and grown until an OD600 of 0.6-0.8 was reached (300 cycles/minute 
in a rotary shaker). For efficient transformation, it is essential that the number of 
viable cells should not exceed 108 cells/ml. To monitor the growth of the culture, 
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determine the OD600 every 20-30 minutes. The cultures were placed on ice for 15 
minutes and then centrifuged at 4000g for 15 minutes at 4oC. The supernatant 
was decanted off and tubes were inverted to allow the last traces of media to 
drain. Pellets were then resuspended in 1ml ice cold 0.1M CaCl2 and kept on ice. 
Tubes were then spun at 4000g at 4oC for 10 minutes. Supernatant was 
decanted off the pellets and the tubes were inverted to drain traces of fluid. 
Pellets were resuspended in 2ml of ice cold 0.1M CaCl2 and dispensed into 
aliquots and stored at -80oC. Alternatively the cells were used immediately for 
transformation (section 2.2.3). The cells maintain competency under these 
conditions. 
 
Section 2.2.2.2 Transformation of Calcium competent E.coli 
 
500µl of competent cells were thawed on ice. 50ng in less than 10µl vol. (0.1M 
Tris pH 8.0) was added to 100ul of cells and placed on ice for 10 minutes. The 
cells were then heat shocked at 42oC for 90 seconds and then placed 
immediately on ice for 2 minutes. 900µl of L-Broth (-Amp) was added to the cells 
and the cells were cultured for 1 hour at 37oC. Dilutions of cells were then plated 
out on to L-Broth and Ampicillin and Tetracycline petri dishes. Plates were 
incubated overnight at 37oC. 
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Section 2.2.3 Preparation of electro-competent XL-1 blue E.coli 
 
Colonies were treated as in section 2.2.2.1, except that after the first 
centrifugation the pelleted cells were resuspended in 50ml of ice-cold sterile UHP 
water. Cells were then pelleted by centrifugation at 4000g for 15 minutes at 4oC 
and re-suspended in ice-cold sterile UHP water a further 5 times. Cells were 
finally re-suspended in 2ml of sterile UHP water, 20% glycerol and stored as 
200µl aliquots at -80oC. 
 
Section 2.2.4 Electro-transformation of  XL-1 blue E.coli 
 
An aliquot of XL-1 Blue electro-competent cells was thawed and placed on ice for 
5 minutes. Electroporation cuvettes and cuvette are pre-chilled on ice prior to 
use. 10-50ng of DNA was added to 50µl of cells and allowed to incubate on ice 
for a further 10 minutes. A BioRad Genepulser cuvette (1mm path length), was 
used to electroporate the cells at a voltage of 1.8kV. The cells were immediately 
resuspended in 1ml of LB broth and incubated for 1 hour at 37oC. The 
transformed cells were selected by growing the transformed bacteria on LB agar 
plates, containing the appropriate selection antibiotics. 
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Section 2.2.5 Plasmid DNA preparation 
 
Section 2.2.5.1 Plasmid DNA preparation by Alkaline Lysis 
 
Bacterial clones were used to inoculate LB broth containing the appropriate 
selection antibiotics. The culture was incubated overnight at 37oC. A modified 
method of the Birnboim 1983 alkaline lysis mini-prep method was used to extract 
plasmid DNA. 1.5ml of bacterial culture was spun at 15000rpm for 1 minute. The 
supernatant was discarded and the cell pellet was resuspended in 100µl of 
solution 1(50mM glucose, 25mM Tris-HCL pH 8.0, 10mM EDTA and RNase A 
100µg/ml). 200µl of freshly made solution 2 (200mM NaOH, 1% SDS) was added 
to each tube and the solutions were mixed by inversion. Tubes were allowed to 
stand at room temperature for 5 minutes.150µl solution 3 (5M potassium acetate, 
11.5% glacial acetic acid) was added and the tubes were placed on ice for 10 
minutes, to allow for the precipitation of the bacterial lysate. Samples were then 
spun at 15000rpm for 10 minutes. Supernatant was added to a fresh eppendorf 
tube and extracted with phenol/chloroform. (Section 2.2.6) and isopropanol 
precipitated at room temperature (section 2.2.7). Pellets were washed in 75% 
ethanol and allowed to air dry. Pelleted plasmid DNA was resuspended in 20µl of 
UHP water and stored at -20oC. 
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Section 2.2.5.2 Purification of plasmid DNA using Qiagen columns 
 
Section 2.2.5.3 Mini-preps 
 
Sequencing grade plasmid DNA was prepared using a Qiagen-tip 20 plasmid 
mini-kit. 3ml of an overnight culture was pelleted by centrifugation at 15000g for 
one minute. The pellet was resuspended in 0.3 ml of buffer P1 (50mM Tris-HCl 
pH 8.0, 10mM EDTA and 100ug/ml RNase A). A further 0.3ml of buffer P2 
(200mM NaOH, 1%SDS) was added and the solutions mixed thoroughly and 
incubated at room temperature for 5 minutes. 0.3ml of chilled Buffer P3 (3M 
potassium acetate pH 5.5) was then added, mixed by inversion and incubated on 
ice for 10 minutes. The sample was then centrifuged for 15 minutes at 15000 
rpm. A Qiagen tip-20 was equilibrated by the addition of 1ml buffer QBT (750mM 
NaCl, 50mM MOPS pH 7.0, 15% ethanol, and 0.15% Triton X-100). After Buffer 
QBT was allowed to drain through the column the supernatant resulting from the 
centrifugation step was placed on to the Qiagen tip-20 column and allowed to 
drain. Using 1ml of buffer QC (1.0M NaCl, 50mM MOPS pH7.0 and 15% ethanol) 
the column was then washed four times. Plasmid DNA was eluted from the 
column using 0.8ml of buffer QF (1.25M NaCl, 50mM Tris-HCl pH 8.5 and 15% 
ethanol) and collected into a fresh microcentrifuge tube. Plasmid DNA was then 
precipitated by adding 0.7 volumes of isopropanol at room temperature for 20 
minutes. The solution was then centrifuged for 30 minutes at 15000rpm, washed 
in ice cold 70% ethanol and re-pelleted. The pellet was then air-dried and 
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resuspended in 25µl of UHP water. Plasmid DNA obtained from this method was 
of adequate quality to be sequenced by an ABI 373A fluorescent sequencer. 
 
Section 2.2.5.4 Maxi-preps 
 
To prepare larger quantities of sequencing grade plasmid DNA a Qiagen maxi-
prep column was used. Typically 500ml of bacterial culture was used and a 
similar protocol to the above for mini-preps was performed according to the 
manufacturers instructions. The DNA pellet was re-solubilised in 500µl of UHP 
water and stored at -20°C. 
 
Section 2.2.5.5 Ligation of DNA 
 
This reaction is catalysed by the presence of T4 ligase, which requires ATP to be 
present. A balance between the ratios of vector DNA to insert DNA must be 
found when performing a ligation reaction. The simplest ligation is formed when a 
1:1 ratio of vector DNA to insert DNA is formed. Here the reaction volume takes 
place in 10ml and consists of 4ml of vector DNA, 4ml of insert DNA, 1ml of T4 
ligase (1U/µl) and 1ml 5x T4 ligase buffer (250mM Tris-HCl (pH 7.6), 50mM 
MgCl2, 5mM ATP, 5mM DTT and 25% (w/v) polyethylene glycol-8000) made up 
with UHP water. The tube was vortexed and then centrifuged for 10 seconds. 
The solution was incubated overnight at 4°C. This solution can then either be 
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used directly for transforming calcium competent cells or ethanol precipitated and 
resuspended in 10ml UHP water if using electro-competent cells. 
 
Section 2.2.6 Phenol/Chloroform treatment of nucleic acids. 
 
Phenol and Chloroform in equal volumes was added to the nucleic acid sample 
and vortexed into an emulsion. Organic and aqueous phases are separated by 
centrifugation at 15000 rpm for 5 minutes. Contaminant proteins partition at the 
interface between the organic and aqueous phases. The aqueous phase is kept 
for ethanol precipitation of nucleic acid. 
Section 2.2.7 Ethanol and Isopropanol precipitation of nucleic acids. 
 
Two volumes of ethanol or 1 volume isopropanol are added to the nucleic acid 
sample. In addition ¼ volume ammonium acetate was added to the sample, 
which was when kept at -20°C to precipitate the nucleic acid. Nucleic acids were 
pelleted by centrifugation at 15000rpm for 25 minutes and subsequently washed 
in 75% ethanol. Nucleic acid pellets were air-dried. 
 
Section 2.2.8 Restriction Digest 
 
An analytical restriction enzyme reaction was usually performed in a volume of 
approximately 20µl on 0.2-1.5µg of substrate DNA using a 2-to 10-fold excess of 
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enzyme over DNA, based on unit definition. Use of an unusually large volume of 
DNA or enzyme may give aberrant results. Caution should be exercised to 
prevent higher than normal concentrations of EDTA and glycerol. The following is 
an example of a typical analytical single restriction enzyme digestion:  
 
1.Under sterile conditions the following components, in the order stated, was 
added to a sterile micro-centrifuge tube.  
 
Sterile, nuclease-free water    14µl 
Restriction enzyme 10X buffer                            2µl 
BSA, Acetylated (1mg/ml)     2µl 
DNA sample 0.2-1µg, in water or TE buffer 1µl 
Restriction enzyme, 2-10U    1µl 
Final volume      20µl 
 
2.Mix gently by pipetting. Centrifuge briefly at 15000rpm in a micro-centrifuge to 
collect the contents at the bottom of the tube.  
3.Incubate at the optimum temperature for 1-4 hours.  
4.Add 4µl DNA loading buffer, and proceed to gel analysis.  
 
Larger scale restriction enzyme digestions can be accomplished by scaling this 
basic reaction proportionately. The reaction was then stopped by adding a 
quarter volume of 7M ammonium acetate (12.5µl) and then 2 volumes of ethanol 
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(125µl) and placed on ice for 30 minutes. This precipitates the DNA. The tube 
was then centrifuged at 15000rpm for 5 minutes and the supernatant removed by 
gentle pipetting. The pellet was then washed with 1ml cold 70% ethanol and 
centrifuged again for 2 minutes. The ethanol was then removed and the pelleted 
DNA was then air-dried and re-suspended in 5µl of clean filter sterilised UHP 
water.  
 
Section 2.2.8.1 Automated DNA sequencing 
 
DNA was purified using a Qiagen mini-prep kit (see section 2.2.5.3) before 
sequencing could be carried out. J. Keyte, Biochemistry Dept. Nottingham 
University performed automated sequencing, using the Perkin Elmer ABI 373A 
Fluorescent Sequencer and an ABI Cycle sequencing Kit. DNA was sequenced 
on both strands, unless otherwise stated. Sequencing was performed using the 
forward and reverse primers, T7 and SP6 as well as custom made primersfor 
oligonucleotide directed sequencing. 
 
Section 2.2.9 Mouse genomic DNA extraction  
 
This method is derived from a protocol by Laird et al (1991). 0.5g of liver or 5mm 
of mouse tail was obtained at necropsy The tissue sample was added to 500µl of 
extraction buffer (10 mM Tris, pH 7.5, 400 mM NaCl, 100 mM EDTA, 0.6% SDS) 
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and 35µl of proteinase K (20mg/ml). The tissue was then incubated overnight at 
56oC. Equilibrated phenol (Tris pH 8.0) was then added and the mixture was 
vortexed and centrifuged at 15000g for two minutes at room temperature. The 
aqueous phase was removed to a new tube and an equal volume of 
chloroform/isoamyl alcohol (49:1) was added. After mixing vigorously the sample 
was spun at room temperature at 15000g for two minutes. The aqueous phase 
was placed in a new tube. 250µl of 7.5M ammonium acetate and 750µl 
isopropanol was added and the tube was mixed by inversion. Samples were then 
centrifuged at 15000g for five minutes at room temperature. Pellets were washed 
in 70% ethanol, centrifuged and air dried. DNA pellets were then resuspended in 
400µl UHP water at stored at -20oC. DNA was visualised by 1% TBE-Agarose 
and quantified by measuring the optical density at 260nm (section 2.3) 
 
Section 2.3 Spectrophotometric Quantification of DNA and RNA 
 
The spectrophotometer was zeroed at 260nm using water as a blank. 1µl of DNA 
or RNA samples was diluted 1:1000 in water and pipetted into a quartz cuvette. 
Absorbance readings were taken at 260nm and the concentration of nucleotides 
was calculated as shown below. 
 
Nucleic acid concentration (µg/ml) = (Absorbance (260nm) X 50) X dilution factor 
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As  1A260nm = 50µg/ml double-stranded DNA  
And 1A260nm = 40µg/ml single-stranded RNA 
 
Protein and salt contamination can affect the absorbance at 260nm. To examine 
the effect this could have on determination of nucleic acid concentration a 
measurement was taken at 280nm. A 260:280nm ratio was then calculated. 
Values below 1.7 or above 2.0 indicate a sample is contaminated with protein or 
salt. If this was the case the samples was purified by phenol:chloroform 
extraction( section 2.2.6) and re-quantified. 
 
Section 2.3.1 Electrophoresis 
 
Section 2.3.2 Agarose electrophoresis of nucleic acids 
 
Electrophoresis in agarose or polyacrylamide gels is the most usual way to 
separate DNA molecules according to size. DNA and RNA agarose 
electrophoresis was performed using a submarine Pharmacia GNA-100 gel 
electrophoresis kit or a Stratagene gel kit. 0.7-2.0% (w/v) agarose gels were 
prepared by dissolving the appropriate amount of agarose in 1XTBE buffer 
(45mM Tris HCl, 44mM Boric acid and 1mM EDTA). If a denaturing agarose gel 
was used to determine the integrity of RNA, 0.1% SDS (w/v) was added after to 
microwaving. Agarose was dissolved into 1XTBE by microwave heating of the 
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solution. To allow visualisation of the nucleic acid in the gel ethidium bromide 
was added to the agarose to a final concentration of 0.5µg/ml. The gel mixture 
was then poured into the gel casting mould and a comb fitted before setting. After 
cooling the gel was placed into the gel tank and immersed in 1XTBE. DNA 
samples were prepared in a 10% solution of 10X loading buffer (30% glycerol, 
0.25% bromophenol blue and 0.25% xylene cyanol FF) and loaded into the gel 
wells. RNA samples were loaded in the same way but with a denaturing 10% 
loading buffer (90% formamide (v/v), 0.25% bromophenol blue and 0.25% xylene 
cyanol FF and 1XTBE). At a constant voltage nucleic acid samples were run 
typically at 6V/cm, until the desired migration had been reached. Gels were 
visualised by illumination with an UV trans-illuminator. 
 
Section 2.3.3 Polyacrylamide gel electrophoresis 
 
Polyacrylamide gels are used to separate DNA fragments between 2000-6 base 
pairs. Polyacrylamide gels were made so that they contained a percentage of 
between 5-20% acrylamide depending upon the size resolution required. 
Acrylamide gels were run on Mini Biorad Protean II vertical electrophoresis kits. 
Acrylamide monomer is copolymerised with N,N’methylenebisacrylamide in the 
presence of a catalyst accelerator-chain initiator mixture. This mixture consists of 
freshly prepared ammonium persulphate as catalyst (0.1 to 0.3% w/v) together 
with an equal amount of N,N,N’,N’-tetramethylenediamine (TEMED) as initiator. 
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This mixture is then pipetted into the gel casting kit according to the 
manufacturers instructions. One hour was allowed for polymerisation after which 
the comb was removed and the resulting wells flushed with 1XTBE buffer. After 
loading of the samples the gel was run at 15V/cm. Polyacrylamide gels were 
post-stained with ethidium bromide (10mg/ml stock) in 100ml of UHP water to 
give a final concentration of 0.5µg/ml for 15 minutes. The gel was then rinsed in 
UHP water and visualised by illumination with an UV trans-illuminator. 
 
Section 2.4.1 Genotyping Transgenic Mice by Polymerase Chain Reaction 
(PCR) 
 
To gain an insight into the function of peroxisome proliferator activated receptor 
(PPAR) isoforms in rodents, Lee et al (1995) have disrupted the ligand-binding 
domain of the α isoform of mouse PPAR (PPARα) by homologous recombination 
(HR). This technique introduces HR constructs into embryonic stem cells. The 
HR construct in this case was the phophoribosyltransferase II gene conferring 
neomycin resistance To generate mice lacking an mPPARα protein, exons 7 and 
8 of the gene which encodes the ligand binding domain of the protein the neo 
gene was inserted and replaced 83bp of the coding region of exon 8. This work 
produced mice derived from the Sv129 strain (Lee et al 1995). 
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Section 2.4.2 Primer Design for geno-typing of PPARα wild type and null 
mice. 
 
Primers specific to the exon 8 and neo insert were used to amplify PCR products 
of either 111bp or 180bp respectively. For PPAR α wild type mice the forward 
primer (P1) has the sequence 5’-GTC TTA ACC GGC CCA ATG TT-3’ and the 
reverse primer’s (P2) sequence is, 5’-GTG GCA GGA AGG GAA CAG AC-3’. 
This reaction amplifies the region between 511-622bp of exon 8. These primers 
were designed using the EMBL database entry accession number X75294 
(M.musculus gene for peroxisome proliferator activated receptor alpha exon 8). 
For PPAR α null mice containing the neo insert, the forward primer (N1) had the 
sequence, 5’-ATG TTT CCA CCC AAT GTC GAG CAA ACC CCG CCC AGC 
GTC-3’. The reverse primer (N2) has the sequence 5’-CCA TCT TGT TCA ATG 
GCC GAT CCC ATA TTG GCT GCA GGG TCG C-3’. This reaction amplifies the 
region between 578-758bp of the neo insert. These primers were designed using 
the EMBL database entry accession number U43612 (cloning vector pMC1neo-
polyA, complete sequence). 
 
Section 2.4.4 Optimisation of PCR geno-typing of mPPARα transgenic 
mice 
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Optimising the PCR geno-typing of the transgenic mice involved altering the Mg2+ 
concentration of the reaction mix. Reactions were set up between 0.5mM-5mM 
and the reactions were then run at varying Tm. from 50-64oC. The following 
reaction cocktail was used for PCR geno-typing of PPAR wild type mice; Taq 
DNA Polymerase: 1µl (5U, Sigma), 25mM MgCl2 1-20µl, 10X reaction buffer 
(without MgCl2, 100mM Tris HCl pH8.3, 500mM KCl) 5µl, Genomic mouse DNA: 
1µg, UHP water: up to 50µl, 10mM dNTPs: 1µl, 5’-Primer: 1µl (70pmol), 3’-
Primer: 1µl (70pmol). The PCR reaction was overlaid with 50µl of mineral oil to 
prevent evaporation. PCR was performed on a Perkin Elmer DNA Thermal 
Cycler 480.It was determined that the optimal conditions for PCR of exon 8 in 
PPARα wild-type mice were 
 
2 minutes denaturing  95oC 
1 minute annealing  56oC 
1 minute extending  56oC  20 cycles 
1 minute denaturing  95oC 
5 minutes extending 56oC 
 
For PPARα null mice a different method was used to amplify the neo insert 
present. ABgene PCR master mixes, which contain all the components for PCR 
with the exception of template and primers, were employed. Each master mix 
contained Thermoprine Plus polymerase (0.025U/µl), Tris HCL pH 8.8 (75mM), 
(NH4)SO4 (20mM). Tween 20 (0.01% v/v), dNTPs (200uM). On addition of 1µl of 
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forward and reverse primer (70pmol) and 25µl master mix the following 
conditions were used: 
 
2 minutes denaturing 94oC 
1 minute annealing  72oC 
1 minute extending  72oC  30 cycles 
1 minute denaturing  94oC 
5 minutes extending 72oC 
 
Samples were stored at -20oC or loaded on to a 12% or 15% acrylamide and 
post-stained in ethidium bromide (0.5µg/ml). Negative controls of UHP water and 
C.elegans DNA which does not contain PPARα was included in all PCR 
reactions. 
 
Section 2.4.3 Sub-Cloning of mouse Slp by PCR 
 
The sequence of the mouse Slp gene is known (Nakayama et al 1987). Primers 
homologous to sequence in exon 3 were designed based on this sequence 
(figure 2.1, EMBL accession number M12974). The forward primer (Slp1) has the 
sequence 5’-TTG CTC CTG TTT TCC CCT TCT G-3’ and the reverse primer’s 
(Slp2) sequence is, 5’-CTC AAG GCT GAG CAG CAC AAA G -3’. PCR was 
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performed on genomic DNA from s129 PPARα wild-type mice using the following 
reaction 
 
2 minutes denaturing  95oC 
1 minute annealing  59.6oC 
1 minute extending  56oC  25 cycles 
1 minute denaturing  95oC 
5 minutes extending 56oC 
 
PCR is predicted to generate a 192bp fragment (180-371b.p). The PCR product 
was cloned into PGEM-T and its identity was confirmed by sequence analysis 
(not shown). 
 
1   GGATCCTCCA GCCATGCGGC TCCTCTGGGG GCTGGCTTGG GTGTTCAGCT TCTGTGCCTC 
61  ATCCCTGCAG AAGCCCAGGT CCCGGGGAAG ACACTGGCGT TTGCGTGGGC CAGGGGTGAG 
121 AGAGAGTGGG GTGGTGGGGT TCGGCTGGGT CTGAAGATGT ACCTCACTGT TCTCCTAGGT 
181 TGCTCCTGTT TTCCCCTTCT GTGGTTAATT TGGGGACTCC CCTGTCAGTG GGGGTACAGC 
241 TCCTGGATGC CCCTCCAGGA CAGGAGGTAA AAGGATCAGT GTTCCTCAGA AACCCAAAGG 
301 GTGGTTCCTG CTCCCCAAAG AAGGACTTTA AGCTGAGCTT GGGAGATGAC TTTGTGCTGC 
361 TCAGCCTTGA GGTAACCAGT ACCAGCACCC CTGCTGTTTC TCAGGTCTCT CTGCTGCACC 
421 CCATTGTCTG CTTATTTAGC AGCAGACAGG AGCTTGTTAT GTGACATAGG CTGGCTTTGA 
481 ACTCACAGCT GTCCTCTTGC CTCAGCCCCC AAAGTGCTAA GATTTACAAG TACACCTGGT 
541 TTGCCTGTTG CCTTTTGTTT TATTGTTTAG TTTTGCTTTT GAGACGGGAT TTCAGGGTGT 
601 AACCTAGATT GATTGAAATT GCTCAGTGAC CCTACTGTGG GCCTCTCAAG TGTTGGGATT 
661 ACAGCCGGGA GCCATTGTGC CTGGCACTTC TGTTGCCTTT TCCATCCCTG TCCCCCTCAA 
721 TGACTTCCTA CCTCTCTCTC CTCTGGCACA ATGGCCTTGC TGTCCCTACC TTAGGCTCTG 
781 TATTGTGTTC CTTTTGCTCT GTTTGATAGT CTCCTTCTGT CTTGATAGGT CCCACTGGAA 
841 GATGTGAGGA GCTGTGGCCT CTTTGACCTG CGCAGAGCCC CCTACATCCA GCTGGTAGCT 
901 CAGTCTCCGT GGCTAAGGAA CACAGCTTTC AAAGCCACAG AGACTCAGGG TGTC 
Figure 2.1. PCR of the Slp gene. Nucleotides in bold represent the position of primers 
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Section 2.5 RNA Manipulation and Diethylpyrocarbonate treatment of 
solutions 
 
To prevent degradation of RNA all solutions must be RNase free. Solutions and 
glassware used in RNA-orientated work were treated with diethylpyrocarbonate 
(DEPC) to inactivate any RNase by ethoxyformylation. Plasticware can be 
treated in a 2-3% hydrogen peroxide solution to remove any RNase 
contamination. DEPC in solution at a concentration of 0.1% v/v is a potent 
inhibitor of RNase activity. During all work involving RNA DEPC treated water 
and solutions were used. DEPC stock solution (1:10 in 100% ethanol) was added 
to give a final concentration of 0.1% (v/v) and incubated at 37oC for 1 hour or at 
room temperature for 24 hours. DEPC treated solutions were then autoclaved for 
20 minutes at 120oC.  
Section 2.5.1 Phenol Preparation 
 
Prior to use phenol must be equilibrated to remove contaminant substances and 
to adjust the pH. At a pH less than 7.8 liquefied phenol’s acidic nature prevents 
efficient separation of proteins from nucleic acids. 500g of crystalline phenol was 
melted at 68oC and 0.1% (w/v) hydroxyquinoline was added. An equal volume of 
0.5M Tris HCl (pH 8.0) was added to the melted phenol and this was stirred for 
15 minutes. The phenol was then allowed to separate and the aqueous phase 
was discarded. 0.1M Tris HCl (pH 8.0) was added to the phenolic phase stirred 
for 15 minutes. The mixture was allowed to separate again and the pH was 
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determined. This final equilibration step was repeated until the phenolic phase 
was greater than 7.8. After equilibration and the final aqueous phase discarded 
0.1 volumes of 0.1M Tris HCl (pH 8.0) was added. The Phenol solution was 
stored under Tris HCl (pH 8.0) in the dark at 4oC for up to one month. 
 
Section 2.6 Isolation of Total RNA from Mammalian Tissue. 
 
The method used to extract total RNA from mammalian tissue is derived from a 
method first devised by Green et al (1976) and modified by Auffray and Rougeon 
(1980). At necropsy tissue was removed from the animals and flashed frozen 
with liquid nitrogen. Tissue samples were then stored at -80oC to prevent RNA 
degradation. Alternatively tissue was placed in a RNase-free poly-propylene tube 
containing 15ml lysis buffer (6M Urea, 3M lithium chloride, 3M sodium acetate pH 
5.2, and 10% SDS). Using a Silverston homogeniser the tissue was 
homogenised in bursts of 30 seconds to prevent over heating which would lead 
to denaturing. Homogenate was transferred to a clean RNase-free tube and 
stored at 4oC overnight. The homogenate was spun for 20 minutes at 11000g at 
4oC. Resulting supernatant was decanted off and the clear white pellet re-
suspended in 5ml aqueous buffer (DEPC water, 10mM Tris HCl pH 7.4, 0.2% 
SDS). To this 2.5ml Tris-buffered phenol pH 8.0 and 2.5ml chloroform: isoamyl 
alcohol (IAA) 24:1 was added and the solution was shaken vigorously on a flask 
shaker for 15 minutes. The mixture was then spun for 20 minutes at 11000g for 
20 minutes at 4oC, and the upper aqueous phase removed to a new tube. Again 
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2.5ml Tris-buffered phenol pH 8.0 and 2.5ml chloroform:(IAA) was added to the 
tube and this was mixed and spun as before. The consequent aqueous phase 
was chloroform extracted with 5ml of chloroform:IAA (24:1), mixed, spun for 10 
minutes at 11000g at 4oC. Supernatant was ethanol precipitated (with two 
volumes absolute ethanol and ¼ volume sodium acetate pH 5.2) overnight at -
20oC. This was spun at 11000g for 30 minutes at 4oC and the RNA pellet washed 
with 70% ethanol. The resulting pellet was air-dried and resuspended in 250µl 
DEPC treated water. RNA was then stored at -20oC until required. 
 
Section 2.7 DNA template preparation 
 
Anti-sense transcripts for Cyp4a10, Cyp4a12, Cyp4a14 was synthesised by in 
vitro transcription of DNA templates. These templates were first prepared by 
linearising the cloning vector containing the target sequence by restriction digest. 
pGEM7-4a10 and pGEM74a12 were both linearised using a Eco RI restriction 
digest. pGEM74a14 was linearised using BamHI restriction digest. The probe 
lengths for Cyp4a12 and 10 were 480b.p. and 190b.p. respectively. The 
protected fragments were 401b.p. and 157b.p respectively. The probe length for 
Cyp4a14 is 237.b.p and the protected fragment is 157b.p. A Qiagen maxi-prep 
30µg aliquot of template DNA was linearised with 4U of the appropriate 
restriction enzyme, 5ul of restriction digest buffer and made up to 30ul with DEPC 
treated water. Visualisation of the linearised template was achieved by running 
an 1% TBE-agarose gel. Template DNA was then purified by first inactivating the 
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restriction enzyme by the addition of 100ug/ml of proteinase K and 0.1% SDS 
(w/v) and incubating at 37oC for 1 hour. Phenol:chloroform extraction (1:1 v/v) 
removed protein contamination and the sample was then centrifuged at 15000g 
at 4oC for one minute. Purified linear template was precipitated from the aqueous 
phase by addition of absolute ethanol  (two volumes) and ¼ volume of 3M 
sodium acetate (pH 5.2) for 25 minutes at -20oC. The sample was then 
centrifuged at 15000rpm for 25 minutes at 4oC. The resulting pellet was 
resuspended in 15ul of DEPC treated water. 
Section 2.7.1 In vitro transcription of DNA templates 
 
In vitro transcription was performed by adding 4µl 5x TCS (200mM Tris-HCl pH 
7.9, 30mM MgCl2, 10mM spermidine, 50mM NaCl), 1µl 100mM DTT, 1µl 
RNAguard (Pharmacia), 2ul NTP mix (5mM ATP, GTP, UTP), 1µl 100uM CTP, 
13µl DEPC treated water, 5µl [α-32P] CTP (12.5µM [α-32P] CTP, specific activity 
600Ci/mmol), 1.5ul (1-2µg) template DNA, and 1µl SP6 or T7 RNA polymerase. 
The transcription mix was vortexed and pulse-spun in a micro-centrifuge and 
then incubated at either 37oC or 42oC for SP6 or T7 RNA polymerases 
respectively, for 1 hour. To stop the reaction 1µl of DNase I was added and the 
sample was incubated for a further 25 minutes at 37oC. The radio-labelled probe 
was then phenol/chloroform (one volume) extracted and ethanol precipitated. The 
pellet was washed in 70% ethanol, and after air drying resuspended in 15µl of 
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deionised formamide. Probes were stored at -20oC. Incorporation of radioactive 
CTP into the probe and specific activity was estimated using the DE81 test. 
 
Section 2.7.2 Determination of percent incorporation  
 
DE81 ion-exchange filters have a high affinity for polynucleotides and a low 
affinity for single nucleotides. 1µl of synthesised probe was pipetted to each half 
of an Whatman DE81 filter and allowed to dry. One half of the filter was washed 
in 10ml 0.5M Na2HPO4 for minute, this was repeated five times each time the 
solution being replaced. The filter was then washed for one minute, twice in 
DEPC treated water and twice in absolute ethanol. After air drying both filters 
were placed into scintillation vials containing 3ml of scintillation fluid and the 
radioactivity measured for 1 minute on a 32P program using a Packard 1900 TR 
liquid scintillation analyser. The percent incorporation was measured by 
calculating the equation below: 
 
cpm washed filter     X  100% =         incorporation (%) 
cpm unwashed filter  
 
Incorporation efficiency of 5% or greater was acceptable, but was routinely over 
40%. 
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Section 2.7.3 Probe Specific Activity 
 
The specific activity of a probe in a transcription reaction is independent of the 
yield of RNA. The specific activity of a probe in a transcription reaction is 
determined solely by the ratio of [32P]-NTP to unlabelled NTP added and is, 
therefore, independent the yield of RNA.  
 
The actual yield of RNA must be determined experimentally by establishing how 
much [32P]-CTP was incorporated into transcript product (the ratio of labelled to 
unlabelled CTP incorporated is assumed to reflect the ratio of labelled to 
unlabelled CTP available in the reaction). The amount of 32P incorporated into 
RNA can be determined by the DE81 test (section 2.7.2).  
 
A 30µl transcription reaction contains 5ul of [32P]-C (800Ci/mM, 10mCi/ml) and 
1µl of 100µm unlabelled CTP. At the end of the synthesis reaction, 1µl of DNase 
I, is added, after incubation a DE81 test is performed and the percentage 
incorporation is calculated. 
 
Section 2.7.4 RNase Protection Assay 
 
This assay involves the preparation of radiolabeled anti-sense RNA probes, 
hybridisation of these probes to total RNA in solution, and subsequent removal of 
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un-hybridized RNA by RNase digestion. RNase protection assays were based on 
a method described by Melton et al (1984). The RNase Protection Assay used 
was obtained from Pharmingen Ltd, commercially available as. RiboquantR An 











Figure 2.2. Overview of an RNase protection assay 
 
Standard precautions were applied to avoid RNase contamination and exposure 
to radioactivity. The Riboquant assay system contained the following reagents; 
1X hybridisation buffer, 1X RNase buffer, RNase A+T1 (80ng/ml and 250U/µl), 
1X Proteinase K buffer, Proteinase K (10mg/ml), yeast tRNA (2mg/ml), 4M 
ammonium acetate, 1X loading buffer.30µg of total RNA was ethanol precipitated 
(100µl absolute ethanol, 50µl DEPC treated water, and 15µl 7M ammonium 
acetate) and the pellets solubilised by vortexing in 8µl hybridisation buffer. 
Riboprobe was diluted 100-fold in hybridisation buffer and 2µl of this solution was 
Probe Day 1 RNA preparation 
Overnight Hybridisation 
RNase treatment and 
purification of protected 
probes 
Gel Preparation 
Electrophoresis on Denaturing 
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added to each sample. Samples were topped with mineral oil and pulse spun in a 
microcentrifuge. Hybridisation was started by placing samples in a water bath at 
90oCfor 3 minutes. Samples were then transferred to another water bath at 56oC 
and incubated overnight. Controls included in the assay were two 30µg yeast 
tRNA samples. Following hybridisation 100µl of RNase cocktail (2.5ml RNase 
buffer, 6ul RNase A+T1) was pipetted beneath the oil layer to each aqueous 
sample. Tubes were pulse spun for ten seconds and incubated at 30oC for 45 
minutes. To a new tube 18µl of Proteinase K cocktail (390µl Proteinase K, 30µl 
Proteinase K, 30µl yeast tRNA) was added. From the RNase digested samples 
the aqueous layer was pipetted off and added to the fresh tubes for proteinase K 
treatment. After addition the samples were vortexed and centrifuged for 10 
seconds, before incubation at 37oC for 15 minutes. Each protected sample was 
then treated with 65µl of Tris-saturated phenol and 65ul of chloroform:isoamyl 
alcohol (50:1). The samples were vortexed into an emulsion and spun at 15000g 
for 5 minute at room temperature. The aqueous layer from each sample was 
pipetted off and added to a new tube. 650µl ice-cold absolute ethanol and 120µl 
4M ammonium acetate was added and the samples were mixed by inversion. 
Samples were then incubated at -80oC for 30 minutes. Samples were then 
centrifuged at 15000g for 15 minutes at room temperature and the supernatant 
carefully removed. Pellets were washed with 100µl ice-cold 90% ethanol and 
centrifuged for 5 minutes at 15000g. Supernatant was removed from the samples 
and allowed to air dry completely. 5µl of 1X loading buffer was added and the 
pellets solubilised by vortexing for 2-3 minutes. Tubes were then pulse spun and 
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heated at 90oC before being placed immediately on ice prior to loading on to a 
denaturing polyacrylamide gel (section 2.7.5). Also loaded onto the gel was a 
labelled DNA ladder (section 2.7.7). 
 
Section 2.7.5 Denaturing Polyacrylamide electrophoresis Gel 
 
To separate RNA on absolute size and not secondary structures denaturing 
acrylamide electrophoresis is used in RNase protection assays. Using a BioRad 
Protean II vertical electrophoresis kit gels were cast between plates cleaned with 
detergent to remove any dirt or acrylamide residue 6% gels were prepared by 
adding sequagel concentrate (23.7g acrylamide, 12.5g methylene bisacrylamide, 
and 450g urea (7.5M) per litre) and Sequagel diluent (450g urea (7.5M) per litre) 
The following equation was ueed to calculate the amounts of concentrate and 
diluent to be used in order to make a fixed percentage gel.  
 
(% acrylamide gel required) x (volume of gel) / 25 = volume of concentrate needed 
volume of gel - (1/10th volume of gel +volume of concentrate) = volume of diluent 
 
For a 6% gel 2.88ml of concentrate, 7.88ml of diluent, 1.2ml 10XTBE, 120µl 
APS, and 7.2µl of TEMED was added and mixed. A 25-well gel was then cast by 
pipetting the acrylamide mix in between the glass plates and allowed to 
polymerise for approximately an hour.  After setting, the gel was placed in the gel 
tank and 1XTBE was used to fill the anode and cathode compartments. Prior to 
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loading samples, wells were flushed with 1XTBE using a needle and syringe. 
Gels were run at 120V for approximately 90 minutes according to the size of the 
protected fragments. Gels were then fixed by placing them in 10% (v/v) 
methanol, 10% (v/v) acetic acid solution for 25 minutes. Fixed gels were then 
placed on to 3M Whatman paper and dried for 2 hours at 85oC in a Bio Rad 583 
flatbed gel dryer under a vacuum. 
 
Section 2.7.6 Autoradiography and Phosphor imaging 
 
Gels were placed in a intensifying screen and exposed to Kodak BioMax MS film 
for between 12-24 hours. Intensifying screens were stored at -80oC and then film 
was developed using 1X Kodak LX24 X-ray developer for 3 minutes. Film was 
then plunged into tap water before fixing in 1X rapid fixer from Ilford Hypam for 3 
minutes. The film was again rinsed in tap water and allowed to dry. Films were 
also placed under a blanked phosphor screen for approximately 12 hours or 
when samples were within the linear range of the screen. After exposure the 
phosphor screen was scanned using the GS-250 molecular imager at 100µm 
intervals. Volume analysis was performed using Bio Rad software version 1.0. 
Volume analysis is expressed as average radioactive density/mm2. The density 
of protected fragments was normalised to the density of the negative control at 
the same mobility. Raw data was exported directly from the software into other 
data analysis software.  
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Section 2.7.7 Synthesis of [α-32P] dCTP labelled 100bp DNA ladder 
 
100bp ladder (Gibco BRL, Life Technologies) was labelled with [α-32P] dCTP by 
a Klenow reaction. 3µl 5X labelling buffer (250mM NaCl, 150mM Tris HCl (pH 
7.5), 50mM MgCl2), 3.5µl nuclease free water, 1.5µl 10mM dA, dG, dTTP, 5ul [α-
32P] dCTP (3.3µM, specific activity 600Ci/mmol), 5µg 100bp ladder and 1µl 
Klenow DNA polymerase. The reaction mix was vortexed and briefly spun before 
incubating at room temperature for 2 hours. After which a DE81 incorporation test 
was performed (section 2.7.2). 100bp DNA ladder was diluted 1/10 in UHP water 
and 1µl of this diluted in 10µl of denaturing loading buffer. This sample was 
heated at 85°C for 3 minutes before loading 5ul to the denaturing polyacrylamide 
gel. 
 
Section 2.8 Preparation of Microsomal fractions from whole tissue  
 
Throughout the whole procedure the tissue and tissue fractions were kept cold 
(0-4oC) by using pre-cooled buffers and centrifuge rotors, and by keeping tissue 
homogenizers, beakers and centrifuge tubes in crushed ice. Fresh tissue (liver or 
kidney) was homogenised to generate a 25% (w/v) homogenate. The 
homogenisation buffer contained 0.05M KPO4 (pH 7.4), 0.15M KCl, 0.6mM 
EDTA, 0.2mM PMSF (phenylmethylsulfonyl fluoride). 0.05M Potassium hydrogen 
phosphate was made by adding 80.2ml of 1M K2HPO to 19.8ml of 1M KH2PO4. 
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Homogenisation took place on ice using a 10ml Potter-Elvejem homogeniser. 
The pestle was mounted on a drill motor (15/2 Inch Drill Press), which can be 
rotated between 1000 and 2500 rpm. Homogenate was transferred to Beckman 
ultracentrifuge tubes and centrifuged at 11000g at 4oC for 20 minutes. Pellets 
were discarded and supernatant was ultra-centrifuged at 100,000rpm for 1 hour 
at 4oC. Microsomal pellets were transferred to a 2ml Dounce homogenisation 
tube and gently resuspended in 1ml of storage buffer (0.01M KPO4 (pH 7.4), 
0.1mM EDTA, 20% glycerol, 0.1mM DTT). Microsomal fractions were stored at -
80oC  
 
Section 2.8.1 Spectral Determination of microsomal Cytochrome P450 
integrity  
 
The purpose of this protocol is to describe the method for rapid determination of 
the total Cytochrome P450 (i.e., the sum of the various isoenzymes) in 
microsomal fractions using a spectrophotometric technique. The principle of the 
spectral determination of Cytochrome P450 is that the reduced haemoprotein 
combines with carbon monoxide to give a characteristic absorption spectrum with 
a maximum at 450nm. Microsomal samples were split into microcentrifuge tubes 
in 200ul aliquots. Samples were diluted down by addition of 1.8ml UHP water. A 
few granules (3-4mg) of sodium dithionate crystals were added to each sample 
and scanned from 500nm to 400nm in a dual-beam spectrophotometer to 
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establish a baseline. To one sample carbon monoxide was bubbled into the 
microsomal dilution for 10 seconds. Gassing of the test cuvette with carbon 
monoxide was carried out soon after dithionite addition, as the reduced ferrous 
form of Cytochrome P450 is relatively unstable. The samples were then re-
scanned at 400-500nm. Samples were assayed on three occasions to have a 
total of three replicates for each microsomal preparation. 
 
Section 2.8.2 Bradford Assay for determining protein concentration 
 
To determine the concentration of protein samples the Coomassie blue method 
of Bradford (1967) was employed. Bradford reagent is prepared from 100mg 
Serva blue G dissolved in 100ml 85% phosphoric acid and 50ml of 95% ethanol, 
made up to 1 litre. The spectrophotmeter was warmed for 15 minutes before use. 
30µl of protein sample was added to 50µl of 1M NaOH and to this 950µl Bradford 
reagent is added and mixed immediately. Absorbance was measured at 590nm. 
The absorbance maximum of the dye in an acidic solution shifts from 465nm to 
595nm after adding protein due to stabilisation of the anionic form of the dye by 
both hydrophobic and ionic interactions. The dye principally reacts with arginine 
residues and to a lesser extent with histidine, lysine, tyrosine, tryptophan, and 
phenylalanine residues. A standard curve was constructed using bovine serum 
albumin (BSA) at concentrations between 0-30µg/ml. All assay samples and 
standards were measured in triplicate and the means determined. A standard 
curve of BSA concentrations against Absorbance at 590nm produces a linear plot 
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on what a linear regression can be calculated. R2 values greater than 0.95 were 
used and sample concentrations were based on the linear regression. 
 
Section 2.8.5 Measurement of lauric acid hydroxylase (LAH) activity  
 
This assay was performed by using a HPLC method developed by Dr.D.A Barratt 
and Ms.M,Bruce at the School of Pharmaceutical Sciences, University of 
Nottingham, University Park, NG7 2RD. 
 
Section 2.8.6 Measurement of DNA synthesis in vivo in transgenic mice. 
 
In order to measure the level of S-phase in mouse liver in vivo, cells that 
underwent replicative DNA synthesis were labelled through the administration of 
a base analogue intra-peritoneally. The method used here involved the base 
analogue bromodeoxyuridine (BrdU). S129 PPAR α wild type and knockout mice 
were used to study the role of PPARα in non-genotoxic carcinogenesis. These 
mice were a kind gift from F.Gonzalez from the National Institute of Health, USA 
Crystalline BrdU was stored as a stock at -20oC. For dosing intra-peritoneally 
BrdU was used at 100mg/kg in phosphate buffer and injected into the lower 
abdomen. BrdU was always dosed 2 hours before sacrifice to allow the BrdU to 
circulate and incorporate into the tissue.  
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Section 2.8.7 Dosing of Animals 
 
The peroxisome-proliferator Ciprofibrate was used to dose mice at doses ranging 
from 12.5-75mg/kg in phosphate buffer. To determine the time course of 
induction ciprofibrate was administrated over varying time points from 0-48 hours. 
Another peroxisome proliferator Methylclofenapate was used as a positive control 
in some experiments at a dose of 25mg/kg in phosphate buffer. Both these drugs 
were administered intra-peritoneally. During these experiments animals were 
kept on a 12-hour light cycle at 23oC± 2oC 40-70% humidity. Animals were fed 
and watered ad libitum. Animals were sacrificed by spinal dislocation and tissue 
was removed, and fixed in 10% neutral buffered formalin for 2 weeks at 4oC. As a 
positive control to ensure that the BrdU had circulated into high proliferating 
tissue, duodenum tissues were also collected. 
 
Section 2.8.8 Histology and Immunohistochemistry of tissue 
 
Fixation with 10% neutral buffered formalin results in the formation of methylene 
bridges with side chain amino groups of proteins. Processing to histological wax 
block was carried out according to routine histological procedures. Sections (2um 
thickness) were mounted on polysine or similar adhesive coated slides and dried 
at 37oC before staining. Immunohistology for BrdU was performed by dewaxing 
the sections in xylene for 30 minutes. The section was then taken to eater and 
treated with freshly made 0.1% trypsin at 40oC for 10 minutes. After rinsing in 
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water for 5 minutes sections were treated with 1M HCl at 40oC for 30-45* 
minutes. Sections were then washed twice in water for 5 minutes each and then 
treated with 3% H2O2 (1:10 dilution) for 10 minutes. Sections were rinsed in water 
for 5 minutes and then in phosphate buffered saline (PBS) pH 7.3 for a further 5 
minutes. Slides were treated with normal rabbit serum (1:20 dilution in PBS) for 
10 minutes and washed briefly in PBS. Primary antisera, Mouse-anti-Human 
BrdU (1:100 dilution in PBS) was added for 1 hour and the sections were then 
rinsed in water twice for 5 minutes each. Secondary Rat-Anti-Mouse 
immunoglobulins (1:50 dilution in PBS) was added for 20 minutes and again the 
slides were rinsed in water twice for 5 minutes each. Sections and tertiary 
antisera, Mouse PAP (1:50 dilution in PBS) was incubated for 20 minutes and 
then rinsed in PBS twice for 5 minutes each. A Biogenex liquid DAB kit was used 
to develop the stain for 5-10 minutes£. A counterstain of Harris’s haematoxylin 
was used and applied for 1 minute. Sections were then dehydrated, cleared and 
mounted. 
 
*Hydrolysis times may vary between mouse tissues, i.e. Pancreas and 
Duodenum: 30 minutes and liver, kidney and thyroid 45 minutes. 
£
 The above times changed following microscopical examination of control slides.  
 
In addition to the study slides being stained, positive and negative (exclusion of 
primary antisera) were included to ensure confidence of the results. To monitor 
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consistency within each run, a positive slide was included as the first and last 
slide. 
 
Section 2.9 Quantification of DNA synthesis 
 
In order to prevent reader bias, the printed slide label was printed with a 
randomised animal number. Slides were viewed under x200 magnification. Nuclei 
that showed very faint staining were counted as negative. Nuclei that were 
positive had a blue appearance. In total 1000 nuclei were counted and the 
number of labelled to unlabelled were calculated as a percentage and designated 
the labelling index. visualisation under light microscopy (magnification x10).  
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Chapter 3 Results  
 
Section 3.1 Total RNA extraction in vivo 
 
Total RNA was isolated from untreated mouse liver and kidney using the method 
of Green et al (1976) as described in methods. The approximate yield of total 
RNA from 1g of liver and kidney was 1.2 and 0.5mg, respectively. Figure 3.1 
shows the integrity of RNA as analysed by agarose gel electrophoresis. 
 
 
Figure 3.1. Agarose gel electrophoresis of mouse liver RNA. RNA was extracted from 1g of tissue 
using the method of Green et al as described in methods, and re-suspended in 500µl DEPC 
treated water. 1µl of sample from four different liver samples was run on a 1.0% agarose gel 
(containing 0.1% SDS and 0.5µg/ml ethidium bromide) at 70V for 2 hours using 1xTBE. The 
arrow shows intact 28S and 18S rRNA bands. The gel was photographed under UV 
transillumination. 
  1         2         3      4 
28S
18S
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Section 3.1.1 Extraction of Genomic DNA from mouse tissue 
 
DNA was extracted from mouse livers using a modified technique described by 
Laird et al (1991). This method uses a salt solution to lyse cells with subsequent 





Figure 3.2. Agarose gel electrophoresis of mouse liver genomic DNA. DNA was extracted 
from 1g of tissue using a technique described by Laird et al. (Laird, P. W., A. Zijderveld, K. 
Linders, M. A. Rudnicki, R. Jaenisch, and A. Berns) and re-suspended in 1µl UHP water.. 
1µl of sample from each preparation (samples 1-5 are from five different liver samples) was 
run on a 1.0% agarose gel containing 0.5µg/ml ethidium bromide at 110V for 2 hours using 
1xTBE. The gel was photographed under UV trans-illumination. 
        1    2     3     4   5     6 
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Section 3.1.2 PCR genotyping of PPARα mice null and wild-type 
 
Mice were genotyped by polymerase chain reaction (PCR), using two assays 
designed to discriminate between PPARα wild type and null mice. Genomic DNA 
was isolated from individual 7-8 week old Sv/129 and mPPARα -/- mice. (Lee et 
al 19975). 20mer primers were designed to amplify a segment of exon 8 of the 
PPARα gene, which is absent from PPARα -/- mice (Lee et al 1996, figure 3.3). 
Primers specific to 511-622 b.p exon 8 of the mouse PPAR-α gene (Gearing et al 
1993) were used to amplify a PCR product of 111b.p from wild-type mice. 
 
TCCCCACATC CTTTCTGAAT GGGCACTTCT AAGACTACCT GCTACCGAAA      450 
TGGGGGTGAT CGGAGGCTAA TAGGATTCAG ACAGTGACAG ACAATGGGAG      500 
P1 CCCCAGTCTG GTCTTAACCG GCCCAATGTT AATCAATGCA CAGCACTCTA      550 
CGTTGCGTTT ATAATTCGCC ATTAATTAAC GGGTAACCTC GAAGTCTGAG      600 
P2 CGGTCTGTTC CCTTCCTGCC ACCCTTCTGG ATATGTGCAC TCTCTTAAAT      650 
CCCTGAAAAC TAATCTGCAC TTTTTAACCT TTGAAAACCT ACAAGTCAAG      700 
GTGTGGCCCA AGGTTAGCCA TTTAAATGTG GCAAAAAAAA AAAAATATGT      750 
 
Figure 3.3. PCR of mouse PPARα gene. Nucleotides in bold represent the position of 
primers P1 and P2 designed to amplify DNA from wild-type mice. Exon 8 in PPARα null 
mice has been substituted by the neor gene. 
 
AAAAAGCCTC TCCACCCAGG CCTGGAATGT TTCCACCCAA TGTCGAGCAG TGTGGTTTTG 540 
CAAGAGGAAG CAAAAAGCCT CTCCACCCAG GCCTGGAATG TTTCCACCCA ATGTCGAGCA 600 
AACCCCGCCC AGCGTCTTGT CATTGGCGAA TTCGAACACG CAGATGCAGT CGGGGCGGCG 660 
CGGTCCCAGG TCCACTTCGC ATATTAAGGT GACGCGTGTG GCCTCGAACA CCGAGCGACC 720 
CTGCAGCCAA TATGGGATCG GCCATTGAAC AAGATGGATT GCACGCAGGT TCTCCGGCCG 780 
CTTGGGTGGA GAGGCTATTC GGCTATGACT GGGCACAACA GACAATCGGC TGCTCTGATG 840 
CCGCCGTGTT CCGGCTGTCA GCGCAGGGGC GCCCGGTTCT TTTTGTCAAG ACCGACCTGT 900 
 
Figure 3.4. PCR of neor gene Nucleotides in bold represent the position of primers (N1 and 
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The presence of the PPARα null allele was determined by PCR using 43mer 
primers complementary to the neor gene inserted into exon 8 of the mouse 
PPARα gene. Primers specific to neor were complementary to 578-758b.p of the 
neor gene sequence to amplify a PCR product of 180bp. (Figure 3.4).  
 
In order to obtain a fragment in the wild-type mice optimisation of the PCR was 
required. Magnesium concentration is a crucial factor affecting the performance 
of Taq DNA polymerase (Hu et al 1992). Reaction components, including 
template DNA, chelating agents present in the sample (e.g. EDTA or citrate), 
dNTPs and proteins, all affect the amount of free magnesium. In the absence of 
adequate free magnesium, Taq DNA Polymerase is inactive. Conversely, excess 
free magnesium reduces enzyme fidelity (Eckert et al 1990.) and may increase 
the level of non-specific amplification (Williams et al 1989, Ellsworth et al 1993). 
For these reasons, it is important to empirically determine the optimal MgCl2 
concentration for each reaction. There is no detectable amplication from 
C.elegans DNA (lane 6) demonstrating that the primers used are specific to 
PPARα from mouse. No PCR product in the reaction lacking any input DNA (lane 
7) demonstrates that there is no contamination of the PCR mixture with mouse 
PPARα gene. A magnesium concentration of 2.0mM was found to be optimal for 
amplification of the PCR product when inputting 1µg of genomic DNA (figure 3.5). 
2.0mM Mg2+ was used in subsequent PCR with these primers. 
 
 






Figure 3.5. Optimization of PCR for PPARα gene. Primers specific to exon 8 of mouse 
PPAR-α was used to amplify a PCR product of 111bp from S129 mouse genomic DNA. 
Lane 1 is a 1KB Plus DNA ladder. 1µl of sample from each preparation (samples 2-6) was 
run on a 1.0% agarose gel at 110V for 2 hours using 1xTBE. The gel was photographed 
under UV trans-illumination. Lanes: 1 100bp ladder, 2: 2.0mM, 3: 2.5mM, 4: 5.0mM, 
5:10mM, 6: C.elegans genomic DNA, 7:negative control: H2O. 
 
 
A region (511-622b.p) of exon 8 of the mouse PPARα gene was amplified from 
mouse genomic DNA. Figure 3.6 shows that these primers amplify the sequence 
to generate a 111b.p. product which is the size expected from the sequence 
(Gearing et al 1994). No amplification product is present in lane 2, which 
contained genomic DNA from a PPARα null homozygous mouse. PCR 
genotyping for the PPARα wild- type gene was thus able to discriminate between 
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Figure 3.6 PCR genotyping for mPPAR-α+/+ mice. Primers specific to exon 8 of mouse 
PPAR-α was used to amplify a PCR product of 111bp. Lane 1 is a 100bp DNA ladder.PCR 
reactions were carried out on a PPARα -/- mouse (lane 2). Lanes 3-5 are samples from 
Sv/129 mPPAR-α +/+ mice. 1µl of sample from each preparation (samples 1-5) was run on a 




Figure 3.7. PCR genotyping for neor gene. Primers specific for the neo gene was used to 
amplify a PCR product of 180bp Lane 5 is a 1KB Plus DNA ladder. Lane 1-3 are genomic 
DNA samples from Sv/129 mPPAR-α-/- mice. Lane 4 is a sample from a Sv/129 mPPAR-α 
+/+ mouse. 1µl of sample (samples 1-5) was run on a 15% polyacrylamide gel at 110V for 2 
hours using 1xTBE and post-stained with 0.5µg/ml ethidium bromide. The gel was 
photographed under UV trans-illumination. 
 
PPAR-α -/- mice homozygotes have had the mPPAR-α gene, disrupted by 
replacement of exon 8 of the ligand-binding domain by 
phosphoribosyltransferase II gene conferring neomycin resistance (Neo; derived 
1 2 3 4 5 
180 bp PCR 
product 
111b.p PCR product:  
1       2       3      4     5 
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from plasmid pMC1NeoPolyA; Stratagene) inserted in the opposite direction of 
transcription of the genomic clone. (Lee et al 1996) Thus primers were designed 
to amplify the phosphoribosyltransferase II gene. PCR yielded a product of 
180b.p (figure 3.7 lanes 1-3.) as expected from the sequence of the neor gene 
(Lee et al 1996). Lane 4 is the product of the PCR of PPARα wild type mice; no 
DNA product is visible demonstrating that wild type mice do not contain the neor 
gene and confirming the specificity of the primers. Genotyping by PCR was 
completed by inclusion of negative controls including a genomic DNA from 
C.elegans which does not contain the homologous sequence and DEPC-treated 
water which should not contain DNA. PCR of both these negative controls did not 
result in a DNA product for both PPAR-α and neor.(data not shown). 
 
Primers were designed to amplify mouse PPAR-α exon 8 and the 
phosphoribosyltransferase II gene, and it was shown that these were specific for 
wild-type and knockout mice respectively. It was possible to determine that the 
colony is composed of pure homozygous PPARα +/+ and -/- mice. In order to 
confirm the integrity of the colony, breeding pairs were genotyped after a litter 
and their offspring were used for subsequent experiments. 
 
Section 3.2 Constitutive expression of murine Cyp4a genes. 
 
It has previously been shown that there is male-specific hepatic expression of a 
Cyp4a protein (Hiratsuka et al 1996) in ddY mice, although data from a variety of 
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sources appears conflicting (see introduction pg 23). The aim of this study was to 
examine the expression of the Cyp4a12 gene in several inbred mouse strains in 
order to describe any strain or sex differences and determine whether Cyp4a12 
is the gene that exhibits sex and strain differences in expression. 
 
Section 3.2.1 Template preparation and in vitro transcription 
 
Probes were designed from 3’ half of the gene  (nucleotides 1474-1711 for 
Cyp4a14, and 958-1380 for Cyp4a12 and Cyp4a10), have previously been 
shown to be specific for their respective genes (Bell et al 1993, Heng et al 1997. 
Cyp4a10 and 12 anti-sense probes were transcribed from the SP6 promoter of 
EcoRI digested templates, which gave 190bp and 480bp full-length probe, and 
157bp and 401bp protected fragments, respectively. The anti-sense probe for 
Cyp4a14 was transcribed from the T7 promoter, producing a full-length transcript 
of 237bp and a protected fragment of 157bp. Cyp4a10, 12 and 14 clones were in 
the pGEM7 vector (Figure 3.8). 
















Figure 3.8 Cyp4a gene templates for in vitro transcription. Fragment of the 3’ end of the 
Cyp4a was cloned into the polylinker of the pGEM7 cloning vector. This vector contains 
bacteriophage polymerase promoters, which allow the synthesis of “run-off” transcripts. 
In vitro transcription of anti-sense riboprobe of Cyp4a10 is generated from EcoRI digested 
template by SP6 polymerase yielding a 190bp full-length probe of which 157bp 
corresponds to the cDNA insert. In vitro transcription of anti-sense riboprobe of Cyp4a12 
is generated from EcoRI digested template by SP6 polymerase yielding a 480bp full-length 
probe of which 401bp corresponds to the cDNA insert. Anti-sense riboprobe of Cyp4a14 is 
generated byT7 polymerase in vitro transcription of BamHI cut template, resulting in a 
237bp probe length and a 157bp insert. 
 
Section 3.2.2 Cyp4a12 in inbred mouse strains 
 
In order to analyse the strain and sex differences of Cyp4a12 RNA expression in 












237       157 
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performed (figure 4.0). Two strains were assayed at a time, and the same 
riboprobe was used in all four experiments and prior to contemporaneous data 
acquisition. Expression of Cyp4a12 RNA was compared between sexes by 
calculating the ratio of male versus female from phosphor image analysis (figure 
4.1) 
 
The Cyp4a12 probe was shown to be substantially full-length (RNase –ve track), 
and to be present in excess over the signal in test samples (figure 3.9). The 
RNase positive track demonstrates an absence of signal when hybridised to 
yeast tRNA, demonstrating the specificity of the signal in samples. Finally, the 
size of the protected fragment in mouse samples was substantially shorter than 
the full-length probe; in agreement with RNase removal of 79bp of unprotected 




Figure 3.9. RNase protection assay specificity. Riboprobe was hybridisation to yeast tRNA 
and treated with RNase A/T1. No detectable signal was observed after yeast tRNA 
hybridisation with probe and RNase A/T1 treatment verifying that the radioactive signal 
observed in test samples was due to specific hydridisation of probe to RNA. Yeast tRNA 
was also hybridised to probe without RNase treatment to confirm that the input probe was 
in excess, that the probe was substantially intact, and that the reagents were RNase free. 
The size of protected fragment in the mouse sample (30µg total RNA) was substantially 




      RNase -     RNase+  sample 
Full-length probe 
Protected fragment 
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The specificity of the assay was shown by hybridisation of the riboprobe to yeast 
tRNA. No detectable signal was observed after yeast tRNA hybridisation with 
probe and RNase A/T1 treatment verifying that the radioactive signal observed in 
test samples was due to specific hydridisation of probe to RNA. Yeast tRNA was 
also hybridised to probe without RNase treatment to confirm that the input probe 
was in excess, that the probe was substantially intact, and that the reagents were 
RNase free. 

















Figure 4.0 Expression of Cyp4a12 in mouse liver and kidney. RNase protection assay was 
performed on 30µg total RNA of untreated mouse liver (L) and kidney (K) (M) denotes male 
and (F) female tissue samples, as described in the methods (pg 72). A 480bp length probe 
was generated which gave a 401bp protected fragment representing the Cyp4a12 
sequence. Two control yeast tRNA samples were hybridised to the probe, without or with 
RNase A/T1 (-veor +ve). All RNase protection assays were analysed contemporaneously. 
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Figure 4.1 Ratio of male: female expression of hepatic Cyp4a12. Radioactive signal from 
each strain is obtained by phosphorimage analysis onf the gel from figure 3.8. Data points 
are adjusted for tRNA background and are from equal areas on the gel. Ratios (left Y-axis 
and bars) are calculated by dividing total radioactivity (right Y-axis) in the male with total 
radioactivity in the female. This provides an indication of how male expression compares 
with female expression of Cyp4a12. The line plot is the male level of Cyp4a12. 
 
Sex differences in hepatic Cyp4a12 RNA were examined by calculating the ratios 
of male to female expression (figure 4.1). DBA/2 mice exhibited the greatest ratio 
of 1190:1 (male vs female). Balb/c displayed a ratio of 810 (male vs female). A/J 
male mice had Cyp4a12 levels 465 times greater than females. The remaining 
strains also exhibited sex-specific expression of Cyp4a12 with ratio of 7.5, 16, 48, 
63, 9.6 for ddY, C57BL/6, SWR, AKR, and SJL/J respectively. Therefore there is 
sex specific expression of Cyp4a12 RNA in all strains examined, but the ratio 
between male and female expression showed variation between the strains. 
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Strain variations in male specific expression were observed Balb/c mice had a 5-
fold greater level of Cyp4a12 than C57BL/6 and DBA/2. Also SJL/J mice had a 
15-fold greater Cyp4a12 level than SWR mice. ddY mice exhibited 6- and 1.2-
fold greater Cyp4a12 expression than C57BL/6 and Balb/c mice respectively  so 
ddY mice have greater levels of hepatic Cyp4a12 RNA than C57BL/6 and Balb/c 
mice. Another conclusion is that the ratio of male:female is not simply a reflection 
of the absolute level of Cyp4a12 in male liver. 
 
Cyp4a related protein and LAH activity had been reported to be male and strain 
specific, with hepatic expression in ddY but not C57BL/6 and Balb/c mice 
(Hirasuka et al 1996a). The data in figure 3.8, obtained using a specific RNase 
protection assay shows that Cyp4a12 RNA is not a strain specific P450, but that 
it is male specific in the liver of the eight inbred mouse strains examined (Bell et 
al 1993). 
 
Cyp4a12 RNA hepatic and renal expression in female was very low compared to 
males. The female liver mouse RNA was intact and lacked RNase activity (data 
not shown); further, these samples gave a signal with other probes (e.g. 
Cyp4a10, 14). Therefore, the low signal in female livers in figure 4.0 is not due to 
an artefact of degraded RNA, but reflects the level of Cyp4a12 in these samples. 
 
This data with a gene specific probe for Cyp4a12 demonstrates that Cyp4a12 is 
male specific in mouse liver. This is in contrast to other reports of strain 
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differences in expression of mouse hepatic Cyp4a proteins (Hiratuska et al 
1996). My original hypothesis, that reported strain and sex specific differences in 
expression of mouse Cyp4a were due to expression of Cyp4a12, is not 
supported by the data. 
  
Figure 4.2 Female expression of renal Cyp4a12. Radioactive signal from each strain is 
obtained by phosphor image analysis on the autoradiograph in figure 3.8. Data points are 
adjusted for tRNA background and are from equal areas on the gel. Ratios (left Y-axis and 
bars) are calculated by dividing total radioactivity (right Y-axis) in the male with total 
radioactivity in the female. This provides an indication of how male expression compares 
with female expression of Cyp4a12. The line plot is the male level of Cyp4a12. 
 
Sexes differences in renal Cyp4a12 RNA were examined by calculating the ratios 
of male to female expression (figure 4.2). ddY mice exhibited the greatest ratio of 
4335:1 (male vs female). A/J male mice had Cyp4a12 levels 1098 times greater 
than females DBA/2 male mice had Cyp4a12 levels 1930 times greater than 
females. Balb/c displayed a ratio of 220:1 (male vs female). The remaining 
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strains also exhibited sex-specific expression of Cyp4a12 with ratio of 911, 26, 
83, 148 for C57BL/6, SWR, AKR, and SJL/J respectively.  
 
These strain differences in Cyp4a12 RNA expression may explain reported 
sexual differences in the renal microsomal lauric acid metabolism; I propose that 
the putative LAH activity of Cyp4a12 would account for these sex differences 
(Henderson et al 1990, Henderson et al 1994 and Hirasuka et a 1996a). Renal 
Cyp4a related protein and LAH activity has been reported to be male specific in 
ddY, C57BL/6, Balb/c, C3H/HeN and C3H/HeJ mice (Hirasuka et al 1996a) and 
C3H, DBA. C57L and AKR (Henderon et a 1990). Figure 4.0 shows that Cyp4a12 
RNA is a sex-specific P450 in the kidney of the mouse strains examined. 
However it is anomalous that the Cyp4a12 expression profile is consistent with 
published reports of renal LAH and Cyp4a expression, but not with reports of 
hepartic LAH and Cyp4a expression. 
 
Hirasuka et al (1990b) found that Cyp4a protein and LAH activity to be sex-
specific in the kidney of ddY, Balb/c, C57BL/6, C3H/Hen and C3H/HeJ mice. 
Therefore these results confirm reports of a male specific Cyp4a (Henderson et 
al 1994, Hiratsuka et al 1996) and extend the data by showing that Cyp4a12 is a 
principal sex-regulated renal Cyp4a/LAH. 
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Section 3.2.3 Tissue expression of male Cyp4a12 
 
Figure 4.3 Ratio of male liver: kidney Cyp4a12 expression. Radioactive signal from each 
strain is obtained by phosphor image analysis on the autoradiograph in figure 3.8. Data 
points are adjusted for tRNA background and are from equal areas on the gel. Ratios (left 
Y-axis and bars) are calculated by dividing total radioactivity (right Y-axis) in the male with 
total radioactivity in the female. This provides an indication of how liver Cyp4a12 
expression compares with kidney in male animals. The line plot is the male level of 
Cyp4a12. 
 
Tissue expression of Cyp4a12 was compared by calculating the ratio of liver 
versus kidney (figure 4.3). Mouse strains C57BL/6, Balb/c, DBA/2 and SJL/J are 
expressed Cyp4a12 at comparable levels in the liver and kidney (ratios of 1.01, 
1.1,1.02, 1.2). Hepatic Cyp4a12 expression is less than renal in ddY (0.15), A/J 
(0.5) and AKR (0.7) strains. SWR mice had a higher level of Cyp4a12 in the 
kidney than liver with a ratio of 1.7. 
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Section 3.2.4 Tissue expression of female Cyp4a12 
 
Figure 4.4 Ratio of female: liver: kidney expression of Cyp4a12. Radioactive signal from 
each strain is obtained by phosphor image analysis on the autoradiograph in figure 3.8. 
Data points are adjusted for tRNA background and are from equal areas on the gel. Ratios 
(left Y-axis and bars) are calculated by dividing total radioactivity (right Y-axis) in the male 
with total radioactivity in the female. This provides an indication of how liver Cyp4a12 
expression compares with kidney in female animals. The line plot is the female level of 
Cyp4a12. 
 
In female liver (DBA/2) the absolute levels of Cyp4a12 (figure 4.4) is 
approximately 2400-fold lower compared with those of the male (SJL/L) (figure 
4.4). Female mice of ddY and C57BL/6 strains have liver: kidney ratios of 41 and 
122 respectively, which shows that levels of Cyp4a12 in the liver are greater than 
in the kidney. This is also the case, but not the same degree of magnitude for 
DBA/2, A/J, SJL/L female mice which have ratios of 1.65, 1.23 and 20 
respectively. SWR, AKR and Balb/c mice have equivalent or less liver Cyp4a12 
than kidney indicated by their ratios (0.99,0.95, 0.30 respectively). Strains SWR, 
AKR, DBA/2, AJ all exhibit equal levels of Cyp4a12. 
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Data here shows that Cyp4a12 expression is male specific in the liver and 
kidney. Females have lower levels of Cyp4a12 in agreement with the lower 
Cyp4a protein and LAH activity but in 3/8 of the mouse strains measured 
Cyp4a12 expression was similar in liver and kidney. 
 
Section 3.2.5 Expression of Cyp4a in ddY mouse strains 
 
Data here shows that Cyp4a12 is a male specific gene found in the liver and 
kidney of several inbred mouse strains (figures 4.0). However Hiratsuka et al 
(1996) report a strain –specific hepatic Cyp4a protein, suggesting that there are 
genetic variations in the expression of Cyp4a genes. Data here shows that this 
cannot be solely due to Cyp4a12. 
 
Possible explanations for this include the existence of another Cyp4a gene that is 
expressed in male ddY mice. Investigation in the genetic variations of Cyp4a 
expression was conducted using ddY mouse tissue. 
 
Cyp4a10 and Cyp4a14 are the other two members of the Cyp4a mouse family. 
RNase protection assay were used to determine the expression pattern of these 
two genes due to assay’s ability to discriminate between the individual genes. 
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Section 3.2.6 Expression of Cyp4a10 in ddy mice 
 
Constitutive expression of Cyp4a10 was studied in the liver and kidney of ddY 
mice. RNase protections were performed on total RNA using a riboprobe for 
Cyp4a10 (figure 4.5). Hybridisation of riboprobe to total tissue RNA resulted in a 
protected fragment, which is detected in a denaturing urea/polyacrylamide gel. 
The specificity of the assay was shown by hybridisation of the riboprobe provided 
in excess with yeast tRNA; No detectable signal was observed after RNase A/T1 
treatment verifying that the radioactive signal observed in test samples was due 
to specific hydridisation of probe to target RNA. Yeast tRNA alone was also used 






Figure 4.5 Expression of Cyp4a10 in ddy mice. A RNase protection assay was performed 
on 30µg total RNA of untreated male (M) and (F) mouse liver (liv) and kidney (kid). The 
position of the full length, 190bp length probe is shown by a solid arrow and the 157bp 
protected by a dashed arrow. RNase protection assays for Cyp4a10 were performed as 
described in methods (pgX.) and visualised on a phosphorimager. The specificity of the 
probe was determined by inclusion of two control yeast tRNA samples and hybridised to 
the probe. One sample was treated without RNase A/T1 (-ve), while the other was treated 
with RNase A /T1 (+ve). Each experiment was repeated twice using different tissue 
samples. 
 
+ve -ve  
RNase 
F kid M liv M kid F liv 
Full-length probe 
Protected fragment 

















Figure 4.6. Expression of Cyp4a10 gene in ddY mice. Radioactive signal from each strain 
was obtained by phosphor image analysis on the gel from figure 4.3. Data points are 
adjusted for tRNA background and are from equal areas of the gel. Protected bands were 
quantified using a phosphorimager and the results are expressed as the mean total 
radioactive signal (n=3 per data point). Data points are adjusted for tRNA background and 
are from equal areas on the gel. Each experiment was repeated twice using different tissue 
samples. 
 
Figure 4.5 shows that the liver and kidney samples have a specific protected 
fragment of 157bp, corresponding to the expected size of the Cyp4a10 RNA 
message. 
 
In ddY mice Cyp4a10 is expressed constitutively in both male and female liver 
and kidney (figure 4.6). Levels of Cyp4a10 in ddY mice do not show a sex 
specific expression as calculated by a bonferroni post-hoc, multiple comparisons 
test (P>0.05). This data is similar to other reports that show Cyp4a10 RNA and 
protein expression is not sex specific in C57BL/6 and NMC mice (Bell et al 1993, 
Heng et al 1997).  
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Section 3.2.7 Cyp4a10 polymorphism between ddY and C57BL/6 mice 
 
The Cyp4a10 probe detects an unambiguous signal in ddY (figure 4.5). However 
it is possible that an allelic variant might explain the discrepancy between the 
RNAse protection data and the proteina and enzyme data of Hiratuka et al 
(1996). A polymorphism of the Cyp4a10 gene has been reported in ddY. 
Examining the cDNA sequence on Cyp4a10 in the two strains there is a 1b.p 
difference in 5’end of the Bell et al (1993) probe (figure 4.7). It is unlikely to effect 
the probe specificity and no polymorphism exists between ddy Cyp4a10 and 











Figure 4.7. Cyp4a10 polymorphism between ddY and C57BL/6 mice. Alignment of Cyp4a10 
genes in ddY (ab018421), C57BL/6 (x69296) and NMC (x71478) mice was aligned using the 
programme gcg, and displayed using Genedoc, as described in methods(pg X). 
Highlighted sequence represents the 5’ end of the cDNA sequence and shows the 1bp 
difference between the strains. 
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Figure 4.7 Polymorphism in Cyp4a10  between C57BL/6 and ddY mice 
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Section 3.2.8 Expression of Cyp4a14 in ddy mice  
 
Constitutive expression of Cyp4a14  was studied in the liver and kidney of ddY 
mice (figure 4.8). RNase protections for Cyp4a14 was performed as described 
in methods (pg 74). The position of the full-length, 237bp probe is shown by a 
solid arrow, and the 157bp protected fragment by a dashed arrow. No 
detectable signal was observed RNase A/T1 treatment verifying that the 
radioactive signal observed in test samples was due to specific hybridisation 
of probe to target RNA. Yeast tRNA alone without RNase treatment to confirm 
input probe integrity. Figure 4.8 presents an RNA protection assay for 
Cyp4a14
 in ddY mice. An autoradiograph of this gel was produced by an 






Figure 4.8 Expression of Cyp4a14 in ddy mice. A RNase protection assay was 
performed on 30 µg total RNA of untreated male (M) and female (F) mouse liver (liv)and 
kidney(kid). The position of a 237bp length probe is shown by a solid arrow, and the 
157bp protected fragment by a dashed arrow. RNase protections for Cyp4a14 were 
performed as described in methods (pg X). Two control yeast tRNA samples were 
hybridised to the probe, with (+ve) and without (-ve) RNase A /T1. Each experiment was 
repeated twice using different tissue samples. 
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Figure 4.9 Expression of Cyp4a14 gene in ddY liver. Radioactive signal from each 
strain was obtained by phosphor image analysis on the autoradiograph in figure 4.4. 
Data points are adjusted for tRNA background and are from equal areas of the gel. 
Protected bands were quantified using a phosphorimager and the results are 
expressed as the mean total radioactive signal (n=3 per data point). Data points are 
adjusted for tRNA background and are from equal areas on the gel. Each experiment 
was repeated twice using different tissue samples. Renal Cyp4a14 is significantly 
higher in female mice compared to male mouse liver ( * P<0.05) and kidney (# P<0.01). 
Cyp4a14  expression between male liver and female liver is not significant 
 
Male hepatic Cyp4a14  is approximately 5-fold greater than male kidney 
(figure 4.9). Hepatic Cyp4a14  in the female is 2.5-fold greater than in the 
male. Female kidney Cyp4a14  expression is approximately 2-fold higher than 
female liver. Renal Cyp4a14  is significantly higher in female mice compared 
to male mouse liver (P<0.05) and kidney (P<0.01). The difference in Cyp4a14  
expression between male liver and female liver is not significant. These data 
show that Cyp4a14  in ddY mice exhibit a female specific pattern. In NMC 
mice Cyp4a14  expression (using the same riboprobe) was found to be 
expressed at low levels in control liver of both male and female mice (Heng et 
al
 1997) suggesting that this gene is subject to strain variability. Northern blot 
analysis of kidney Cyp4a isoform expression showed that Cyp4a14  is 
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The female-specific expression of Cyp4a14  fails to explain the strain-specific 
and male-specific hepatic expression of LAH and Cyp4a protein reported by 
Hirasuka et al (1996). 
 
Section 3.2.9 Hepatic LAH activity for C57BL/6 and ddY mice 
 
Data here demonstrates the male-specific expression of Cyp4a12  in mouse 
liver. However LAH activity is strain and sex-dependent (Henderson et al 
1990, Henderson et al 1994 and Hirasuka et a 1996a). In order to determine if 
the putative LAH activity of Cyp4a12  accounts for these sex differences, LAH 
activity was measured in ddY and C57BL/6 mice. LAH activity was 
determined as described in the methods (section 2.8.5). Results are 
presented in table 3.1 below. 
 
Sample mean (nmol/ml/m in 11H) mean (nmol/ml/min 12H) 
C57BL/6 male 1.765 1.225 
C57BL/6 female  2.325 1.32 
DdY male  0.645 0.69 
Ddy female 0.45 0.305 
 
Table 3.1 Lauric acid hydroxylase activity in the liver of C57BL/6 and ddY mice (n=2). 
Assay was performed as described in the methods (section 2.8.5). 
 
There is no difference in hepatic LAH 11H and 12H activity between male and 
female C57BL/6 mice. Hepatic LAH-12H activity in ddY mice is greater activity 
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in male mice compared to female. Male LAH12 activity is approximately 2.2-
fold greater than in female mice. Therefore in C57BL/6 mice there is no sex 
difference in LAH activity. ddy mice exhibit a sex difference with respect to 
LAH-12H activity. This sex difference in LAH activity therefore supports data 
by Hiratsuka et al (1996a) by confirming the presence of a strain and sex-
specific lauric acid hydroxylase.  
 
Section 3.3 Cyp4a12 gene in S129 PPAR α  wild type and null mice 
 
PPARα  is known to regulate the induction of Cyp4a genes (Bell et al 1993). 
The effect of PPARα  on expression of male-specific genes was therefore 
investigated. RNase protection assays for Cyp4a12  were performed as 
described in the methods (pg 74). 
 
W ild type male mice expressed 2.4-fold greater hepatic Cyp4a12  than in the 
kidney (P<0.05). In PPARα  knockout mice Cyp4a12  was also expressed in 
male liver and kidney (figure 5.0). Cyp4a12  showed a 12-fold difference wild 
type and knockout in the kidney (P<0.01). In knock out mice Cyp4a12  was 
found to be 1.9-fold greater in the liver than the kidney of male mice (P<0.05). 







Figure 5.0 Expression of Cyp4a12 in male and female S129 PPAR α  wild-type (wt) and 
null (ko) mice RNase protection assay was performed using 30 µg total RNA of 
untreated male mouse liver (L) and kidney (K). as described in methods (pg X). The 
position of the full-length, 480bp length probe is shown by a solid arrow, and the 401bp 
protected fragment by dashed arrow. Two control yeast tRNA samples, treated with 
(+ve) and without (-ve) RNase A/T1 demonstrates probe integrity. Each experiment was 





























Figure 5.1. Expression of Cyp4a12 gene in S129 PPAR α  wild type and null mice. 
Radioactive signal from each strain was obtained by phosphor image analysis from the 
gel in figure 4.6. Data points are adjusted for tRNA background and are from equal 
areas of the gel. Protected bands were quantified using a phosphorimager and the 
results are expressed as the mean total radioactive signal (n=3 per data point).. Each 
experiment was repeated twice using different tissue samples. *: Indicates significant 
difference (male liv wt vs male liv ko and male kid wt vs male kid ko P<0.01). # 
Indicates significant difference (male liv wt vs male kid wt and male liv ko vs male kid 
ko P<0.05).  
 
Constitutive expression of Cyp4a12  RNA was found to be high in the male 
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was undetectable in female wild type and knockout mice. In PPARα  knockout 
mice hepatic Cyp4a12  levels were 15-fold less than that found in wild type 
mice (figure 5.1, P<0.01). These findings confirm the previous report where 
Cyp4a12
 has been shown to be regulated differently to other Cyp4a isoforms 
(Bell et al 1993). That study demonstrated that Cyp4a12  is expressed 
constitutively at high levels in male liver and kidney. By contrast Cyp4a12  was 
expressed at low levels in liver of female mice (figure 5.1). The observed low 
expression of murine Cyp4a12  in PPARα  knock out mice demonstrates that 
PPARα  plays a significant role in the constitutive expression of this gene. 
 
Section 3.3.1 Total P450 concentration in S129 PPAR α  wild type and 
knockout mice 
 
Cyp4a12 mRNA in PPARα  wild type mice is 15-fold greater than in knockout 
mice (figure4.6). To determine if the absence of PPARα  results in the 
reduction of total cytochrome P450 protein concentration a spectral 
determination of total P450 protein concentration was performed (table 3.2, 
see methods section 2.8.1) 
Sample nmols P450/mg protein 
Male wt 1.04±0.27 
Male ko 0.77±0.06 
Female wt 0.73±0.12 
Female ko 0.76±0.17 
 
Table 3.2. Total P450 concentration in S129 PPAR α  wild type (n=5) and null mice (n=3). 
Protein and P450 concentration was determined as previously described in the 
methods (section 2.8.1). 
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Data here demonstrates that there is a significant difference in total P450 
concentration between male and female wild type mice and no sex difference 
in knockout animals. There is no significant difference between wild type and 
knockout mice in total P450 concentration. 
 
Section 3.3.2 Hepatic LAH activity in PPAR α  wild type and knockout 
mice 
 
Greater P450 protein concentration in male liver and the male specific 
expression of Cyp4a12  suggests that this gene constituents the predominant 
P450 in male liver. To confirm that male specific Cyp4a12  expression 
corresponds to lauric acid hydroxylase activity, liver microsomes were 
prepared from S129 PPARα  wild type and knockout mice. LAH activity was 
determined by the method described in section 2.8.5 and is presented in table 
3.3. 
 
S129 PPARα  wild type mice S129 PPARα  knock out mice 
Enzyme Male Female Male Female 
LA11 0.59 ± 0.06 0.57±0.06 0.51±0.01# 0.46±0.00# 
LA12 0.71±0.09* 0.60±0.04* 0.57±0.03 0.58±0.05 
 
Table 3.3. Hepatic LAH activity in S129 PPAR α  wild type (n=5)and null mice (n=3). 
Assay was performed as described in the methods (section 2.8.5).* indicates a 
statistical difference between male and female wild type mice (P=0.038). # indicates a 
statistical difference between male and female knock out mice (P=0.0004). 
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Data in table 3.3.1.3 demonstrates that there is a significant sex difference in 
the LAH (12-OH) activity of hepatic microsomes from S129 PPARα  wild type 
mice but not knockout mice. No statistically differences were observed for 
LAH (11-OH) activity. These findings support the hypothesis that the sex 
specific expression of Cyp4a12  corresponds to the increased LAH activity and 
greater total P450 protein concentrations in male S129 PPARα  wild type. It is 
not possible to compare LAH activity between wild type and knock out due to 
unequivalent group sizes. 
 
Section 3.3.3 Cyp4a14 expression in S129 PPAR α  wild type and null 
mice 
 
Since absence of PPARα  decreases male-specific hepatic expression of 
Cyp4a12 , it was of interest to determine if this effect of PPARα  was specific to 
Cyp4a12
 or was common to all Cyp4a genes. The expression of Cyp4a14  
was investigated (figure 5.2). 
 
Cyp4a14
 RNA expression in S129 PPAR PPARα  male wild type and null mice 
was characterised by RNAse protection assay as described in methods (pg 
74)  






Figure 5.2 Expression of Cyp4a14 in S129 PPAR α  wild type (wt) and null mice (ko) A 
RNase protection assay was performed on 30 µg total RNA of untreated male (M) mouse 
liver (liv). The position of the full- length, 237bp length probe is shown by a solid arrow, 
and the 157 bp protected fragment by dashed arrow. Two control yeast tRNA samples, 
treated with (+ve) and without (-ve) RNase A/T1 demonstrates probe integrity. Each 










Male wt Male ko
samples
 
Figure 5.3. Expression of hepatic Cyp4a14 gene in S129 PPAR α  wild type and null 
m ice. Radioactive signal from each strain was obtained by phosphor image analysis on 
the autoradiograph in figure 4.8. Data points are adjusted for tRNA background and are 
from equal areas of the gel. Protected bands were quantified using a phosphorimager 
and the results are expressed as the mean total radioactive signal (n=3 per data point). 
Data points are adjusted for tRNA background and are from equal areas on the gel. 
Each experiment was repeated twice using different tissue samples. *: Indicates 
significant difference (P<0.01). 
 
Constitutive hepatic Cyp4a14  in S129 PPARα  null mice is 4-fold less than in 
wild type (figure 5.3, P<0.01). As with Cyp4a12 , Cyp4a12  is reduced in the 
-ve     +ve 
RNase 
M wt liv M ko liv 
* 
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liver of male mice lacking PPARα . Using riboprobes specific for Cyp4a12  and 
Cyp4a14 , this data demonstrates that PPARα  is a regulator of male Cyp4a 
RNA expression.  
 
Section 3.4 Expression of male specif ic genes in S129 PPAR α  mice. 
 
In order to establish if PPARα  regulates all male specific genes or to 
determine that sexually dimorphic regulation is confined to Cyp4a12  and 
Cyp4a14 , riboprobes were prepared for three other known male specific 
genes. Cyp2d9  is expressed in a sex-specific manner in mouse liver and 
kidney and encodes the male specific activity of testosterone 16α -hydroxylase 
(Harada and Negishi 1984a,b, 1988.) 
 
Mouse urinary protein (MUPI) belongs to a family of homologous proteins that 
form the major urinary proteins excreted by adult male mice and believed to 
assist in the transport of pheromones to the urine (Lehman-McKeeman et al 
1998).  
Section 3.4.1 Preparation of Cyp2d9  and MUPI Image clones 
 
Clones for Cyp2d9  (clone number 931222) and MUP (931184) were obtained 
from the UK HGMP resource centre, Cambridge and supplied in E.coli XL1-
blue in the vector pBluescript SK. As described in the methods section clones 
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were grown overnight at 37oC. Crude mini-preps and restriction digests were 
used to identify the presence of a correctly sized insert in the vector (figure 
5.4). The identity of the DNA clones was confirmed by sequence analysis (not 
shown). Multiple alternative IMAGE clones for each gene were also analysed. 
 
 
     
Figure 5.4. Agarose gel electrophoresis of of pBK-/- MUPI and Cyp2d9 clones and 
pGEMT-Slp. Gel A : Lane 1: 1KB Plus DNA ladder, Lane 2: space, Lane 3: Uncut 
pGEMT-Slp Lane 4: pGEMT-Slp EcoRI digest. Gel B : Lane 1: 1KB Plus DNA ladder, 
Lane 2: uncut pBKMUPI, Lane 3 pBKMUPI EcoRI digest, Lane 4:uncut pBKCyp2d9 , 
Lane 5: pBKCyp2d9 digest EcoRI. 1µ l of sample was run on a 1.0% agarose gel 
(0.5µg/ml ethidium bromide) at 110V for 2 hours using 1xTBE. The gel was 
photographed under UV trans-illumination. Linearised templates were subsequently 
used for in vitro transcription. 
 
Section 3.4.2 Sub-Cloning of  mouse Slp by PCR 
 
The sequence of the mouse Slp gene is known (Nakayama et al 1987). 
Primers homologous to sequence in exon 3 were designed (figure 5.5) and 
PCR was performed on genomic DNA from s129 PPARα  wild-type mice (see 
methods section2.4.3). PCR generated a 192bp fragment (180-371b.p), which 
B 
1   2   3   4   5 
A 
1    2     3   4    
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was mouse specific, as evidenced by the failure to amplify a product from 
C.elegans
 DNA (figure 5.5 lane 6). The PCR product was cloned into PGEM-




Figure 5.5. Agarose gel electrophoresis PCR of genomic DNA using primers for exon 3 
of Slp Lane 1: 1KB Plus DNA ladder, Lane 2-5: 192bp PCR products, Lane 6:Negative 
control (C.elegans DNA). 5 µ l of sample from was run on a 1.0% agarose gel (0.5 µg/ml 
ethidium bromide) at 110V for 2 hours using 1xTBE. The gel was photographed under 
UV trans-illumination and is the PCR product of 25 cycles. 
 
Section 3.4.2 Template preparation and in vitro transcription of Cyp2d9, 
MUP and Slp.  
 
The riboprobe for MUP was designed between the T7 promoter region of the 
pBluescript vector (657-1191bp) and the EcoRI in the multiple cloning site. 
The riboprobe for Cyp2d9  was designed between the T7 promoter region of 
the pBluescript vector (657-1167bp). MUP and Cyp2d9  anti-sense probes 
were transcribed from T7 promoter of EcoRI digested templates, which gave 
781 bp and 800bp full-length probe, and 706 bp and 790bp protected 
fragments, respectively. The anti-sense probe for Slp was transcribed from 
   1  2    3   4   5   6 
192bp PCR product 
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the T7 promoter, producing a full-length transcript of 310 bp and a protected 
fragment of 192 bp. Cyp2d9  and MUP were provided in the pBluescript SK 


















Figure 5.6 Male-specific gene templates for in vitro transcription. Cyp2d9  and MUP 
cDNAs were provided in the vector pBluescript SK. Slp PCR product was ligated into 
the PGEMT-Easy vector from Promega. In vitro transcription of anti-sense riboprobe of 
Cyp2d9 is generated from EcoRI digested template by SP6 polymerase yielding a 
521bp full- length probe of which 510bp corresponds to the cDNA insert. In vitro 
transcription of anti-sense riboprobe of MUPI is generated from EcoRI digested 
template by SP6 polymerase yielding a 545bp full- length probe of which 534 bp 



















Chapter  3                                                                                                                          Resul ts  
121 
polymerase in vitro transcription of BamHI cut template, resulting in a 310bp probe 
length and a 192bp insert. 
 





Figure 5.7 Expression of Cyp2d9 gene in mouse liver. A RNase protection assay was 
performed on 30 µg total RNA of untreated male mouse liver from s129 PPAR α  wild 
type and null mice. RNase protection assays were performed as described in methods 
(pg X). The position of the full- length, 800bp length probe is shown by a solid arrow,. 
Two control yeast tRNA samples, treated with (+ve) and without (-ve) RNase A/T1 












Figure 5.8 Expression of Cyp2d9 in S129 PPAR male wild type and knockout mice. 
Radioactive signal from Protected bands each strain was obtained by phosphor image 
analysis on the autoradiograph in figure 5.4. Data points are adjusted for tRNA 
background and are from equal areas of the gel were quantified using a 
phosphorimager and the results are expressed as the mean total radioactive signal 
(n=3 per data point). Data points are adjusted for tRNA background and are from equal 
RNase 



























Chapter  3                                                                                                                          Resul ts  
122 
areas on the gel. Each experiment was repeated twice using different tissue samples. *: 
Indicates significant difference (P<0.05). 
 
Due to the length of the probe, it is not possible to distinguish between full 
length and protected fragments. Constitutive expression of Cyp2d9  was 
studied in the liver of S129 PPARα  wild-type and knock out male mice (figure 
5.7). RNase protections were performed as described in methods (pg 74). In 
the liver of male knockout PPARα  mice constitutive expression of Cyp2d9  is 
approximately 65-fold less than in wild type mice (figure 5.8, P<0.05). This 
data shows that Cyp2d9  RNA expression is reduced in PPARα  knockout mice 
suggesting a possible role of PPARα  in regulation of male specific gene 
expression.  
 




Figure 5.9 Constitutive expression of MUPI gene in mouse liver.  RNase protection 
assay was performed on 30 µg total RNA of untreated male and female mouse liver from 
s129 PPAR α  wild type and null mice. RNase protection assays were performed as 
described in methods (pg X). A 545 bp length probe (solid arrow) was generated which 
gave a 534bp protected fragment (dashed arrow) representing the Cyp2d9 sequence.. 
One sample was treated without RNase A/T1 (-ve), while the other was treated with 
RNase A /T1 (+ve). All RNase protection assays were performed in twice with tissues 
from different animals. 
 
Male wt Female wt Female ko Male ko
RNase 
-ve        +ve 



























Figure 6.0. Expression of MUPI in S129 PPAR wild type and knock out mice. 
Radioactive signal from each strain was obtained by phosphor image analysis on the 
autoradiograph in figure 5.5. Data points are adjusted for tRNA background and are 
from equal areas of the gel. Protected bands were quantified using a phosphorimager 
and the results are expressed as the mean total radioactive signal (n=2 per data point). 
Data points are adjusted for tRNA background and are from equal areas on the gel. 
Each experiment was repeated twice using different tissue samples. * and # indicates 
significant difference for male and female wild type and male and female knockout 
m ice respectively (P<0.05). 
 
Expression of MUPI was studied in the liver of S129 PPARα  wild-type and 
knock out male and female mice (figure 5.9). RNase protections were 
performed on total RNA using a riboprobe for MUPI .  
 
Expression of constitutive liver MUPI RNA is male specific as reported in the 
literature (Derman et al 1981) with male wild type MUPI 8-fold greater than 
female wild type (figure 6.0, P<0.05). No significant difference in MUPI 
expression was observed between wild type and knock out mice male and 
female animals. Between S129 PPARα  knock out mice, males exhibited a 
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P450 gene, MUPI is a male specific gene found in mouse liver whose 
expression is unaffected by the abolition of the PPARα .  
 
Section 3.4.5 Expression of mouse male specific Slp 
 
Sex-limited protein (Slp) expression was determined by RNase protection 
assay to collaborate the MUP data and further investigate the role of PPARα 






Figure 6.1. Expression of Slp in S129 PPAR α  wild type and knockout mice. A RNase 
protection assay was performed on 30 µg total RNA of untreated mouse liver and 
kidney. A 310bp length probe (solid arrow) was generated which gave a 192bp 
protected fragment (dashed arrow) representing the Slp sequence.. One sample was 





-ve     +ve 
Liver ko Liver wt 
probe kidney kidney 













Figure 6.2 Expression of Slp in S129 PPAR α  wild type mice. A RNase protection assay 
was performed on 30 µg total RNA of untreated mouse liver and kidney.. A 274bp length 
probe (solid arrow) was generated which gave a 210bp protected fragment (dashed 
arrow) representing the Slp sequence. One sample was treated without RNase A/T1 (-
ve), while the other was treated with RNase A /T1 (+ve).. (n=2 per data point). Data 
points are adjusted for tRNA background and are from equal areas on the gel.  
 
Expression of Slp was studied in the liver of S129 PPARα  wild type and knock 
out male (figure 6.1). RNase protections were performed on total RNA using a 
riboprobe for Slp . Female animals were not examined due to time constraints 
but their inclusion would have been used to confirm Slp male specific 
expression. 
 
Expression of hepatic Slp RNA is male specific (Georgatsou et al 1993). No 
statistically significant differences were determined for Slp expression 
between wild type and knock out mice male animals. Renal Slp expression in 
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male mice. Slp expression has been reported to be predominantly in the liver 
(Georgatsou et al 1993) although levels of Slp have been found in other 
tissues including the kidney (Cox et al 1988). Figure 6.1 and 6.2 show that Slp 
RNA levels in S129 mice are greater in the kidney than the liver but are not 
affected by the absence or presence of PPARα  in either liver or kidney. 
 
Section 3.5 Induction of hepatocyte DNA synthesis 
 
In order to characterise changes in gene expression associated with PP-
induced cell proliferation, experiments were designed to establish the optimal 
dose and time period over which S-phase was initiated in hepatocytes. 
 
Section 3.5.1 Time-course Experiment 
 
Based on the literature (Styles et al 1987,1991,1990) a dose of 25mg/kg bw 
i.p. ciprofibrate was administered to S129 wild type mice with 100mg/kg bw 
i.p. BrdU dosed 1 hour before sacrifice (n=8 per group, Styles et al 1988). A 
control group of mice (n=4) was administered 500µ l corn oil (vehicle). At time 
points 0.5, 1, 2, 3, 24 hours animals were sacrificed and 2-4mm longitudinal 
mid-sections of left, median, and right anterior hepatic lobes were removed 
and tissues were fixed in 10% neutral buffered saline. Detection of BrdU-
labelled hepatocytes was performed as described in methods (section 2.8.6). 
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Duodenum samples were also collected and used as a positive control given 
the high replicative nature of this tissue. 
 
Over the time points examined dosed animals did not exhibit any increase in 
BrdU labelled cells (figure 6.3). These results show that DNA synthesis has 
not been increased by ciprofibrate at the dose used (25mg/kg bw i.p.). 
Presence of BrdU in the systemic circulation is demonstrated by the labelling 
of nuclei of cells in the duodenum. 
 
 
Figure 6.3. Time course experiment: S129 wild type mice were administered 25mg/kg 
bw i.p. and liver and duodenum tissues were collected at time points 0.5,1,2,3,24 hr. A: 
This is a represent slide of a treated animal. Ciprofibrate did not increase the number 
of hepatocytes in S-phase compared to control animals. It is estimated that there was 
less than 1% difference between treated and control animals. B: Representative slide 
demonstrating that BrdU entered the systemic circulation and incorporated into the 
duodenum of treated animals. 
A B  
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Section 3.5.2 Factors effecting induction of DNA synthesis 
 
A dose of 25mg/kg i.p. ciprofibrate did not induce DNA synthesis over a 24 
hour period (figure 5.9A). Therefore it was necessary to investigate the effects 
of other variables on the induction of DNA synthesis by peroxisome 
proliferators. 
 
Section 3.5.2.1 Effect of Circadian Rhythms 
 
Hepatocyte replication has been shown to follow circadian rhythm (Smaaland 
1996).A study aimed to measure DNA synthesis over an 18-hour time point to 
investigate the effect of circadian rhythms on control and ciprofibrate treated 
animals. These animals were administered 100mg/kg bw i.p. BrdU as 
previously described (table 3.4). 
 
Dosed     
Timepoint 6am 12pm 6pm 12am 
1 0 0 0.4 0
2 0 0 0 0
3 0 0 0 0
mean 0 0 0.133333 0
Control 0 0 0 0
 
Table 3.4. Effect of circadian rhythm on DNA synthesis. S129 wild type mice 
administered 50mg/kg bw i.p. ciprofibrate and 100mg/kg bw i.p BrdU (n=3). Tissues 
were collected at the time points and labelled nuclei were detected by 
immunohistochemistry. After 18 hours DNA synthesis was not observed in livers of 
either control (n=1) or treated animals except at the 6pm timepoint.  
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Table 3.4 demonstrates that the circadian rhythm of cell division is not 
detectable in the livers of animals used in this experiment. The level of DNA 
synthesis detected in the livers of control or dosed animals was very low. 
 
Section 3.5.2.2. Time course study 
 
A time course study was conducted in order to further characterise the early 
proliferative response by ciprofibrate after 18,24,30,36 and 42 hours. S129 
wild type mice (n=3) were administered 50mg/kg bw i.p. ciprofibrate and 









Figure 6.4.Time course study: S129 wild type mice administered 50mg/kg bw i.p. 
ciprofibrate and 100mg/kg bw i.p BrdU (n=3). Ciprofibrate was re-administered after 
36hr at a dose of 50mg/kg bw i.p. in order to maintain a constant plasma concentration 
(t1/2=36hours). Tissues were collected at the time points and BrdU labelled nuclei were 
detected by immunohistochemistry. An increase in DNA synthesis was observed over 
the 42hour period with the peak LI occurring at 30hr. However DNA synthesis is 
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At 50mg/kg bw i.p. ciprofibrate increased the number of hepatocytes in S-
phase. DNA synthesis is greatest at 30-hour after which it returns to control 
level. However this result is not statistically significant (P>0.05). Labelling 
indices between animals exhibited a large degree of variability suggesting that 
the dosing regime and small group numbers are insufficient for detecting the 
low occurrence of labelled hepatocytes. 
 
Section 3.5.2.3 Oral administration of BrdU  
 
The low induction of DNA synthesis in mouse liver is in contrast to the 
literature (Styles et al 1990, Barrass et al 1993). The high variability of data 
obtained from the LI values suggested that the BrdU labelling schedule was 
inadequate. Administration of BrdU in the drinking water of animals has been 
used to increase the sensitivity of the assay. This technique has been shown 
to be a measure of the cumulative number of hepatocytes in S-phase rather 
than the labelling cells at one time point only (Ton et al 1997). S129 wild type 
mice were administered 50mg/kg bw i.p. ciprofibrate and provided BrdU ad 
libitum in the drinking water at a concentration of 0.8mg/ml (figure 6.5).  










Figure 6.5. Oral administration of BrdU:BrdU (0.8mg/ml) was added to the drinking 
water of S129 wild type mice administered 50mg/kg bw i.p. ciprofibrate (n=3) After 24 
hours dosed animals showed a significant increase in DNA synthesis compared to 
controls (P<0.05). 
 
Figure 6.5 shows that including BrdU in the drinking water of 50mg/kg bw i.p. 
ciprofibrate dosed mice enables the detection of hepatocytes in S-phase. 
There is a 9-fold difference between control and dosed groups after 24 hours. 
This data shows that there is much lower variability and more accurate 
measurement of DNA synthesis when BrdU is given orally in drinking water, 
compared to a single i.p. injection (figure 6.5) 
 
Section 3.5.3 Repeat dose ranging and time course studies 
 
The detection of ciprofibrate-induced DNA synthesis after oral administration 
of BrdU (figure 6.5) prompted a repeat of time course and dose ranging 
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bw ciprofibrate this is level of induction is conflicting with previous work. An 
oral ciprofibrate dose of 250mg/kg bw was required to increase DNA 
synthesis by 15-fold in C57BL/6 mice after four days (Budroe et al 1992). 
Therefore the effect of administering ciprofibrate via the oral route was also 
investigated. 
 
Section 3.5.3.1 Time course study 
 
A time course over 48 hours was used to determine if the induction of S-
phase by ciprofibrate occurs over a greater duration than 24 hours (section 
3.5.3). C57BL/6 male mice (n=6 per group) were administered 50mg/kg i.p. 
bw ciprofibrate and provided free access to BrdU in the drinking water 
(0.8mg/ml).Control mice were injected i.p. with 200µ l corn oil. Mice were 
sacrificed after 24, 36 and 48 hours and liver and duodenum tissues were 
collected as previously described. Labelling indices (LI) were calculated by 
dividing labelled nuclei by unlabelled nuclei and multiplying by 100. 1000 
nuclei were calculated per slide.  
 
Examining the time course of ciprofibrate induced DNA-synthesis (figure 
6.6A), a significant difference was observed between control and treated 
groups over 48 hours (n=6, P=0.0021).  
 
Chapter  3                                                                                                                          Resul ts  
133 
Section 3.5.3.2 Route of Administration 
 
The route of administration was also examined by dosing male C57BL/6 mice 
by gavage 50mg/kg ciprofibrate i.p. bw (n=3, figure 6.4B). No significant 
difference was observed between control or dosed groups administered by 
gavage (n=3, P>0.05). 
 
Section 3.5.3.3 Dose response study 
 
C57BL/6 mice were administered 10,25,50,75mg/kg i.p. ciprofibrate (n=5) and 
BrdU in the drinking water (0.8mg/ml). One group of mice was dosed MCP 
(25mg/kg bw i.p n=5.) as a positive control due to the known proliferative 
effects described in the literature (Styles et al 1990). However no increase in 
DNA synthesis was observed (data not shown). A 2-fold induction with 
50mg/kg i.p. was observed in dosed animals (n=5 P=0.017) indicating the 
start of a proliferative response to ciprofibrate. Statistical differences were 
observed at ciprofibrate doses of 75mg/kg (*: P=0.025) and 100mg/kg (*: 
P=0.008). 
 
Data from figure 6.6C (and figure 6.5) indicates that oral administration of 
BrdU exhibits sufficient sensitivity to detect ciprofibrate induced DNA 
synthesis in the liver of C57BL/6 and S129 mice. However the high variability 
of data presented in figure 6.6A and B indicates that any increase of cells in 
Chapter  3                                                                                                                          Resul ts  
134 
S-phase is small and the group numbers are not large enough to provide 
statistically sufficient results. 
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Figure 6.6. Ciprofibrate was administered to C57BL/6 either i.p. 
(A&C) or by gavage (B). BrdU (0.8mg/ml in drinking water) 
immunohistochemistry was used to determine the LI of treated 
animal livers in experiments A an. 1000 nuclei were counted per 
slide. Experiments B and C were conducted over a 24hr period. 
A: Time course of ciprofibrate induced DNA-synthesis. No 
significant difference was observed between control and 
treated groups over 48 hours (n=6, P>0.05). B: No significant 
difference was observed between control or dosed groups 
administered by gavage (n=3, P>0.05). C: A 2-fold induction 
with 50mg/kg i.p. was observed in dosed animals (n=5 *: 
P=0.017) indicating the start of a proliferative response to 
ciprofibrate. Statistical differences were observed at 75mg/kg 
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Chapter 4 Discussion 
 
Section 4.0 Constitutive expression of murine Cyp4a genes 
 
Previous reports of strain and sex-dependent expression of the Cytochrome 
P450 4a subfamily in the mouse warranted further characterisation of Cyp4a 
gene expression. Strain differences in Cyp4a expression observed by 
Hiratsuka et al (1996) and Henderson & Wolf (1991) were determined by the 
use of non-specific immunoblotting of Cyp4a-related protein using a 
polyclonal antibody to rat CYP4A1. Determination of sex and strain 
differences in the expression of a cytochrome P450 will provide a useful 
model for the study of the regulation of sex-specific gene regulation.  
 
Section 4.1 Hepatic Cyp4a12 expression in inbred mice strains 
 
Constitutive expression of the Cyp4a gene family has been determined in 8 
inbred mouse strains using male and female liver and kidney RNA. Strains 
studied were A/J, DBA/2, AKR, SWR, Balb/c, SJL, C57BL/6 and ddY mice. 
Since members of Cyp4a subfamily show high sequence similarity to each 
other, a RNase protection assay was employed due to its high specificity 
(Myers et al., 1985) and ability to discriminate between the Cyp4a10, 12 and 
14 genes (Bell et al 1993, Heng et al 1997). Probes used for the protection of 
Chapter 4                                                                                                                   Discussion 
137 
4a10 and 12 have been shown to be specific for their respective genes (Bell 
et al 1993). RNAse protection assays allow the quantification of Cyp4a gene 
expression by incorporation of [32P] CTP in the transcription reaction and 
subsequent phosphor imaging. 
 
Male constitutive expression of Cyp4a12 was detectable in the liver RNA of all 
the strains examined (Figure 3.8). In the female liver Cyp4a12 expression was 
very low compared to males. While Cyp4a12 expression was shown to be 
sex-specific determined from the absolute levels of Cyp4a12 expression. The 
ratio between male and female expression showed variation between strains. 
Balb/c mice had a 5-fold greater level of Cyp4a12 than C57BL/6 and DBA/2. 
SJL/J had a 15-fold greater Cyp4a12 level than SWR mice. ddY mice 
exhibited 6- and 1.2-fold greater Cyp4a12 expression than C57BL/6 and 
Balb/c mice respectively. Therefore strain variations seen between the ratio of 
male:female Cyp4a12 and the absolute levels indicate a clear sex-difference 
and fail to account for the sex-specific expression of Cyp4a12. 
 
Thus in the liver Cyp4a12 is not a strain specific cytochrome P450 but is male 
specific in the eight mouse strains examined.  
 
The male specific expression of hepatic Cyp4a12 RNA demonstrated here is 
in disagreement with data from Hiratsuka et al (1996a). Their findings present 
no sex difference in Balb/c and C57BL/6 expression of Cyp4a proteins. Thus 
it appears that there is still a discrepancy between the Cyp4a12 hepatic 
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expression pattern presented here and that of the enzyme and protein 
determined by Hiratsuka et al (1996a). I find a sex difference in expression of 
hepatic Cyp4a12 in all strains examined. While my data is consistent with the 
male-specific expression of LAH and a CYP4A protein in ddY mice, it does 
not explain the lack of sex-specificity seen in other strains (e.g. C57BL/6). 
 
Several other P450 isozymes have been found to be catalysts of the 
hydroxylation of medium- and long-chain saturated and unsaturated fatty 
acids (Orrenius et al 1969, Prough et al 1978). For example CYP2E1 in the 
rat and human is not only inducible by ethanol but is also involved in the 
microsomal (ω-1) hydroxylation of lauric acid and several other fatty acids 
(Fukuda et al 1994, Amet et al 1994, Adas et al 1999, Leclercq et al 2000). At 
present the expression and activity of Cyp2e1 related LAH has yet to be 
investigated to see if this is a possible candidate for the strain and sex-
dependent LAH activity observed in the mouse. 
 
Section 4.2 Renal Cyp4a12 expression in inbred mice strains 
 
Renal Cyp4a12 was also sex-specific as demonstrated by the male:female 
ratios of Cyp4a12 expression (figure 4.0). ddY mice exhibited the greatest 
ratio between male and female (4335:1). Mouse strains Balb/c and C57BL/6 
exhibited ratios of 220:1 and 911:1 respectively. The remaining five strains 
also exhibited male-specific expression of Cyp4a12. These strain dependent 
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differences in the levels of expression may explain the reported sex 
differences in the renal microsomal lauric acid metabolism reported by 
Hiratsuka et al (1996b) and Henderson et al (1990,1991,1994). 
 
Data presented in figure 3.8 supports previous reports in the kidney of ddY, 
Balb/c and C57BL/6 mice, male specific LAH enzyme activity and Cyp4a 
protein. Cyp4a12 expression has also been shown to exhibit a male-specific 
pattern in the kidneys of S129 mice (Holla et al 2001). 
 
Sex differences in the expression of murine renal Cyp4a proteins and lauric 
acid hydroxylase activity have been described (Henderson et al 1990, 
Henderson and Wolf, 1992), as well as in the expression of CYP4A2 in rat 
that shows sex specific regulation similar to Cyp4a12 (Sundseth and 
Waxman, 1992). However it has been shown that rat CYP4A2 is the 
homologue of mouse Cyp4a14. 
 
This data supports the hypothesis that the putative LAH activity of Cyp4a12 
would account for the sex-specific LAH activity and expression of Cyp4a-
related protein. However the data is also anomalous in that the Cyp4a12 
expression profile is consistent with published reports of renal LAH and Cyp4a 
expression, but not with reports of hepatic LAH and Cyp4a expression. 
 
Chapter 4                                                                                                                   Discussion 
140 
Section 4.3 Expression of other Cyp4a genes in ddY mice 
 
Further work proceeded to determine if the anomalous reports of a sex and 
strain dependent expression of a Cyp4a in male ddY mice was due to the 
presence of another Cyp4a gene.  
 
RNase protection assays were used to determine the levels of expression of 
Cyp4a10 and Cyp4a14 in ddY mice. This assay was used as it has been 
shown previously (Heng et al 1997) that the use of specific probes 
distinguishes between genes that share high sequence identity. 
 
Constitutive expression of Cyp4a10 and 14 mRNA was determined in the liver 
and kidney of male and female ddY mice. Cyp4a10 mRNA is expressed in 
both sexes in the liver and kidney (figure 4.3). Cyp4a10 has been shown to be 
expressed in the kidney of male and female S129 mice supporting this data. 
This data agrees with previous reports that Cyp4a10 does not exhibit a sex-
specific expression pattern despite a polymorphism in the 5’end of the probe 
used (figure 4.4; Bell et al 1993, Heng et al 1997).  
 
Hepatic and renal Cyp4a14 expression has previously been shown to be low 
in both sexes of NMC mice. In the kidney no sex-specific pattern of 
expression was detected in ddY (Heng et al 1997). Prolonged exposure of the 
phosphor image was required in order to detect levels of Cyp4a14 (Figures 
4.4). Figure 4.5 shows that in ddY mice renal Cyp4a14 is significantly higher 
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in female than male liver and kidney (P<0.05 and P<0.01 respectively). In 
males, hepatic Cyp4a14 is greater than kidney expression (5-fold). This data 
demonstrates that Cyp4a14 exhibits a predominantly female expression 
pattern in ddY. Similarly northern blot analysis of kidney Cyp4a isoform 
expression showed that Cyp4a14 is expressed, albeit at low levels in both 
sexes (Holla et al 2001). Dissimilar expression between observed between 
ddY and NMC maybe as a result of different autoradiography exposure times. 
Another possibility is that Cyp4a14 is subject to genetic variation between 
strains as seen for Cyp4a12. Evidence for this originates from northern blot 
analysis of S129 mice, which shows low levels of Cyp4a14 RNA in male 
kidney (Holla et al 2001). However it is unclear how specific the northern blot 
technique is for detecting members of the same P450 subfamily. 
 
Reports of a strain and sex-dependent Cyp4a in ddY were investigated using 
the gene specific RNase protection assay. In ddY mice no sex-dependent 
expression of Cyp4a10 was observed and no statistically significant 
differences between male and female animals was determined. In ddy mice 
while in the male Cyp4a14 is expressed at higher levels than the kidney, 
Cyp4a14 expression was found to be predominantly female in both liver and 
kidney samples.  
 
RNAse protection analysis of members of the Cyp4a gene family 
demonstrates clear differences in expression pattern. Cyp4a12 is male 
specific found at high levels in the liver and kidney of inbred mice, and 
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exhibits genetic variation between strains. The male specific hepatic 
expression of Cyp4a12 in ddY and 7 other inbred mouse strains and the 
characterisation of Cyp4a10 and Cyp4a14 expression exclude these genes as 
possible candidates for a sexually dimorphic, strain dependent Cyp4a. 
 
Section 4.4 Hepatic lauric acid hydroxylase activity 
 
Data here demonstrates the male-specific expression of Cyp4a12 in mouse 
liver. However LAH activity is strain and sex-dependent (Henderson et al 
1990, Henderson et al 1994 and Hirasuka et a 1996a/b). In order to determine 
if the putative LAH activity of Cyp4a12 accounts for these sex differences, 
LAH activity was measured in ddY and C57BL/6 mice. Lauric acid 
hydroxylase activities involve the catalysis of two different reactions. LA11H 
(ω-1 hydroxylase) and LA12H (ω-hydroxylase) catalyse the hydroxylation of a 
carbon atom at either the ω-1 or ω position of lauric acid. 
 
C57BL/6 exhibited no sexually dimorphic activity of hepatic LAH11 and 
LAH12 Hepatic LAH12H activity in ddY mice is greater activity in male mice 
compared to female. Male LAH12 activity is approximately 2.2-fold greater 
than in female mice. Therefore in C57BL/6 mice there is no sex difference in 
LAH activity. ddy mice exhibit a sex difference with respect to LAH-12H 
activity. This sex difference in LAH activity therefore supports data by 
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Hiratsuka et al (1996a) by confirming the presence of a strain and sex-specific 
lauric acid hydroxylase. 
 
Hepatic LAH activity in ddY and C57BL/7 mice support previous analysis by 
Hiratsuka et al (1996a). However the sex and strain- dependent differences 
observed in LAH activity do not match the constitutive expression of Cyp4a12. 
Male-specific expression of Cyp4a12 was found in all the strains examined. 
ddY mice did not exhibit strain-specific expression of Cyp4a12, indicating that 
Cyp4a12 is not responsible for the sex and strain dependent LAH activity 
seen in these animals. Expression of Cyp4a10 in ddY mice does not exhibit 
sexual dimorphism, but adduced evidence shows that Cyp4a10 mRNA is 
predominant in the livers of female mice (Henderson et al 1994). However it is 
not clear if a full-length probe was used in the northern blot analysis of 
Cyp4a10. 
 
Data demonstrating high level male specific expression of Cyp4a12, with 
strain-dependent sexual dimorphic LAH activity and female expression of 
Cyp4a10 suggest that although Cyp4a10 mRNA expression is found in 
females, the LAH activity suggests that the message is not translated into the 
protein or the protein has a diminished activity. An alternative possibility is that 
there may be a contribution to hepatic LAH from other P450s such as Cyp2e1 
(Adas et al 1999) 
 
Chapter 4                                                                                                                   Discussion 
144 
Further investigation using specific antibodies for Cyp4a10 is required to 
confirm the association between Cyp4a gene expression and the presence of 
a corresponding protein. 
 
Section 4.5 Cyp4a12 expression in PPARα wild type and knock-out mice 
 
PPARα   knock out mice do not express any level of PPARα (Lee et al 1996). 
These transgenic mice provide a model for investigation of the regulation of 
the Cyp4a gene family. Peroxisome proliferators induce Cyp4a gene 
expression; this indicates that these genes are regulated by PPARα. The 
absence of PPARα in knockout mice allows the study of the regulation of 
constitutive Cyp4a gene expression by this receptor, and may indicate their 
physiological function. 
 
Constitutive expression of Cyp4a12 was found to be high in the male liver of 
both PPARα wild type and knock out mice (Figure 4.7). However compared to 
wild-type control mice, a 15-fold reduction of Cyp4a12 was observed in knock 
out mice. Total P450 concentrations were determined to show if high level 
expression of Cyp4a12 in male liver and reduced levels in knock out mice 
resulted in a reduced protein expression (section 3.3.1). 
 
The significant difference in total P450 concentration between male and 
female wild type mice, observed in PPARα mice indicates Cyp4a12 
represents a major P450 expressed in the male mouse liver (table 3.2). 
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Absence of PPARα diminishes the expression of Cyp4a12 but may also result 
in the reduction of other genes or proteins under its regulation. Decreased 
Cyp4a12 expression and total P450 protein concentration also suggests that 
the reduced mRNA expression of Cyp4a12 also results reduced protein 
expression. However to demonstrate this definitively, characterisation of 
protein levels would need to be conducted using an antibody specific to the 
Cyp4a12 gene. Alternatively the LAH activity in PPARα wild type and 
knockout mice was investigated to examine the effect of this receptor in the 
regulation of LAH enzyme activity. 
 
Sexual dimorphism was observed in the LAH12 activity of hepatic 
microsomes from S129 PPARα wild type mice but not knockout mice. 
 
In summary, Cyp4a12 is expressed in a sexual dimorphic pattern in the 
mouse liver of the inbred mice examined. Strain differences in the male 
specific expression of Cyp4a12 were observed although reports of a strain 
and sex-specific Cyp4a were not confirmed. PPARα transgenic knock out 
mice were used to investigate the possible regulation of Cyp4a12 expression 
by this steroid nuclear receptor. In PPARα male knock out mice Cyp4a12 
mRNA expression is reduced compared to wild type animals. Lower LAH 
activity in PPARα knockout male mice and lower Cyp4a12 mRNA expression 
indicates that PPARα is involved in the regulation of P450 genes encoding for 
LAH enzymes. Supporting this is the reduced total P450 protein concentration 
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in knock out mice, suggesting that PPARα is involved in the regulation of 
Cyp4a12 and possibly other cytochrome P450 genes in the male liver. This is 
confirmed by the expression pattern of Cyp4a14 in PPARα knockout mice. 
Constitutive expression of Cyp4a14 is comparatively low compared to 
Cyp4a14 and is not subject to sexual dimorphic expression in mouse liver 
(Heng et al 1997). In male PPARα knockout mice, Cyp4a14 expression is 4-
fold less compared to wild type (figure 4.9). Expression of Cyp4a12 and 
Cyp4a14 is reduced in the liver of male S129 PPARα indicating that PPARα 
is a key regulator of Cyp4a RNA expression. 
 
Other researchers have found that expression of Cyp4a genes in S129 
PPARα. Mice are not affected by deletion of this gene (Lee et al 1996 and 
Gonzalez et al 1998). However, this maybe due to the lack of sensitivity in 
detecting specific members of the Cyp4a gene family. Northern analysis using 
a probe for rat CYP4A1 and CYP4A3 determined that there was no reduced 
in Cyp4a RNA expression in the livers of PPARα knock out mice (Lee et al 
1997, Kroetz et al 1998, Leone et al 1999, Gueraud et al 1999). Northern blot 
analysis using probes for Cyp4a10 and Cyp4a14 also found no difference in 
Cyp4a expression in control livers of S129 PPARα mice. The absence of any 
observable reduction in Cyp4a expression in these studies may be due to the 
low very level of expression and different exposure times for phosphor 
imaging (Barclay et al 1999).  
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These findings confirm previous reports where Cyp4a12 has been shown to 
be regulated differently than other Cyp4a isoform (Bell et al 1993). That study 
demonstrated that Cyp4a12 is expressed constitutively at high levels in male 
liver and kidney and was non-inducible by MCP. By contrast, the Cyp4a12 
gene was expressed at low levels in both liver and kidney of female mice. 
Treatment of these animals with MCP MCP induced Cyp4a12 mRNA to levels 
comparable with those in the male (M. Choudhury PhD thesis 2000). As 
mentioned sexual dimorphic expression of murine renal Cyp4a proteins and 
lauric acid hydroxylase activity have been described (Henderson et al., 1990; 
Henderson and Wolf, 1992), as well as in the expression of CYP4A2 in rat 
that shows sex specific regulation similar to Cyp4a12 (Sundseth and 
Waxman, 1992). 
 
Low expression of Cyp4a12 and 4a14 genes in PPARα knock out mice 
suggest that PPARα may play a significant role the constitutive expression of 
these genes. Previous work has demonstrated a differential induction of 
Cyp4a12 and 14 by PPs in wild type mice (M. Choudhury PhD thesis 2000). 
Cyp4a14 is high induced by PPs, while Cyp4a12 induction by PPs is 
comparatively low.  The high inducibility of both Cyp4a10 and 14 by PPs and 
their low constitutive expression tend to suggest that they may play an 
important role in peroxisome proliferation in the mouse liver. In contrast, the 
lack of inducibility of Cyp4a12 in the liver and its high constitutive level 
suggest that Cyp4a12 may have house keeping function and is less important 
in peroxisome proliferation in the liver. In addition the reduced constitutive 
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expression and lack of inducibility in knock out mice demonstrate that PPARα 
is involved in the transcriptional regulation of the constitutive and inducible 
expression these two Cyp4a genes. 
 
The reduced expression of Cyp4a12 and 14 seen in the liver of male knock 
out mice and their induction by PPs (Barclay et al 1999) suggest that some 
involvement of PPARα in the constitutive expression of these two genes in the 
male liver of this mouse strain.  
 
Other studies investigating the effect of PPARα on cytochrome p450 
expression are limited to the levels of cholesterol 7 α-hydroxylase (Cyp7a1). 
This gene does not exhibit sex-specific expression and is not reduced in 
PPARα knockout mice (Patel et al 2000). 
 
Although PPARα regulates induction by peroxisome proliferators, it is 
surprising that it regulates the male-specific constitutive expression of 
Cyp4a12. The male-specific expression of Cyp4a12 is unlikely to be due to an 
endogenous peroxisome proliferator inducer (e.g. a lipid), since there is no 
concomitant induction of Cyp4a10 and Cyp4a14 in control males. The effect 
of PPARα on male-specific expression is therefore paradoxical. 
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Section 4.6 Regulation of cytochrome P450 expression by PPARα 
 
To further investigate the role of PPARα in the regulation of the expression of 
male specific genes in the mouse male liver, three genes were chosen due to 
well-documented sex-specific expression pattern. 
 
Mouse urinary protein I (MUPI), Cyp2d9 and sex-limited protein (Slp) exhibit 
expression, which is limited to the male liver (section 3.4). Riboprobes were 
designed to be gene specific using clones acquired either from the IMAGE 
clone consortium (MUPI and Cyp2d9) or sub-cloned by PCR (Slp).  
 
Sequence analysis of all clones were performed to confirm the authenticity of 
each gene to be examined (data not shown). Sub-cloning using PCR was 
successful in amplifying an 192bp fragment of exon 3 of the Slp gene (figure 
5.1) The PCR product was subsequently ligated into PGEM-T and sequence 
analysis was performed to confirm the identity of the amplified sequence. 
 
As for members of the mouse Cyp4a gene family, a RNase protection assay 
was used to detect and quantify the levels of the three male specific genes in 
mouse liver of S129 PPARα wild type and knock out mice. 
 
Male wild type MUPI was 8-fold greater than female wild type MUPI 
confirming the sexual dimorphic expression of this gene (figure 5.6). This is 
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similar to previous work reporting that the expression of MUPI mRNA in male 
adult mice is 5-6-fold higher than in females (Hastie et al 1979, Derman et al 
1981). MUPI is transcriptionally regulated by androgen regulation similar to 
the homologous rat α2u-globulin (Kurtz and Feigelson 1977, Hastie et al 
1979) and Cyp4a12 (Heng et al 1997). Administration of testosterone to 
female mice results in an increase in Cyp4a12 mRNA expression in liver and 
to a greater extent kidney (Heng et al 1997). However no statistical difference 
was observed in MUPI expression between PPARα wild type and knock out 
mice (figure 5.6).  
 
A RNase protection assay used a riboprobe specific to a fraction of exon 3 of 
the Slp gene (figure 5.7). Northern blot analysis of Slp RNA expression has 
previously determined that this gene is male specific in the male livers of 
Balb/c mice (Georgatsou et al 1993). No significant differences were observed 
in Slp expression between wild type and knockout male animals (figure 5.8). 
 
Expression of Slp in the kidney was found to be 2-3-fold higher than in male 
wild type and knockout mice indicating that renal expression is 
transcriptionally regulated in a different to that in the liver. Georgatsou et al 
(1993) demonstrated that hepatic Slp expression is transcriptionally regulated 
by growth hormone and although Slp has been detected with high levels in 
the kidney (Cox et al 1988), its regulation has yet to be investigated. 
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Therefore expression of the non-P450 genes MUPI and Slp, were found to be 
unaffected by the absence or presence of PPARα in male liver or kidney. 
 
Cyp2d9 gene encodes for the testosterone 16α-hydroxlyase enzyme (Harada 
and Negishi 1984). Cyp2d9 sex-specific expression is regulated by growth 
hormone (Sueyoshi et al 1999) via ERα as demonstrated in female ERα 
deficient mice. In males Cyp2d9 expression was unaffected by the absence of 
ERα indicating that ERα is not required for the constitutive expression of 
Cyp2d9. 
 
Further more in growth hormone deficient mice Cyp2d9 expression is induced 
by growth hormone and recently the cellular mechanism mediating the GH-
regulated sex-specific cytochrome P450 expression has begun to become 
apparent (Udy et al 1997, Teglund et al 1998 and Sueyoshi et al 1999).  
 
In PPARα knock out mice Cyp2d9 is 65-fold less than in wild type male liver 
(figure 5.4). This data demonstrates that regulation by PPARα of another 
male-specific cytochrome P450. Table 3.4 illustrates the various mechanisms 
of regulation of Cyp4a12 and Cyp2d9. The male specific expression of 
Cyp4a12 is regulated in a similar manner to the rat CYP4A2 gene  
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Mouse P450 Cyp4a12 Cyp2d9 
Liver ⇑ by MCP in   ⇑ by ER in (ovx)  
⇓ by GH in   
⇑ by GH in   
Kidney ⇓ by test in   
⇑ by test in   
n.d 
Table 3.5. Regulation of Cyp4a12 and Cyp2d9. Administration of MCP to female but not 
male mice results in the induction of Cyp4a12, In the kidney Cyp4a12 expression is 
reduced in males but increased in females by testosterone (test, Heng et al 1997). 
Constitutive expression of Cyp2d9 is regulated by growth hormone (GH) in the male 
liver (Noshiro and Negishi 1986, Sueyoshi et al 1999). Estrogen treatment increases 
Cyp2d9 in ovariectomised (ovx) female mice implicating the role of ERα in the 
regulation of Cyp2d9. 
 
Expression of CYP4A2 was found to be regulated in a sex specific manner 
(Waxman et al., 1991). This apparent sex specific expression is regulated by 
the different growth hormone profiles between the sexes (Waxman et al 
1991). Another member of the mouse Cyp4a family, has been reported to be 
regulated by growth hormone (Henderson et al 1994). Expression of Cyp4a10 
is predominantly female, but following hypophysectomy it is also found in 
males.  
 
Sex-specific expression of Cyp4a12 and Cyp2d9 and reduction in PPARα 
knock out mice indicate that the expression of Cyp4a is regulated by distinct 
mechanisms in male and female animals. The involvement of growth hormone 
and PPARα in the regulation of these P450s is of interest because previous 
work has investigated the mechanisms by which these pathways regulate 
sex-specific P450 expression (section 1.3.6). Park et al (1999) report that 
STAT5b is involved in the regulation of GH-regulated expression of genes in 
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the liver. GH pulse induced expression of male-specific Cyp genes require 
STAT5b-DNA interactions (Park et al 1999) 
 
Potential cross-talk between JAK-STAT (janus kinase-signal Transducer and 
activator of tran-scription) and PPARα has been described by Zhou and 
Waxman (1999). Inhibition of clofibrate-induced peroxisomal β−oxidation by 
growth hormone (GH) has been described in rats (Yamada et al., 1994; Sato 
et al., 1995). This inhibition is thought to occur following binding of the GH to 
its membrane-bound receptor, leading to receptor dimerisation. This activity 
eventually leads to the activation of a cytoplasmic transcription factor STAT 
through JAK2 kinase mediated phosphorylation. GH inhibition of PPARα 
activity was dependent upon the presence of active STAT5b and GH receptor. 
Since STAT5b was unable to bind HD-PPRE, the inhibitory effect of GH may 
be due to competition for an essential PPARα coactivator or synthesis of a 
more proximal PPARα inhibitor. 
 
Alternatively there may be a factor specific to Cyp4a12 and Cyp2d9, and 
different to MUPI or Slp, which is preventing male-specific transcription. This 
may be due to both genes being P450s. For example, if a male-specific part 
of the haem synthesis pathway is switched off, then that may cause 
transcriptional repression of P450s such as that in porphobilinogen 
deaminase-deficient mice (Jover et al 2000), and animals treated with lead 
acetate (Jover et al 1996). However, this is less likely, since there is no 
decrease in the absolute amount of P450 (table 3.2) 
Chapter 4                                                                                                                   Discussion 
154 
 
The identification of male-specific genes in mouse liver such as Cyp4a12 and 
Cyp2d9 provide model systems, which may be used to further investigate the 
pathways GH-activated signaling pathways that activate members of the 
cytochrome P450 family and to establish the precise roles that STAT5a and 
STAT5b play in their expression. 
 
Section 4.7 Induction of hepatocyte DNA synthesis in vivo 
 
It has been demonstrated that PPs result in a hyperplastic response involving 
liver enlargement due to an increase in transient or sustained stimulation of 
cell replication as measured by DNA synthesis, in a dose-dependent manner 
(Lock et al 1988, Styles et al 1988). A 16-fold induction in DNA synthesis has 
been observed in vivo (Price et al 1992). In order to study the initial changes 
in gene expression mediated by PPARα, replicative DNA synthesis is a useful 
marker of peroxisome proliferation. With the aim of determining genomic 
changes in PPARα +/+ and -/- mouse liver after acute exposure to a PP, it 
was necessary to detect the earliest time point of S-phase induction.  
 
25mg/kg bw i.p ciprofibrate was administered to S129 PPARα wildtype mice 
and induction of S-phase was assessed using BrdU immunohistochemistry 
(Eldridge et al 1990). Over the time points examined (0.5,1,2,3,24hr) dosed 
animals did not exhibit any increase in BrdU labelled (figure 6.3A) despite 
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evidence that BrdU was present in the systemic circulation via intraperitoneal 
administration as demonstrated by labelling of intestinal sections (figure 6.3B). 
 
These results are anomalous to more detailed studies, which have 
established time, and dose-dependent changes seen after acute exposure to 
peroxisome proliferators. In Snell dwarf mice dosed 25/mg/kg MCP (oral) the 
incidence of hepatocytes in S-phase (by BrdU pulse labelling) peaked at 36 
hours in heterozygote animals (Styles et al 1990). The number of binucleated 
hepatocytes also decreased in response to exposure to MCP indicating a 
susceptible sub-population of hepatocytes to acute hyperplasia. This initial 
hyperplastic response is due to the conversion of binucleated cells to 
mononucleated tetraploids by amitiotic cytokinesis following S-phase (Styles 
et al 1987,1988, 1990a/b). 
 
Therefore it was necessary to determine if other factors were responsible for 
the failure to detect or induce S-phase in the livers of ciprofibrate treated 
mice. Circadian variations of liver cell proliferation have been described 
including hepatocyte DNA synthesis and mitotic activity (reviewed in 
Smaaland et al 1996). Over an 18-hour period, hepatocyte replication was 
assessed by in control and ciprofibrate treated animals. Animals were 
administered 100mg/kg bw i.p. BrdU as previously described (table 3.4). In 
both treatment groups the level of DNA synthesis was very low and the 
experiment was unable to demonstrate a circadian rhythm in hepatocyte DNA 
synthesis (table 3.4). 
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After 25mg/kg bw i.p. ciprofibrate was administered to S129 PPARα mice 
DNA synthesis was not observed after 24 hours. Previous studies have 
reported a peak activity after 36 hours (Styles et al 1990). Therefore the time 
course over which DNA synthesis was extended up to 42 hours and 
ciprofibrate was administered at 50mg/kg bw i.p (figure 6.4). A non-statistically 
significant increase in BrdU-labelled nuclei was observed at the 30hour time 
point. Labelling indices between animals exhibited a large degree of variability 
suggesting that the dosing regime and small group numbers (n=3) were 
insufficient for detecting the low occurrence of labelled hepatocytes. 
 
BrdU may be administered as a pulse dose by intraperitoneal injection or by 
continuous dosing via a osmotic mini-pump (Eldridge et al 1990) or via the 
drinking water (Ton et al 1997). A pulse dose of BrdU permits the evaluation 
of replicative DNA synthesis during a relatively narrow time course and is 
most useful in tissues with a fast turnover rate such as the gastrointestinal or 
integumentary systems (Goldsworthy et al 1993). Because detectable blood 
plasma levels of BrdU decline after several hours following a pulse dose 
(Kitchin and Brown 1995), such a discontinuous method of BrdU 
administration may not detect the long term fluctuations in cell proliferation 
following treatment with a peroxisome proliferator.  
 
Data in figures 6.3 and 6.4 indicate that in order to evaluate the replicative 
DNA synthesis in the liver a continuous method of BrdU dosing may provide 
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increased sensitivity. The use of osmotic mini-pumps present technical 
difficulties in terms of transplantation, cost, and time. Therefore the 
administration of BrdU in the drinking water was chosen due to its easier 
application, faster experimental implementation and avoidance of surgery-
associated stress to the animals.  
 
S129 wild type mice were administered 50mg/kg bw i.p. ciprofibrate and 
provided BrdU ad libitum in the drinking water at a concentration of 0.8mg/ml 
(figure 6.5). A BrdU dose of 0.8mg/ml was used based on the previous 
literature demonstrating that water consumption was unaffected and the 
absence of hepatoxicity by histological analysis (Ton et al 1997). Limitations 
of this method of delivery are acknowledged however as the BrdU dosage is 
entirely reliant on the drinking behaviour of the animals under treatment and 
the pharmacokinetics of target tissue concentrations of BrdU are unknown. A 
9-fold difference between control and dosed groups in labelling indices was 
observed 24 hours after ciprofibrate administration. In addition the data 
exhibits reduced inter-animal variability, excluding the necessity to 
dramatically increase group sizes. 
 
Time course and dose ranging studies were repeated using oral 
administration of BrdU as previously described. Although a significant 9-fold 
induction was observed at 50mg/kg i.p. bw ciprofibrate this level of induction 
is conflicting with previous work. An oral ciprofibrate dose of 250mg/kg bw 
was required to increase DNA synthesis by 15-fold in C57BL/6 mice after four 
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days (Budroe et al 1992). Therefore the effect of administering ciprofibrate via 
the oral route was also investigated in the C57BL/6 strain of mouse. No 
significant difference was observed between control or dosed groups (figure 
6.4B).  
 
Further to the results from the previous time course study 50mg/kg bw i.p. 
ciprofibrate was administered to male C57BL/6 mice with free access to BrdU 
in the drinking water. A significant difference between control and treatment 
groups were determined after 48 hours demonstrating that this dosing 
protocol was capable of detecting the induction of hepatocyte S-phase in 
PPARα +/+ mice.  
 
A dose-response relationship was determined in order to establish a lowest 
observable effect level (LOEL) for the induction of DNA synthesis by 
ciprofibrate.  
 
One group of mice was dosed MCP (25mg/kg bw i.p n=5.) as a positive 
control due to the known proliferative effects described in the literature (Styles 
et al 1990). However no increase in DNA synthesis was observed (data not 
shown). This is anomalous to previous reports and may be explained by the 
very low levels of induction occurring in the liver, which are not statistically 
significant when using small group numbers. 
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A 2-fold induction with 50mg/kg i.p. was observed in dosed animals (n=5 
P=0.017) indicating the start of a proliferative response to ciprofibrate. 
Statistical differences were observed at ciprofibrate doses of 75mg/kg and 
100mg/kg. Data from figure 6.6C (and figure 6.5) indicates that oral 
administration of BrdU exhibits sufficient sensitivity to detect ciprofibrate 
induced DNA synthesis in the liver of C57BL/6 and S129 mice. However the 
high variability of data presented in figure 6.6A and B indicates that any 
increase of cells in S-phase is small and the group numbers are not large 
enough to provide statistically sufficient results. 
 
C57BL/6 mice administered 50mg/kg bw i.p. ciprofibrate exhibited a 2-fold 
increase in BrdU labelled nuclei. This induction also appears not to have 
reached it maximal induction after 24 hours. Studies using 25mg/kg bw i.p 
MCP have reported maximal induction 20-30 hours after administration 
(Styles et al 1988,1990a). Data here demonstrates that ciprofibrate is different 
to MCP in its ability to induce S-phase after acute administration in vivo. Such 
quantitative differences in induction, dose, route, strain and labeling technique 
make comparison of studies difficult. Experiments using greater size numbers 
and a similar route of administration are more favorable in order to 
characterise generic changes seen in liver cytology and associated gene 
expression. 
 
However in order to characterise the possible early changes seen in gene 
expression after PP administration, a dose response relationship is required 
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that involves the induction S-phase at the earliest possible stage of the 
hyperplastic response. Therefore intraperitoneal administration is the obvious 
choice for delivery of xenobiotic directly into the systemic circulation. High 
inter-animal variability in LIs suggests that any small changes seen after PP 
administration will not be detected if that response is transient and is 
determined using small group sizes. This data demonstrates that pulse-
labelling of BrdU is not the best method of detection of hepatocytes in S-
phase. Continuous labeling of BrdU increases the sensitivity of the experiment 
as it provides a measure of the magnitude of induction over the duration of the 
assay as well as ensuring that BrdU reaches the systemic circulation. 
 
Failure of ciprofibrate to induce DNA synthesis to levels previously reported 
for MCP may reflect differences in potency between the two compounds. 
Another possible explanation are strain differences as reported between 
C57BL/6 and Balb/c mice. When administration orally at doses ranging from 
0.1 to 250ppm increased LI were observed at 1.0ppm in Balb/c mice but not 
C57BL/6 animals after 3 days (Budroe et al 1992). C57BL/6 mice require 
doses of 100 and 250ppm before significant increases in LI were detected. In 
this group of studies S129 or C57BL/6 mice were used, however the previous 
studies of Styles et al have used predominantly rats and heterozygous and 
homozygous Snell dwarf mice. Studies investigating the mechanisms of 
hepatocarcinogenesis by PPs should consider strain difference in 
responsiveness to PPs when producing experimental designs from previous 
literature. 
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